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Abstract 
The spliceosome is a highly dynamic megadalton ribonucleoprotein (RNP) complex that catalyses 
the removal of introns from eukaryotic precursor messenger RNA (pre-mRNA) in two consecutive 
transesterification reactions. The spliceosome is assembled de novo on each pre-mRNA intron by 
the sequential recruitment of five RNA-protein complexes (snRNPs) and numerous non-snRNP 
factors in a dynamic manner, driven by numerous DExH/D box ATPases or RNA helicases. After 
the U1 and U2 snRNPs bind to the 5’ splice site (ss) and branch site (BS) of the pre-mRNA, 
respectively, the pre-formed U4/U6.U5 tri-snRNP is recruited to give spliceosomal complex B, which 
lacks an active site. Catalytic activation of the B complex occurs in a stepwise manner. Initially, 
Brr2 RNA helicase dissociates the U4/U6 snRNA duplex, allowing U6 snRNA to restructure and 
to form an intricate U2/U6 RNA network, which is at the heart of the catalytic centre of 
the spliceosome. During activation, all of the U4/U6 and several U5 proteins are dissociated, while 
more than 20 new proteins including the Prp19 complex proteins (NTC) are stably integrated into the 
spliceosome, yielding the Bact complex, which is still pre-catalytic. Catalytic activation requires the 
ATP-dependent action of the RNA helicase Prp2, which displaces several proteins and remodels the 
U2 SF3A and SF3B complex proteins, yielding the B* complex. B* then catalyses the first step of the 
splicing reaction, generating the C complex. Following an additional restructuring step, the resulting 
C* complex catalyses the 2nd step of the splicing reaction to form the mRNA product. 
During the last two years, high-resolution electron cryo-microscopy (cryo-EM) structures have been 
published for several assembly intermediates of the yeast spliceosome including the B, Bact, C, C* and 
intron-lariat complexes, providing completely new insight into the complex structure of the yeast 
spliceosome and its structural dynamics during the catalytic cycle. As of now, only the human 
C* complex has been investigated by cryo-EM. In this work, I have used cryo-EM to investigate 
the 3D structure of the human Bact complex. Human and yeast activated spliceosomes share a large 
number of conserved proteins but differ in their protein composition in several aspects. Human 
Bact contains numerous proteins that are absent in yeast, including numerous peptidyl-prolyl 
isomerases (PPIases) and the RNA helicase Aquarius (Aqr), which is required for catalytic activation of 
the human spliceosome in addition to Prp2. On the other hand, proteins conserved between yeast 
and human are missing from the human Bact spliceosome, raising the possibility that the 3D structure 
of the human and yeast Bact complexes may differ to some extent. 
The Bact complex was assembled in HeLa nuclear extracts using a pre-mRNA construct, PM5-10, which 
contained the 5’ exon and an intron that is truncated 10 nucleotides (nts) after the BS, and was 
affinity-purified for cryo-EM analysis. After exhaustive 3D multi-reference 
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refinement (3D classification) of the human Bact particles, two major forms, termed A and B, of the 
Bact structure were obtained at resolutions of 5.3 Å and 8.1 Å, respectively. While their overall 
structure is largely similar, forms A and B differ with respect to the presence/absence of several 
densities, as described below. The structure of the central domain of the human Bact complex, 
including the catalytic U2/U6 RNP core, is highly conserved between the human and yeast 
spliceosomes. At the catalytic U2/U6 RNA centre, density for catalytic metal ion 2 (M2) is present but 
not for M1, indicating that the catalytic centre in this state is not yet functionally active. The 5’ end of 
the intron is engaged in base-pair interactions with the U6 ACAGA box and an additional ca. 10 nts of 
U6 snRNA, a distinctive feature not present in yeast spliceosomes. The 5’ss is positioned close to the 
catalytic centre but the 5’-terminal GU nts of the intron are engaged in protein interactions with 
Rnf113A (hCwc24) and probably also with U2 SF3A2. The BS forms an extended helix with U2 snRNA, 
which is clamped between the terminal HEAT repeats of the toroidal HEAT domain of SF3B1. 
The BS-adenosine (BS-A) is occluded in a protein pocket, comprised of C-terminal HEAT repeats and 
the PHF5A (hRds3) and is spatially separated from the catalytic centre by ca. 5 nm. The hPrp2 RNA 
helicase is bound to the convex side of SF3B1’s HEAT domain, close to the site, where the 3’ end of 
the intron exits the HEAT domain, but spatially separated from the U2/BS helix by ca. 7 nm. Thus, in a 
similar way to the scenario proposed for yeast Bact spliceosomes, the ATP-dependent Prp2-mediated 
remodelling may lead to conformational changes in SF3B1’s HEAT domain that liberates the first-step 
reactants for catalysis. 
In the human Bact structure, the U2/U6 helix II adopts a significantly different conformation, when 
compared with the yeast Bact structure and other spliceosomal assembly intermediates including 
human C*. Moreover, the conserved Syf2 protein, which binds to the base of U2/U6 helix II in yeast 
Bact, is absent from human Bact, probably because in the latter the U2/U6 helix II is sandwiched 
between two other proteins. This raises the interesting possibility that in humans the catalytic 
activation is more complex than in yeast and requires remodelling of U2/U6 helix II and concomitant 
integration of hSyf2 as a pre-requisite for B* complex formation. Another distinguishing feature of 
the human Bact structure is the existence of an intricate protein-protein interaction network that 
connects the complex of the Aqr helicase and protein Xab2 (hSyf1) to the main body of the 
spliceosome. Interestingly, all four PPIases present in human Bact are involved in protein-protein 
interactions, indicating that one of their functions appears to be that of serving as bridges between 
various protein modules of the spliceosome. 
Finally, while forms A and B of the human Bact structure obtained by 3D classification share most of 
the structural features described above, they differ in respect of the presence/absence of densities 
for several protein domains. The most dramatic difference is the absence of density for the large 
elongated Prp19 helical bundle in form A, while its well defined density is present in form B of the 
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Bact structure. At the same time, density for Ppil1 appears in form B, forming a bridge between the 
centre of the helical bundle and the central body of Bact. Moreover, the position of the U5 40K WD40 
domain also differs in form A and B. Experimental evidence further indicates that the absence of a 
protein density in one of the forms is not due to the physical absence of the respective proteins, but 
instead indicates conformational flexibility of the protein domains. Further evidence indicates that 
form A is a precursor of form B of the Bact structure. Thus, it was possible to capture by cryo-EM 
analysis two conformational states of the human Bact complex that differ in their degree of 
conformational maturation towards the catalytic activation step. As it is unlikely, that an 
ATP-requiring step is involved in the transition of the Bact complex from form A to B, this suggests 
that the observed conformational changes of the various protein domains are facilitated by the 
thermal energy of the system. 
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1 Introduction 
Prokaryotes and eukaryotes store the blueprints for proteins and non-coding RNAs (e.g. tRNA and 
rRNA) as DNA-encoded information in their genomes. Transcription of genes into messenger RNA 
provides the templates for ribosomal translation into proteins. While prokaryotic transcripts are 
readily usable for protein synthesis, a eukaryotic transcript is initially transcribed in the nucleus as a 
precursor messenger RNA (pre-mRNA). Numerous maturation steps of the nuclear pre-mRNA are 
required before translation of the mature mRNA takes place on ribosomes in the cytoplasm. One of 
the most dramatic maturation steps that a pre-mRNA has to undergo is due to the fact that most 
eukaryotic genes, unlike prokaryotic genes, are "genes in pieces", i.e. the coding segments (called 
exons) of a gene are interspersed with non-coding segments (called introns) (Berget, Moore et al. 
1977, Chow, Gelinas et al. 1977, Gilbert 1978, Tonegawa, Maxam et al. 1978). Since the primary 
transcript is a faithful copy of the DNA sequence containing the complete string of exons and introns 
as coded in the DNA, a maturation step is required to remove the introns and reconnect the exons. 
This process of precise excision and re-ligation is called splicing and takes place in the nucleus 
concomitantly with or right after transcription and is catalyzed by a highly dynamic macromolecular 
machine called the spliceosome. The mosaic structure of eukaryotic genes dramatically increases the 
coding capacity of the rather limited number of genes in eukaryotes. Unlike the prokaryotic "one 
gene – one protein" situation, one eukaryotic gene can code for a large group of related proteins. 
This variety is created during splicing when exons of a particular gene are either included or excluded 
from the mature mRNA ("alternative splicing"). Additional maturation steps modify the 5’ end with a 
7-methylguanosine "cap" (m7G) and the 3’ end with a polyadenylated "tail" (Colgan and Manley 
1997, Shatkin and Manley 2000).  
The spliceosome is a large RNA-protein complex comprised of five major RNA-protein subunits, the 
small nuclear ribonucleoprotein (snRNP) particles, and an additional group of non-snRNP trans-acting 
factors. Each of the snRNP subunits consists of one or two (in case of the U4/U6 di-snRNP) uridine-
rich small nuclear RNAs (U1, U2, U4, U5, U6 snRNA), common proteins and a set of specific 
proteins (Wahl, Will et al. 2009). Within the spliceosome these subunits contribute to an intricate 
network of RNA-RNA, RNA-protein and protein-protein interactions. 
1.1 Pre-mRNA structure 
When various organisms are compared, pre-mRNAs are found to vary dramatically in number and 
length of introns. In the yeast Saccharomyces cerevisiae less than 5% of the approximately 
6 000 genes are known to have introns. They are generally around 100 nucleotides (nts) 
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long (Spingola, Grate et al. 1999). In contrast, an average human gene (with ca. 20 000 protein-
coding genes in total) contains about 6-9 introns, varying in length from less than 10 to more than 
100 000 nts (Sakharkar, Chow et al. 2004). 
The spliceosome assembles de novo on each individual intron to be spliced. For finding and 
recognizing the precise splicing position, the spliceosome assembly is guided and governed by 
recognition of evolutionarily conserved cis-elements within the pre-mRNA substrate. Recognizing 
these splice sites with high precision is required in order to avoid aberrant splicing products and 
subsequent aberrant proteins. In eukaryotes (e.g. Homo sapiens) these cis-elements are comprised 
of consensus sequences at the 5’ splice-site (5’ss), the branch site (BS) and the 3’ss (Aebi, Hornig et 
al. 1986, Stephens and Schneider 1992) (Figure 1.1). 
 
  
Figure 1.1: Conserved intronic consensus sequences in H. sapiens and S. cerevisiae 
Schematic representation of conserved consensus sequences defining an intron. The branch point adenosine is underlined 
and the poly-pyrimidine tract is indicated by Yn. Y stands for pyrimidines and R for purines. The degree of conservation in 
higher eukaryotes is generally lower than in yeast (Burge, Tuschl et al. 1999). 
Furthermore, regulatory RNA elements called exonic and intronic splicing enhancers (ESE and ISE) 
and silencers (ESS and ISS) are also recognized; these affect all splicing decisions by recruiting trans-
acting protein factors that activate or repress spliceosome assembly at specific sites (Black 2003). 
The 5’ss marks the exon/intron junction at the 5’ end of the intron and includes the conserved 
GU dinucleotide. At the other end of the intron, the 3’ss region has the following conserved 
sequence elements: the BS with the highly conserved BS-adenosine, followed by a pyrimidine-rich 
region called the poly-pyrimidine tract (PPT), followed by the terminal AG dinucleotide (Reed 1989). 
The PPT plays an important regulatory role in the early stage of spliceosome formation, ensuring the 
fidelity of splice-site recognition (Coolidge, Seely et al. 1997). In human pre-mRNAs the branch point 
is usually located 18-40 nts upstream of the 3’ss (Zhang 1998), while in yeast the BS-A is usually 10-
40 nts upstream of the 3’ss (Spingola, Grate et al. 1999). 
There are two types of introns in higher eukaryotes, so-called U2- and U12-introns, which are 
removed by two different spliceosomes. The U12-type introns, which are not very abundant (less 
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than 1 % of introns in human), have more highly conserved 5’ss and BS (Figure 1.1). The consensus 
sequences are recognized during splicing by multiple snRNAs and proteins, ensuring the fidelity of 
splice-site definition.  
1.2 The two-step mechanism of splicing 
The excision of pre-mRNA introns requires two sequential transesterification reactions (Peebles, 
Perlman et al. 1986, Moore and Sharp 1993). The 2’-hydroxyl group of the BS-A performs a 
nucleophilic attack at the phosphodiester bond of the 5’ss (Figure 1.2). 
 
 
Figure 1.2: Chemistry of the splicing reaction 
Two consecutive transesterification reactions lead to the excision of the intron with a lariat structure and the joining of the 
5’ and 3’exons. 
This first reaction results in a free 5’ exon and a lariat intermediate, the latter containing the intron 
and the downstream 3’ exon. The BS-A and the G at the 5’ end of the intron are connected by 
a 2'-5' phosphodiester bond. The second reaction occurs by the nucleophilic attack on the 3’ss by 
the free 3’ hydroxyl of the 5’ exon, leading to the spliced mRNA and intron lariat. Splicing of group II 
introns uses the same reaction mechanism producing the same intermediates and products. 
The resulting free intron lariat is debranched and degraded, while the spliced mRNA is transported to 
the cytoplasm. Pre-mRNA splicing requires ATP hydrolysis during several steps of spliceosomal 
assembly and structural rearrangements. 
1.3 U snRNPs, the major building blocks of the human spliceosome 
The major (U2-type) spliceosome is formed through the interaction of five snRNPs (U1, U2, U5, 
U4/U6). Each snRNP contains a uridine-rich small nuclear RNA (U snRNA) (two in the case of the 
U4/U6 snRNP) and a variable number of proteins. A common set of proteins is made up by the seven 
Sm or Sm-like (LSm) proteins. U1, U2, U4 and U5 snRNA, but not U6, contain a binding site for the Sm 
proteins that is characterized by high uridine content. The seven Sm proteins bind to this single-
stranded RNA stretch of the Sm site and form a ring-like protein structure (Guthrie and Patterson 
1988, Will and Luhrmann 2001). SnRNAs with Sm-binding sites are transcribed by RNA polymerase II 
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as precursors containing a m7G-cap and share a common maturation pathway undergoing multiple 
maturation steps including export to the cytoplasm (Matera, Terns et al. 2007, Matera and Wang 
2014). The maturation of these snRNAs requires export to the cytoplasm, where the Sm-proteins B, 
D1, D2, D3, E, F and G are assembled on a uridine-rich stretch of the respective snRNA in a ring-like 
structure. Following the assembly of the Sm ring, the m7G-cap is hypermethylated to a 2, 2, 7-
trimethylguanosine cap and the 3’ end of the snRNAs is trimmed. The Sm core and the 
hypermethylated cap then induce the re-import of the spliceosomal snRNAs into the nucleus for 
further maturation (Fischer, Sumpter et al. 1993). The newly imported snRNPs transiently 
accumulate in Cajal bodies, where they undergo site-specific pseudouridylation and 2′-O-methylation 
directed by scaRNAs (Kiss 2004). 
The U6 snRNA, in contrast, does not bind Sm proteins, but rather LSm proteins. It is transcribed by 
RNA polymerase III, whose transcripts are characterized by a -monomethyl cap. The U6 snRNP does 
not assemble an Sm ring; instead, seven LSm (LSm 2-8) proteins assemble into a similar heptameric 
ring-like structure at the 3’ end of U6 snRNA (Achsel, Brahms et al. 1999). The biogenesis and 
maturation of U6 snRNA are confined to the nucleus. During its maturation, the U6 snRNA also 
undergoes site-specific pseudouridylation and 2′-O methylation. However, in contrast to Sm snRNAs, 
internal modification of the U6 snRNA is mediated by small nucleolar RNAs (snoRNAs) (Kiss 2001, Kiss 
2004). 
While the characteristic secondary structures of the snRNAs are highly conserved in all eukaryotes, 
phylogenetic comparison of orthologous snRNAs reveals that U snRNAs from different species have 
high sequence diversity. Although the primary sequence is not conserved, the U4 and U6 snRNAs in 
metazoan as well as in yeast are always extensively base paired, forming a Y-shaped structure (Brow 
and Guthrie 1988, Will and Luhrmann 2006) (Figure 1.3). SnRNA regions involved in interactions with 
the pre-mRNA consensus sequences or other snRNAs, are highly conserved. The proposed secondary 
structures of the human snRNAs are shown in Figure 1.3. These structures are substantially 
rearranged during spliceosome assembly. 
Although human and yeast snRNAs are remarkably similar in their critical secondary structure 
features, there are also some significant structural differences between them. Unlike humans, which 
possess one "long" U5 snRNA (Chanfreau, Elela et al. 1997), yeast has two distinct U5 snRNAs that 
differ only in their length at the 3' end (U5L/S for long and short U5 snRNA). Furthermore, U1 snRNA 
in yeast is significantly longer than its human counterpart (Kretzner, Krol et al. 1990). The most 
dramatic difference is observed in the yeast U2 snRNA. While the structural features of the human 
U2 are retained, yeast U2 displays a huge (non-essential) insertion of 945 nucleotides replacing the 
human stem loop III immediately downstream of the Sm site. 
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Figure 1.3: Sequences and predicted secondary structures of the human spliceosomal snRNAs 
The proposed secondary structures of the human snRNAs. U4 and U6 snRNAs are extensively base paired, forming a Y-
shaped structure. The Sm-sites are indicated as black boxes. 
The minor U11, U12, U4atac and U6atac snRNAs, functional analogues of the major snRNAs, also 
show high level of similarity in secondary structure fold, despite only limited sequence homology and 
a lower degree of conservation of their sequence (Tarn and Steitz 1996). 
In addition to the group of common proteins, the other important group of protein constituents of 
snRNPs is that of the particle-specific proteins. The human U1 snRNP contains only three particle-
specific proteins, U1-70K, U1-A and U1-C (Hinterberger, Pettersson et al. 1983, Bringmann and 
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Luhrmann 1986). This composition results in an observed Svedberg (S) value of 12S. U1-C is involved 
in stabilization of the initial base pairing interactions between U1 snRNA and the 5’ss of 
the pre-mRNA (Heinrichs, Bach et al. 1990), whereas U1-70K interacts with SR proteins to stabilize 
the interaction of U1 snRNP with the pre-mRNA (Kohtz, Jamison et al. 1994). 
The human 17S U2 snRNP is composed of proteins U2-A’, U2-B’’ and the heteromeric sub-complexes 
SF3A and SF3B. First the U2-A' and U2-B'' proteins bind to stem loop IV of U2 snRNA as a dimer, thus 
forming a 12S U2 snRNP. The SF3A and SF3B proteins help to stabilize the base pairing between the 
U2 snRNA and the BS by interactions with the pre-mRNA around the BS (Krämer and Utans 1991, 
Gozani, Feld et al. 1996, Valcárcel, Gaur et al. 1996), whereas SF3B6 (p14) can be crosslinked to 
the BS-A (Will and Luhrmann 2001). The SF3A complex consists of three subunits with molecular 
weights of 120, 66 and 60 kDa (hereinafter termed SF3A1, SF3A2and SF3A3, respectively) (Brosi, 
Hauri et al. 1993), whereas the SF3B complex consists of seven subunits (SF3B155, SF3B145, 
SF3B130, SF3B49, SF3B10, SF3Bp14 and SF3B14b) (hereinafter termed SF3B1 – B6 and PHF5A, 
respectively) (Will, Urlaub et al. 2002). Additionally, a set of protein factors has been identified as 
the U2-related proteins. This set of proteins, including hPrp43, Spf45, Spf30, Spf31, SR140, CHERP, 
PUF60, hPrp5 as well as the U2AF65/35 heterodimer, is loosely associated with the 17S U2 snRNP 
(Will, Urlaub et al. 2002). 
 
Figure 1.4: Composition of the spliceosomal U snRNPs 
Each snRNP consists of one (or two) snRNA molecules and different numbers of complex-specific proteins. The secondary 
structure of the human U snRNAs is shown schematically. The protein composition of the U snRNPs is shown in boxes of 
different colors. The U4/U6.U5 tri-snRNP is composed of U5 and U4/U6. Sm/Lsm proteins are shown in gray boxes. Protein 
names are indicated according to yeast (human) nomenclature. “h” stands for “human”.   
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The 20S U5 snRNP harbors eight particle-specific proteins, hPrp8, hBrr2, hSnu114, hPrp6, hPrp28, 
hLin1, 40K and hDib1 (Bach, Winkelmann et al. 1989). The hPrp8 protein is the largest protein in the 
spliceosome and was shown to be in contact with the 5’ss, 3’ss and the BS at different time points of 
the splicing cycle (Teigelkamp, Newman et al. 1995, Teigelkamp, Whittaker et al. 1995, Reyes, Kois et 
al. 1996, Reyes, Gustafson et al. 1999, McPheeters and Muhlenkamp 2003, Grainger and Beggs 
2005). The U5-specific proteins hPrp28 and hBrr2 are RNA helicases were identified as crucial players 
during formation of the pre-catalytic spliceosome and its subsequent activation, respectively 
(Raghunathan and Guthrie 1998, Laggerbauer, Liu et al. 2005). hBrr2 unwinds the U4/U6 di-snRNP 
during spliceosome activation, hPrp28 instead displaces the U1 snRNP from the 5'ss (Strauss and 
Guthrie 1994, Möhlmann, Mathew et al. 2014). The U5-specific proteins hPrp8 and hSnu114 have 
been shown to regulate hBrr2 activity (Small, Leggett et al. 2006, Maeder, Kutach et al. 2009, 
Mozaffari-Jovin, Wandersleben et al. 2013, Mozaffari-Jovin, Wandersleben et al. 2014).  
The U4/U6 di-snRNP is associated with the five specific proteins hPrp3, hPrp31, hPrp4, CypH and 
hSnu13, resulting in an S value of 13S (Behrens and Luhrmann 1991, Lauber, Plessel et al. 1997). 
Upon association of the 13S U4/U6 di-snRNP with the 20S U5 snRNP the 25S U4/U6.U5 tri-snRNP is 
formed, which additionally gains three tri-snRNP-specific proteins hSnu66, hSad1 and 27K (Black and 
Pinto 1989, Behrens and Luhrmann 1991). The U5-specific protein hLin1 is proposed to play a role 
during assembly of this 25S particle, but it is no longer present in the mature U4/U6.U5 tri-snRNP 
(Laggerbauer, Liu et al. 2005). The assembly of the U4/U6.U5 tri-snRNP appears to be mediated 
mainly through protein-protein interactions. The proteins hPrp6 and hPrp31 are important bridging 
factors, as removal of either protein abolishes U4/U6.U5 tri-snRNP formation in vitro and in vivo 
(Makarova, Makarov et al. 2002, Schaffert, Hossbach et al. 2004). 
1.4 Dynamic assembly pathway of the spliceosome 
Spliceosome assembly occurs by the ordered interaction of the five snRNPs and numerous splicing 
factors with the pre-mRNA. The spliceosome assembles de novo on each intron and follows a 
sequence of defined stages (Figure 1.5). Assembly and remodeling of the spliceosome during the full 
splicing cycle creates the catalytic center for intron excision and ligation of exons. The dynamic 
assembly and dismantling of the spliceosome requires several different driving forces and control 
mechanisms, which are provided by DExD/H-box ATPases or RNA helicases, a group of important 
non-snRNP proteins (Wahl, Will et al. 2009, Cordin, Hahn et al. 2012). These molecular motors use 
the energy of nucleoside triphosphate (NTP) hydrolysis for the rearrangement of RNA-RNA and RNA-
protein interactions modulating the structure and function of specific RNAs and/or RNPs (Staley and 
Guthrie 1998, Pyle 2008). Eight DExD/H-box helicases (human/yeast: UAP56/Sub2, DDX46/Prp5, 
hBrr2/Brr2, DHX16/Prp2, DDX23/Prp28, DHX38/Prp16, DHX8/Prp22 and DHX15/Prp43), conserved 
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between humans and yeast, are sufficient to drive splicing in S. cerevisiae, whereas spliceosomes of 
higher eukaryotes possess four additional helicases: SF3B125, Aquarius (Aqr), Abstrakt, and DHX35 
(De, Schmitzova et al. 2016). 
 
Figure 1.5: Stepwise assembly of the human spliceosome 
Schematic representation of splicing cycle. For simplicity the U snRNPs are represented as circles labeled with its respective 
U snRNA. The spliceosomal complexes are named according to the metazoan nomenclature. The eight conserved 
DExD/H-box ATPases/helicases, which are required for important RNP remodeling events, are indicated. Exons and introns 
are indicated as colored boxes and bold lines, respectively [modified from Will and Lührmann, 2011]. 
Assembly of the spliceosome is initiated by recognition of the 5’ss by the U1 snRNP (Figure 1.5). At 
the same time, SF1 and U2AF65/35 bind to the BS and the PPT/3’ss, respectively (Ruskin, Zamore et 
al. 1988, Berglund, Chua et al. 1997). These associations lead to the formation of the so-called 
E complex (Reed 1990). The U2 snRNP is already present in the E complex, but an ATP-dependent 
rearrangement mediated by the RNA helicase Prp5 is required to establish a firm interaction of 
U2 snRNP with BS, which results in formation of the A complex (Dalbadie-McFarland and Abelson 
1990, Fleckner, Zhang et al. 1997). These interactions involve base pairing of the U2 snRNA with 
the BS, which leads to the "bulging-out" of the BS-A and interactions of the U2-SF3A/B proteins near 
the BS. The BS-A is directly contacted by the SF3B6 protein (Query, Moore et al. 1994, Will and 
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Luhrmann 2001). Moreover, SF3B1 not only interacts with the pre-mRNA, but also with U2AF65 to 
stabilize the binding of U2 snRNP to the pre-mRNA (Gozani, Potashkin et al. 1998). Thus, the 
recognition of several splicing signals is a general mechanism of spliceosome assembly and splicing 
catalysis that ensures splicing accuracy. 
Next, the U4/U6.U5 tri-snRNP is recruited to the spliceosome, forming a 37S pre-B complex, in which 
the tri-snRNP is only loosely bound (Boesler, Rigo et al. 2016). Stable integration of the U4/U6.U5 tri-
snRNP into the spliceosome requires the action of Prp28, which destabilizes the binding of U1 snRNP 
and yields the B complex. During stabilization of the B complex the U4/U6.U5 tri-snRNP associated 
factors hPrp31 and hPrp6 are phosphorylated by the hPrp4 kinase, which was shown to be essential 
for pre-mRNA splicing in vitro (Schneider, Hsiao et al. 2010). The B complex is still in a catalytically 
inactive state. Activation of the spliceosome is initiated by the RNA helicase Brr2, which leads to the 
dissociation of U4 snRNP from the spliceosome and to the formation of the activated spliceosome or 
Bact complex (Laggerbauer, Achsel et al. 1998, Raghunathan and Guthrie 1998). 
Subsequent action of the helicase Prp2 then transforms the Bact spliceosome into a catalytically 
activated state, the so-called B* complex, which carries out the first step of splicing, resulting in 
the C complex. The C complex contains the excised 5’ exon and the 3’ exon-intron lariat 
intermediate. Upon the action of the RNA helicase Prp16 the spliceosome undergoes another 
structural rearrangement, yielding the intermediate complex C*, which performs the second step of 
splicing (Umen and Guthrie 1995). During the second step, the lariat intron is excised and the 5’ and 
3’ exons are ligated. Prp22 is needed for the release of the spliced mRNA from the intron-lariat 
spliceosome (Company, Arenas et al. 1991) and the mRNA is exported to the cytoplasm. Finally, 
Prp43 RNA helicase promotes the disassembly of the intron-lariat spliceosome, and the released 
snRNPs are reshuffled for a fresh round of splicing and the intron is degraded (Martin, Schneider et 
al. 2002, Fourmann, Schmitzova et al. 2013). 
1.5 The dynamic network of spliceosomal RNA-RNA interactions and RNA-
metal-mediated catalysis of pre-mRNA splicing 
During spliceosome assembly an intricate network of RNA-RNA interactions involving snRNAs and 
the pre-mRNA substrate is established (Wahl, Will et al. 2009, Will and Luhrmann 2011). This 
network of RNAs undergoes significant rearrangements during the spliceosome's transition from one 
distinct type of complex to the next. Spliceosome assembly is initiated by the recognition of the 5’ ss 
through base-pairing interactions with the 5’ end of U1 snRNA (see Figure 1.6) (Zhuang and Weiner 
1986) and the formation of a base-pairing interaction of the U2 snRNA with the BS (Parker, Siliciano 
et al. 1987, Wu and Manley 1989). In the short U2/BS helix, the BS-A is branched out. In the 37S 
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pre-B complex the 3' end of the U6 snRNA is base-paired to the 5' end of the U2 snRNA, forming the 
U2/U6 helix II (blue in Figure 1.6). In the pre-B complex, U1 snRNA is still base-paired to the 5’ ss and 
the tri-snRNP is not yet stably bound. Within the tri-snRNP the U4 and U6 snRNA are base-paired and 
form a Y-shaped structure composed of stems I and II and the U4 snRNA internal stem-loop. 
The ACAGA sequence directly upstream of stem I within the U6 snRNA (the so-called ACAGAG box) is 
highly conserved. 
 
Figure 1.6 Rearrangements of the RNA-RNA network during formation of a catalytically activated spliceosome 
The exons are shown as rectangular boxes. The RNA molecules are depicted as black and grey lines respectively. Important 
RNA sequences that are involved in dynamic base-pairing interactions are depicted in colour. See the text for the detailed 
explanation. 
For stable integration of the tri-snRNP into the spliceosome, Prp28 removes the U1 snRNA from 
the 5’ss, allowing the latter to base-pair with ACAGA-box of the U6 snRNA (violet in Figure 1.6). In the 
B complex the stem-loop I of U5 snRNA interacts with the 3’ terminal nucleotides of the 5’ exon. The 
U5 loop I plays a role also later, in the positioning of both exons for both steps of splicing (Grainger 
and Beggs 2005). Activation of the pre-catalytic B complex by Brr2 helicase leads to the disruption of 
the U4/U6 base-pair interactions and the displacement of U4 snRNP from the spliceosome. U6 
snRNA is now restructured, forming the intramolecular stem-loop (U6 ISL), and engages in new base-
pair (bp) formation with U2 snRNA, yielding the U2/U6 helices Ia and Ib. (Figure 1.6) (Madhani and 
Guthrie 1992). The Bact complex is then catalytically activated by Prp2 RNA helicase, yielding the B* 
complex, which can catalyze the first step of the splicing reaction. Biochemical and genetic studies in 
yeast have provided strong evidence that within the Bact complex a catalytic U2/U6 RNA-RNA 
interaction network is assembled that is highly similar to the catalytic RNA network of group II self-
splicing introns (Fica, Tuttle et al. 2013), and this was recently further confirmed by cryo-EM 
structures of yeast and human spliceosomes (Rauhut, Fabrizio et al. 2016, Yan, Wan et al. 2016). 
Thus, similar to the catalytic domain V of group II introns, the U2/U6 helix Ib and the U6 ISL adopt a 
secondary structure in which a conserved AGC triad is situated 5 bp away from a conserved bulged-
out nt in U6 (U6-U80 in S. cerevisiae). Moreover, the U6 catalytic metal ligands, situated in the triad 
and the bulge, correspond one-to-one to the domain V ligands (Figure 1.7). Finally, similar to the 
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group II intron catalytic core, a group II-like triple helix also appears to form in U6 snRNA to juxtapose 
the two metal binding sites at the U6-U80 bulge loop and the AGC triad.  
 
Figure 1.7 Model for catalytic metal interactions 
Catalytic metal interactions during domain V hydrolysis (A) and pre-mRNA splicing (B). The reactive oxygens are colored 
red, the pre-mRNA scissile phosphate is depicted in a transition state, and interactions between specific ligands and the 
reactive oxygens mediated by M1 and M2 are shown as light magenta dashed lines. Modified from Fica et. al., 2014. 
(C) 3D model of the catalytic triad, which comprises the ISL of U6 snRNA and helix I of the U2/U6 duplex (PDB 3JB9, Hang et 
al., 2015) 
In yeast, this spliceosomal triplex comprises Hoogsteen interactions of the terminal G52 and A53 of 
the conserved U6 ACAGA box with nucleotides G60 and A59, and of U6-U80 with C61 of the AGC 
triad. Cryo-EM 3D structures of the S. cerevisiae Bact complex demonstrated that this intricate 
catalytic U2-U6 RNA network is already in place in the activated spliceosome (Rauhut, Fabrizio et al. 
2016, Yan, Wan et al. 2016). Moreover, the cryo-EM 3D structures of the yeast C complex (Galej, 
Wilkinson et al. 2016, Wan, Yan et al. 2016), the yeast and human C* complexes, which are activated 
for catalysis of step II of splicing (Bertram, Agafonov et al. 2017, Fica, Oubridge et al. 2017, Yan, Wan 
et al. 2017) and of the S. pombe intron-lariat spliceosome (ILS) (Hang, Wan et al. 2015, Yan, Hang et 
al. 2015), revealed that the catalytic U2-U6 RNA core exhibits a similar overall 3D structure during the 
two catalytic phases of the spliceosome. 
1.6 Non-snRNP proteins of the spliceosome 
The isolation of spliceosomal complexes representing distinct snapshots of the full spliceosomal 
cycle, combined with mass-spectrometric analysis, identified a large number of so-called non-snRNP 
proteins (Will and Luhrmann 2006). These include the groups of early splicing proteins and the 
spliceosomal RNA helicases discussed above. Altogether, more than 170 proteins have been 
identified in the human spliceosome, while only about 90 proteins have been detected in yeast 
spliceosomal complexes (including snRNP proteins). Interestingly, the vast majority of the yeast 
spliceosomal proteins have counterparts in the human spliceosome, indicating that the yeast 
spliceosome is the evolutionarily conserved core design of the splicing machinery. In the following, 
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emphasis is placed on the description of the non-snRNP proteins of the activated spliceosome, as 
these play an important role in the generation of a functionally active U2/U6 catalytic RNA core and 
will be discussed in detail in the cryo-EM structure of the human Bact complex in the results section 
below. Moreover, several of the non-snRNP proteins of the Bact complex are pre-organized into stable 
multimeric protein complexes.  
In yeast, a major protein complex is represented by the so-called NineTeen Complex (NTC). All but 
two of the NTC proteins are evolutionarily conserved in humans; however, they are pre-organized in 
different sub-complexes. For example, the human NTC proteins Cdc5, Prl1, AD002, Spf27 (yeast 
analogues: Cef1, Prp46, Cwc15 and Snt309, respectively) and hPrp19 are present in the human 
hPrp19/Cdc5L complex, which in addition contains the CTNNBL1 and Hsp73 proteins. The NTC 
proteins Isy1 and Syf1 are part of the so-called intron binding complex (IBC) which also contains 
the RNA helicase Aqr, the cyclophilin E (CypE) and CCDC16 (De, Bessonov et al. 2015) (Figure 1.8). 
 
Figure 1.8 Organisation of yeast NTC proteins and their human analogues 
In yeast, 10 proteins are recruited as a pre-formed complex (left). Ntc20 is depicted in dark red, it has no counterparts in 
human. Proteins depicted in orange are human-specific. Human proteins are pre-organised into two major building blocks. 
The human homologues of the S. cerevisiae NTC complex proteins, Skip (hPrp45), Crnkl1 (hSyf3) and 
hSyf2, are not part of the human Prp19/Cdc5L or IBC complexes (Figure 1.8). Except for hSyf2, which 
is recruited first to the human C complex, all other proteins are recruited to the Bact spliceosome and 
play an important role in the formation of the catalytic U2/U6 RNP core (see below). 
The heterotrimeric RES (for REtention and Splicing) complex is a conserved spliceosome-associated 
protein module that was shown to enhance the splicing of a subset of transcripts and to promote the 
nuclear retention of unspliced pre-mRNAs in yeast (Gottschalk, Bartels et al. 2001, Dziembowski, 
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Ventura et al. 2004). The human homologues of the yeast RES complex subunits, hBud13, Snip1 
(hPml1) and RbmX2 (hSnu17) associate stably with the spliceosome during its activation phase 
(Deckert, Hartmuth et al. 2006, Bessonov, Anokhina et al. 2008, Bessonov, Anokhina et al. 2010). 
Additional proteins that associate with the human activated spliceosome are KIAA1604 (hCWC22), 
Rnf113A (hCwc24), hPrp17, CCDC12, Rbm22, G10 (hBud31), PRCC, the cyclophilins PPIL1, PPIL2, and 
NY-CO-10 (hCwc27), and the exon junction complex (EJC) proteins eIF4A3, Y14 and Magoh 
(Bessonov, Anokhina et al. 2010) (Figure 1.9). 
Several of the proteins that are recruited to the Bact complex are later displaced from the 
spliceosome. Also, other defined sets of non-snRNP proteins are transiently recruited to other 
assembly intermediates of the spliceosome, as will be discussed below. 
Finally, another important group of non-snRNP splicing factors regulating splicing activity and 
modulating alternative splicing, consist of two families of proteins. The first is represented by 
serine/arginine-rich (SR) proteins. SR proteins share common structural features, such as one or 
more amino-terminal RNA recognition motif(s) (RRMs) and a variable number of arginine/serine (RS) 
repetitive dipeptides in their carboxy-terminal domain (Birney, Kumar et al. 1993, Graveley 2000, 
Long and Caceres 2009). Therefore, these proteins can interact at the same time with both RNA 
through their RRM domains and with other proteins through their RS domain (Graveley and Maniatis 
1998). For example, the recognition of ESE regions of a pre-mRNA by SR proteins promotes 
spliceosome assembly at adjacent splice sites. SR proteins can also promote snRNP interactions with 
the pre-mRNA, such as stabilization of the U1/5′ss base-pairing interaction at the initial stage of 
splicing assembly, and thus modulate alternative splicing events (reviewed in Graveley, 2000). RS 
domains are also found in non-SR proteins, for instance, in U2AF subunits (Zamore, Patton et al. 
1992).  
Members of the second family, the hnRNP proteins, have antagonistic effects on splice site usage. 
Most hnRNP proteins have RRMs and glycine-rich domains (RG) and regulate alternative splicing. 
They bind to ESS elements of the pre-mRNA and impede/obstruct exon recognition by hindering the 
use of neighboring splice sites. HnRNP proteins counteract the positive regulators of splicing and/or 
recruit factors that block splicing, thereby initiating splicing repression/silencing (Smith and Valcarcel 
2000). 
1.7 The dynamics of the protein composition of the human spliceosome 
Proteins account for the largest share of the spliceosome's mass and play important roles throughout 
the entire splicing cycle. They enable all conformational and structural rearrangements needed for 
the catalytic activity of the spliceosome. A total of more than 170 different spliceosome-associated 
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proteins were identified in affinity-purified human spliceosomal complexes, with each complex 
containing approximately 120 different proteins (Wahl, Will et al. 2009). Mass spectrometry analysis 
of purified spliceosomes confirms that the protein composition of the spliceosome is highly dynamic, 
with extensive changes of the protein inventory from one splicing step to the next (Deckert, 
Hartmuth et al. 2006, Behzadnia, Golas et al. 2007, Bessonov, Anokhina et al. 2008, Fabrizio, 
Dannenberg et al. 2009). Validation of quantitative changes of proteins was furthermore helped by 
2D gel electrophoresis (Agafonov, Deckert et al. 2011).  
 
Figure 1.9: Compositional dynamics of the human spliceosome  
The protein composition of the human B, Bact, and C complexes based on 2D gel-electrophoresis and mass spectrometry 
analysis is shown. The relative abundance of proteins is indicated by bold (stoichiometric amounts) or light 
(substoichiometric amounts) lettering. Proteins are grouped according to snRNP association, function and presence in a 
stable heteromeric complex or association with a particular spliceosomal complex, as indicated.  
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In the following paragraphs, I will summarize the dynamic behavior only of the most abundant 
proteins that are found in the purified human B, Bact and C complexes (Figure 1.9). Stable 
B  complexes, which have been isolated in the presence of ATP-γ-S (Agafonov, van Santen et al. 
2016), contain all the U2 and tri-snRNP proteins, except that Prp28, Rbm42 and Sad1 are already 
largely absent. On the other hand, a set of 8 proteins, termed B-specific proteins, RED, Smu1, Mfap1, 
Fbp21, hPrp38, hSnu23, Npw38 and Npw38BP have been recruited to the stable B complex, and 
these are not present in the 37S pre-B complex. Moreover, small amounts of the hRES complex 
proteins are also present (Agafonov, Deckert et al. 2011, Boesler, Rigo et al. 2016).  
The most dramatic exchange of proteins occurs during the transition from the B complex to the 
activated spliceosome. On the one hand, all of the U4/U6 specific proteins, the tri-snRNP proteins 
and the U5 proteins hPrp6 and hDib1, most of the B-specific proteins, as well as some A complex 
proteins are largely absent from the Bact complex. On the other hand, the hPrp19/CDC5L and IBC 
complex proteins and all other Bact proteins mentioned above, as well as hPrp2 and its co-activator 
GPKOW, are stably recruited to the Bact complex. Moreover, the RES proteins and the EJC proteins 
eIF4A3, Y14 and Magoh are also present in significant amounts in the Bact complex (Figure 1.9).  
In contrast to yeast, the catalytic activation of the human Bact complex to the B* complex has not yet 
been investigated, nor has the hB* complex been isolated. In yeast, Prp2 and its co-activator are 
sufficient to transform the Bact into the B* complex. This is accompanied by major RNP-remodeling 
events. For example, the yeast Bact proteins Cwc24 and Cwc27, as well as part of the RES proteins are 
displaced from the spliceosome (Warkocki, Odenwälder et al. 2009, Ohrt, Prior et al. 2012). 
Moreover, the U2 SF3A/B proteins are destabilized and their association with the spliceosome 
becomes salt-sensitive (Warkocki, Odenwälder et al. 2009, Lardelli, Thompson et al. 2010, Ohrt, Prior 
et al. 2012). As in the human C complex Rnf113A and NY-CO-10 are also largely underrepresented 
and the U2 SF3A/B proteins are likewise destabilized, it is reasonable to assume that these 
remodeling events also occur in the human spliceosome, already during the catalytic activation 
process (Bessonov, Anokhina et al. 2010). However, there is evidence that the catalytic activation 
process of human Bact complexes is more complex than in yeast. For example, the ATPase activity of 
the RNA helicase Aqr, which is absent in S. cerevisiae, is also required for generating a human B* like 
complex (De, Sessonov et al. 2015). Moreover, at least two DExH/D box RNA helicases are abundant 
in the purified human C complex, and it is not known whether one or both of these proteins may also 
play a role in B* formation.  
The protein composition of the purified human C complex differs significantly from that of the Bact 
complex. In addition to Rnf113A and NY-CO-10 also Ccdc12, Ccdc16, Ppil2 and hPrp2 and its 
coactivator GPKOW are largely absent in the C complex. On the other hand numerous proteins, 
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including the RNA helicases Abstrakt and DDX35, the cyclophilins Ppil3b and and Ppwd1, the step 2 
factors hSlu7, hPrp18 and hPrp22, and the proteins Cactin, Cxorf56 and Fam32A are first recruited to 
the C complex. While these represent the more abundant C complex-specific proteins, several others 
are also present in C complexes but are clearly sub-stoichiometric (Bessonov, Anokhina et al. 2008, 
Agafonov, Deckert et al. 2011). 
1.8 3D structures of snRNPs and spliceosomes 
Until very recently, the molecular architecture and three-dimensional (3D) organization of the 
spliceosome remained only poorly understood. A number of high resolution 3D structures of several 
larger protein domains or protein-protein and protein-RNA complexes were obtained primarily by 
X-ray crystallography. These include, among others, the helicase domain of Brr2 (Santos, Jovin et al. 
2012, Nguyen, Li et al. 2013), parts of Prp8 (Pena, Liu et al. 2007, Pena, Rozov et al. 2008, Ritchie, 
Schellenberg et al. 2008, Yang, Zhang et al. 2008, Galej, Oubridge et al. 2013), various U4 (Li, Leung et 
al. 2016) and U6 RNA-protein complexes (Montemayor, Curran et al. 2014) and even recombinantly 
produced (Kondo, Oubridge et al. 2015) or native U1 snRNPs (Pomeranz Krummel, Oubridge et al. 
2009). However, for a large ensemble such as the spliceosome, which contains many flexible parts, 
crystallisation appears to be a major challenge if not unreachable. Therefore, cryo-EM is the method 
of choice for studying the structures of large RNP complexes.  
 Low to medium-resolution (12–40 Å) 3D cryo-EM structures of the human pre-spliceosomal A, 
spliceosomal B and C complexes (Boehringer, Makarov et al. 2004, Jurica, Sousa et al. 2004, 
Behzadnia, Golas et al. 2007), as well as some of their building blocks such as the U1 snRNP (Stark, 
Dube et al. 2001), the U2-associated SF3B protein complex (Golas, Sander et al. 2003, Golas, Sander 
et al. 2005), or the U4/U6.U5 tri-snRNP were initially reported. Moreover, immuno-labeling of 
spliceosomal components was used to assign major building blocks in the low resolution structures 
of the spliceosome (Stark and Lührmann 2006). 
Recently, mainly owing to the invention of direct detectors and powerful software packages, a 
revolution has taken place in the EM field, allowing the near-atomic resolution of large molecular 
ensembles (Kühlbrandt 2014). A first breakthrough was achieved by the group of Yigong Shi, who 
determined the structure of the major part of the endogenous intron-lariat spliceosome from 
S. pombe (Hang, Wan et al. 2015, Yan, Hang et al. 2015). This provided, for the first time, molecular 
insight into the organisation of the catalytic RNP core of the spliceosome. First of all, it proved that 
the catalytic U2/U6 RNA network adopts a three-dimensional structure very similar to that of the 
catalytic RNA core of group II self-splicing introns, including the existence of the catalytic triplex (Fica, 
Mefford et al. 2014). Moreover, the two catalytic Mg2+ ions were coordinated by nucleotides of the 
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catalytic triplex, which is consistent with biochemical results obtained by phosphorothioate 
substitutions (Fica, Tuttle et al. 2013). Secondly, the cryo-EM structure not only revealed the atomic 
structure of the entire Prp8 protein, but also demonstrated that Prp8 forms an active site, made up 
by the N-terminal domain and part of its central domain, into which the catalytic U2/U6 RNA 
network is docked. In addition, about 10 proteins or major parts thereof, many of them belonging to 
the NTC, interact with the catalytic RNA network, providing clear evidence that a functional catalytic 
U2/U6 RNA structure can only exist as part of this RNP core. Another interesting structural feature of 
the ILS complex is the existence of a helical bundle comprising the coiled-coil domain of the four 
Cwf8 (Prp19) copies, a long C-terminal alpha helix of Cdc5 and a long alpha-helical part of Cwf7 
(Spf27), which was connected to the main body of the spliceosome by small bridges (Yan, Hang et al. 
2015) (Figure 1.10). 
 
 
Figure 1.10: 3D cryo-EM structures of the intron-lariate spliceosome from S. pombe and Bact complex from S. cerevisiae 
EM structures of S. pombe intron-lariat (A) and S. cerevisiae activated spliceosomes (B), modified from Yan et al., 2015, and 
Rauhut et al., 2016, respectively. Position of Prp19 helical bundle in the ILS structure is shown on the left (A). The spatial 
separation of the Prp2 RNA helicase (black, dashed circle) from the U2/BS RNA duplex (red circle) in the Bact spliceosome is 
indicated on the right (B). Proteins and RNA components are colour-coded.  
Most recently, the cryo-EM structures of earlier assembly intermediates of the catalytic cycle of the 
S.cerevisiae spliceosome – such as the B, C and C* complexes, as well as the human C* complex – 
have also been solved (Galej, Wilkinson et al. 2016, Rauhut, Fabrizio et al. 2016, Yan, Wan et al. 2016, 
Bertram, Agafonov et al. 2017, Fica, Oubridge et al. 2017, Plaschka, Lin et al. 2017, Yan, Wan et al. 
2017, Zhang, Yan et al. 2017). Collectively, these structures revealed that the catalytic RNP core not 
only exhibits a very similar structure throughout the catalytic cycle of the yeast spliceosome, but that 
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its structure also reveals many similarities when the yeast and human C* complexes are compared. 
In sharp contrast to the largely stable organisation of U5 snRNA and the U2/U6 catalytic RNP core, 
the 3’ part of U2 snRNA and its Sm core domain is highly mobile and undergoes large-scale 
movement during the catalytic cycle of the spliceosome (Bertram, Agafonov et al. 2017, Plaschka, Lin 
et al. 2017). 
Furthermore, the cryo-EM structure of the yeast-activated spliceosome has shown that the catalytic 
U2/U6 RNP core domain is already largely established in the Bact complex. Moreover, the Bact cryo-EM 
model has provided the structural basis for the earlier biochemical finding that the activated 
spliceosome is still in a pre-catalytic state. That is, the first-step reactants, i.e. the 5’ss and the BS-A, 
were not only occluded by proteins, but in addition were spatially separated by about 5 nm, 
preventing premature first step catalysis. Surprisingly, the Prp2 RNA helicase was found to be 
positioned spatially separated from the U2/BS duplex by more than 7 nm, suggesting that Prp2 
would act from a distance to liberate the first step reactants from their protein clamps, as a pre-
requisite for catalytic activation of the Bact spliceosome (Rauhut, Fabrizio et al. 2016) (Figure 1.10). 
. 
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2 Aims 
During the last two years, high-resolution cryo-EM structures have been published for several 
assembly intermediates of the yeast spliceosome including the B, Bact, C, C* and intron-lariat 
complexes, providing completely new insight into the complex structure of the yeast spliceosome 
and its structural dynamics during the catalytic cycle. However, as of now, only the human 
C* complex has been investigated by cryo-EM. In collaboration with Dr. David Haselbach from the 
Department of Structural Dynamics, MPIbpc, I have used cryo-EM to investigate the 3D structure of 
the human Bact complex. 
Human and yeast activated spliceosomes share a large number of conserved proteins but differ in 
their protein composition in several aspects. Thus, human Bact contains numerous proteins, which are 
conserved in higher eukaryotes but are absent in yeast, including numerous peptidyl-prolyl 
isomerases (PPILs) and the RNA helicase Aquarius (Aqr), which is required for catalytic activation of 
the human spliceosome in addition to Prp2. On the other hand, proteins conserved between yeast 
and human, such as Yju2 and Syf2, are missing from the human Bact spliceosome.  Furthermore, 
conserved proteins of the Prp19/Cdc5L complex are differentially pre-organised in distinct sub-
complexes in yeast and human cells, suggesting that the order of protein recruitment during 
spliceosome activation differs between the two organisms, which together raises the possibility that 
the 3D structure of the human and yeast Bact complexes may differ to some extent. 
The Bact complex was assembled in HeLa nuclear extracts using a pre-mRNA construct, PM5-10, which 
contained the 5’ exon and an intron that is truncated 10 nts after the BS. In the first part of my work, 
I have used affinity-purified Bact complexes for the screening of buffer conditions in a high-
throughput system termed ProteoPlex, to find biochemical conditions, which would stabilize the 
structure of the Bact spliceosome 
After exhaustive 3D multi reference refinement (3D classification) of the human Bact particles, two 
major forms, termed A and B, of the Bact structure were obtained at resolutions of 5.3 Å and 8.1 Å, 
respectively. While their overall structure is largely similar, forms A and B differ with respect to the 
presence/absence of several densities. 
The structure of the central domain of the human Bact complex including the catalytic U2/U6 RNP 
core is highly conserved between the human and yeast spliceosomes. This is also true for the 
architecture of the 5’ss and the U2/BS helix and their occlusion by homologous proteins to prevent 
pre-mature step 1 catalysis of the splicing reaction. However, significant structural differences were 
observed within the peripheral domains of the human Bact structure, including a unique conformation 
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of the U2/U6 helix II. The data are consistent with the possibility that the U2/U6 helix II may have to 
rearrange prior to or during catalytic activation to allow the binding of the conserved Syf2 protein 
close to the rearranged RNA helix. Thus, the catalytic activation process of the human Bact 
spliceosome may be more complex and more regulated than in yeast. 
Finally, while the main forms of the hBact structure obtained by 3D classification share most of the 
structural features, they differ in respect of the presence/absence of densities for several protein 
domains. Experimental evidence further indicates that the absence of a protein density in one of the 
forms is not due to the physical absence of the respective proteins. Instead, the differences indicate 
conformational flexibility of the protein domains. Further evidence indicates that form A is a 
precursor of form B of the Bact structure. Thus, it was possible to capture by cryo-EM analysis two 
conformational states of the human Bact complex that differ in their degree of conformational 
maturation towards the catalytic activation step.  
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3 Materials and methods 
3.1 Materials 
3.1.1 Chemicals 
Acetic acid        Merck, Germany 
Acetobutyrate cellulose in ethyl acetate (Triafol)  Sigma-Aldrich, Germany 
Adenosine triphosphate (ATP)     Amersham Biosciences 
Alkylbenzyldimethylammonium chloride (Osvan solution) Sigma-Aldrich, Germany 
Agarose (low melting point)     Invitrogen, Netherlands 
Agarose        Invitrogen, Netherlands 
Ammonium peroxidisulphate (APS)     Merck, Germany 
Ampicillin        Sigma-Aldrich, Germany 
Bicine (N, N-Bis(2-hydroxyethyl)glycine)   Sigma-Aldrich, Germany 
BisTris (Bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane) Sigma-Aldrich, Germany 
Boric acid        Merck, Germany 
Bromphenol blue       Merck, Germany 
BS3 (Bis[sulfosuccinimidyl]suberate)    Thermo Fisher Scientific, USA 
Coomassie brilliant blue G-250      Serva, Germany 
Creatine phosphate       Sigma-Aldrich, Germany 
Dimethylsulphoxide (DMSO)      Roth, Germany 
di-Potassium hydrogen phosphate     Merck, Germany 
di-Sodium hydrogen phosphate     Merck, Germany 
Dithiothreitol (DTT)       Roth, Germany 
DNA molecular weight marker      Gibco, New Zealand 
EDTA (Disodium salt dihydrate)     Roth, Germany 
Ethanol        Merck, Germany 
Ethidium bromide       Roche, Germany 
Formamide        Merck, Germany 
Glutaraldehyde       Electron Microscopy Sciences, USA 
Glycerol        Merck, Germany 
Glycine        Merck, Germany 
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Glycoblue        Ambion, USA 
Heparin (sodium salt)       Roth, Germany 
HEPES (N-2-Hydroxyethylpiperazin-N-2-ethanesulfonic acid)  Calbiochem, USA 
Hydrochloric acid (HCl)      Merck, Germany 
Isopropanol       Merck, Germany 
IPTG        Merck, Germany 
LB-Agar       Q-Bio-gene, USA 
LB-liquid media       Q-Bio-gene, USA 
Maltose        Merck, Germany 
Magnesium acetate      Merck, Germany 
Magnesium chloride      Merck, Germany 
MES (2-(n-morpholino) ethanesulfonic acid)   Roth, Germany 
Methanol        Merck, Germany 
β-Mercaptoethanol      Roth, Germany 
MOPS        Invitrogen, Netherlands 
PMSF (Phenylmethylsulfonyl fluoride)     Roche, Germany 
Potassium acetate      Merck, Germany 
Potassium chloride       Merck, Germany 
Potassium dihydrogen phosphate     Merck, Germany 
Pre-stained protein-molecular weight marker    Bio-Rad, Germany 
Protease inhibitor tablet, EDTA free    Roche, Germany 
Phenol-chloroform-isoamyl (25:24:1) alcohol (PCI)   Roth, Germany 
Rotiphorese gel 30 solution      Roth, Germany 
Rotiphorese gel 40 solution      Roth, Germany 
Sodium acetate       Merck, Germany  
Sodium chloride      Merck, Germany 
Sodium dodecyl sulfate (SDS)      Serva, Germany 
snRNA marker       In-house 
Sucrose       Merck, Germany 
Spermidine       Sigma-Aldrich, Germany 
SYBR Gold Nucleic Acid Gel Stain    Thermo Fisher Scientific, Germany 
SYPRO orange       Life Technologies 
TERGITOL (Type NP-40) detergent    Sigma-Aldrich, Germany 
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TEMED (N, N, N’, N’-Tetramethylethylendiamine)   Sigma-Aldrich, Germany 
Tris [Tris-(hydroxymethyl)aminomethane]   VWR International, Germany 
Tween 20        Sigma-Aldrich, Germany 
Uranyl formate       In-house 
Urea         Merck, Germany 
Xylene cyanol        Fluka, Switzerland 
3.1.2 Laboratory materials and consumables 
96 well Plates       Bio-Rad, Germany 
Amicon Ultra 0.5 ml, 15 ml (MWCO 50 and 100 kD)  Merck, Germany 
Amylose resin        New England Biolabs, Germany 
Carbon rods, highest grade    Ringsdorff Werke GmbH, Bonn 
Centrifuge tubes       Beranek, Germany  
Copper EM grids, 200 mesh square fine bar   Science Services, Munich, Germany 
Copper EM grids Quantifoil R2/2 and R3.5/1, Cu, 200 mesh Quantifoil Micro Tools GmbH, Jena 
MBPTrap HP Column (1 and 5 ml)    GE Healthcare, Germany 
HiTrap Heparin HP Column (1ml)    GE Healthcare, Germany 
Custom made teflon blocks     in-house 
Dialysis membranes (MWCO 6000-8000 Da)    SpektraPor, USA 
Ethane (liquid)       Messer, Sulzbach, Germany 
Filter paper, 90 mm      Whatman (GE Healthcare) 
Mica, 75x25 mm      Plano, Wetzlar, Germany 
Needles BD Spinal 18GA 3.50 IN 1.2 x 90 mm   Becton Dickinson, Spain 
Nitrocellulose, 0.2 μm      Whatman (GE Healthcare) 
Nitrogen (liquid)      Air Liquide, Paris, France 
NuPAGETM gels (1.5 mm, 4-12%)     Invitrogen, Netherlands 
Parafilm        Roth, Germany 
Pipettes       Eppendorf, Germany 
Pipette tips (1.0, 0.2, 0.01 ml)     Roth, Germany 
Poly-Prep columns       Bio-Rad, USA 
ProbeQuantTM G-25/ G-50 micro columns    GE Healthcare, UK 
Slide-A-Lyzer dialysis units (MWCO 6 kDa)    Pierce, USA 
Sterile filters (0.2 µm or 0.45 µm)     Sarstedt, Germany 
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Microfuge tubes (0.5 ml, 1.5 ml and 2.0 ml)   Eppendorf, Germany 
Microfuge tubes (15 ml und 50 ml)    Sarstedt, Germany 
3.1.3 Commerical kits 
BCA protein assay kit       Pierce, USA 
Bradford Assay       Bio-Rad, Germany 
NuPAGETM gels (1.5 mm, 4-12%)    Invitrogen, Netherlands 
pHClear Screen       Qiagen, Germany 
QIAGEN Plasmid Mini / Maxi Kits    Qiagen, Germany 
3.1.4 Machines 
Autoclaves        H+P Labortechnik, Germany 
Balances       Sartorius, Germany 
Centrifuge Biofuge fresco      Heraeus, Germany 
Centrifuge Biofuge pico      Heraeus, Germany 
Centrifuge Megafuge 1.0R     Heraeus, Germany 
Cryo electron microscope CM200 FEG    Philips, Netherlands 
Cryo electron microscope Titan Krios    FEI, Eindhoven, Netherlands 
Falcon 3EC Direct Electron Detector    Thermo Fisher Scientific, Germany 
FiberLite Fixed Angle Rotor F14-14 × 50    Thermo Fisher Scientific, Germany 
FiberLite Fixed Angle Rotor F14-6 × 250    Thermo Fisher Scientific, Germany 
Fractionator LKB-FRAC-100     Pharmacia Biotech, Sweden 
Fujifilm FLA-7000 laser scanner     FUJIFILM Life Science, USA 
Gel documentation unit      Bio-Rad, Germany 
Gel electrophoresis apparatus      In-house 
Gel dryer model 583       Bio-Rad, Germany 
Glassware       VWR International, Germany 
Gradient master model 106      BioComp Instruments, Canada 
Head-over-tail rotor       Cole-Parmer, USA 
Heating blocks        Eppendorf, Germany 
Ice machine       Ziegra, UK 
Incubators       Heraeus, Germany 
LTQ-Orbitrap Velos      Thermo Fisher Scientific, Germany 
Magnetic Stirrer      IKA Staufen, Germany 
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Microwave oven      Bosch, USA 
Milli-Q-water supply apparatus     Millipore, USA 
Orbitrap Fusion Lumos Tribrid Mass Spectrometer  Thermo Fisher Scientific, Germany 
pH-Meter        Thermo Fisher Scientific, Germany 
Peristaltic Pump P-1      Pharmacia Biotech, Sweden 
Phosphorimager screens     GE Healthcare, Germany 
Phosphorimager Typhoon Trio+    GE Healthcare, Germany 
Pipetting Robot Microlab Star LET    Hamilton, USA 
Power supply EPS 2A200      Hoefer Pharmacia Biotech, USA 
Power supply EPS 3501/XL      Amersham Pharmacia, Germany 
Rocking platform MAX Q3000 and Q2000   Thermo Fisher Scientific, Germany 
Room temperature EM specimen holder   Philips, Eindhoven, Netherlands 
Q Exactive HF Hybrid Quadrupol-Orbitrap Mass Spectrometer Thermo Fisher Scientific, Germany 
Scintillation counter LS 1701      Packard, USA 
Sorvall HB-6 rotor       Kendro, USA  
Sorvall SA800 AT4 rotor      Kendro, USA 
Sorvall SS-34 rotor       Kendro, USA 
Sorvall TH660 rotor       Kendro, USA 
Sorvall TST41.14 rotor       Kendro, USA 
Speed Vac Konzentrator 5301      Eppendorf, Germany 
Spectrophotometer Nanodrop ND-1000    Thermo Fisher Scientific, Germany 
Spectrophotometer Ultrospec 3000 pro    Amersham Pharmacia, Germany 
SureSpin630 Rotor      Thermo Scientific, Germany 
Tabletop centrifuge 5415D      Eppendorf, Germany 
TemCam F415 (slow scan 4K x 4K CCD camera)   Tietz Video Systems, Germany 
Thermomixer       Eppendorf, Germany 
Ultracentrifuge Discovery 90 SE     Sorvall/Kendro, USA 
Ultracentrifuge Discovery M150     Sorvall/Kendro, USA 
Ultracentrifuge Sorvall Evolution RC Lynx 6000   Thermo Scientific, USA 
Ultracentrifuge Sorvall WX ultra 80     Thermo Scientific, USA 
Vitrobot Mark IV      FEI, Eindhoven, Netherlands 
Vortex         Janke & Kunkel, Germany 
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3.1.5 Nucleotides 
Nucleoside-5’-triphosphate (100 mM):    Pharmacia, Germany 
ATP, CTP, UTP, GTP  
Deoxynucleoside-5’-triphsophate (100 mM):   Pharmacia, Germany 
dATP, dCTP, dTTP, dGTP 
7-monomethyl-diguanosine triphosphate   Kedar, Poland 
(m7G(5’)ppp(5’)G-cap) 
 
3.1.6 Radiolabeled nucleotides 
α-32P-UTP [10 µCI/µl, 3000 Ci/mmol]    Perkin-Elmer, Germany 
 
3.1.7 DNA oligonucleotides 
DNA-oligonucleotides RNase H digestions were purchased from IBA, Göttingen, Germany 
Name        Sequence 5’ →  3’  
M6        GGCGGTCTCGTC 
M12        CTCGTCGGCAGC 
 
3.1.8 Enzymes 
Complete protease inhibitor, EDTA-free    Roche, Germany 
Proteinase K        Fluka, Switzerland 
Restriction endonucleases      New England Biolabs, Germany 
RNasin (RNase inhibitor) [40 U/µl]     Promega, USA 
RQ1 DNase [1 U/µl]      Promega, USA 
SP6 RNA polymerase      New England Biolabs, Germany 
T7 RNA polymerase [20 U/µl]     New England Biolabs, Germany 
Sequencing grade trypsin, porcine    Promega, Germany 
Yeast inorganic pyrophosphatase (YIPP) [0.1 U/µl]  New England Biolabs, Germany 
 
3.1.9 Bacteria strains 
E. coli DH5α       Novagen, Germany 
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3.1.10 Cell line 
HeLa S3 cells        GBF, Germany 
(Human adenocarcinoma cell line) 
 
3.1.11 Plasmids 
pMINX U2-dependent pre-mRNA construct (MINX) recloned from pSP65-vector 
under control of SP6 promoter (Zillmann, Zapp et al. 1988) in pUC18-vector 
under control of T7 promoter, AmpR. 
pMS2-MBP   MS2-MBP fusion protein in pMAL vector (NEB), AmpR. 
pPM5-10  U2-dependent pre-mRNA construct (pPM5-10) in pUC18-vector under 
control of SP6 promoter, AmpR (Bessonov, Anokhina et al. 2010). 
 
 
3.1.12 Buffers 
Commonly used media, buffers and solutions were prepared with deionized water (Millipore) and 
autoclaved if necessary (121 °C, 20 min, 1 bar). Solutions with heat-labile components were filter-
sterilized (0.22 µm). 
 
Coomassie staining solution:     100 µM Coomassie G-250 
        0.13 mM (v/v) HCl 
 
6x DNA loading dye:      60 % (v/v) glycerol 
10 mM Tris-HCl, pH 7.5 
        60 mM EDTA, pH 8.0 
0.05% (w/v) bromphenol blue 
        0.05% (w/v) xylene cyanol 
 
10x G-150 buffer:      200 mM HEPES 
        1.5 M KCl 
        15 mM MgCl2 
        Adjust to pH 7.9 
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Fixation buffer:       40% (v/v) Methanol 
        10% (v/v) Acetic acid 
 
1x MBP150 buffer       20 mM HEPES-KOH, pH 7.9 
150 mM NaCl 
0.05% (v/v) NP-40 
 
1x MC buffer:       10 mM HEPES-KOH, pH 7.6 
        10 mM KOAc 
        0.5 mM MgOAc 
        5 mM DTT 
 
5x Native gel loading dye:     1x TBE 
30% (v/v) glycerol 
0.05% (w/v) bromphenol blue 
 
10X PBS (pH 7.4):      1.3 M NaCl 
        160 mM K2HPO4 
40 mM KH2PO4 
 
10X PBS (pH 8.0):      1.3 M NaCl 
        188 mM K2HPO4 
12 mM KH2PO4 
 
2x PK buffer:       200 mM Tris-HCl, pH 7.5 
        25 mM EDTA, pH 8.0 
        2% (w/v) SDS 
 
2x RNA loading dye:      80% (v/v) formamide 
        1 mM EDTA, pH 8.0 
        0.05% (w/v) bromphenol blue 
        0.05% (w/v) xylene cyanol 
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1x Roeder C buffer:      25% (v/v) glycerol 
        20 mM HEPES-KOH, pH 7.9 
        420 mM NaCl 
        1.5 mM MgCl2 
        0.2 mM EDTA, pH 8.0 
        0.5 mM DTT 
        0.5 mM PMSF 
 
1x Roeder D buffer:      10% (v/v) glycerol 
        20 mM HEPES-KOH, pH 7.9 
        100 mM KCl 
        1.5 mM MgCl2 
        0.2 mM EDTA, pH 8.0 
        0.5 mM DTT 
        0.5 mM PMSF 
 
4x SDS loading dye:      40% glycerol 
400 mM β-mercaptoethanol 
200 mM Tris-HCl, pH 6.8 
4% (w/v) SDS 
0.05% (w/v) Xylene cyanol  
0.12% (w/v) Bromphenol blue 
 
5X SP6 / T7 transcription buffer:    600 mM HEPES-KOH, pH 7.5  
160 mM MgCl2 
10 mM spermidine 
200 mM DTT 
 
10x TBE:       0.89 M Tris 
        0.89 M boric acid 
        25 mM EDTA, pH 8.0 
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10X TBS buffer:       200 mM Tris-HCl, pH 7.6 
1.5 M NaCl 
1% Tween 20 
 
3.1.13 Software programs  
Program   Source 
Coot     https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/ 
        (Emsley, Lohkamp et al. 2010) 
coweyes    Custom made (Department of Structural Dynamics, MPI-BPC) 
Eman 2    http://blake.bcm.edu/emanwiki/EMAN2 (Tang, Peng et al. 2007) 
Gautomatch   http://www.mrc-lmb.cam.ac.uk/kzhang/ 
Gctf     http://www.mrc-lmb.cam.ac.uk/kzhang/ (Zhang 2016) 
ImageJ    http://imagej.nih.gov/ij/ (Schneider, Rasband et al. 2012) 
johnHenry   Custom made (Department of Structural Dynamics, MPI-BPC) 
Relion 1.4   http://www2.mrc-lmb.cam.ac.uk/relion (Scheres 2012) 
ResMap   http://resmap.sourceforge.net/ (Kucukelbir, Sigworth et al. 2014) 
UCSF Chimera   http://www.cgl.ucsf.edu/chimera/ (Pettersen, Goddard et al. 2004) 
unblur software suite  http://grigoriefflab.janelia.org/unblur (Campbell, Cheng et al. 2012) 
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3.2 Methods 
3.2.1 Molecular biology standard methods 
3.2.1.1 Transformation of DH5α cells  
For preparation of competent cells according to the CaCl2 method, a pre-culture of DH5α was 
inoculated in 5 ml Luria Bertani (LB) medium and incubated at 37°C overnight. The pre-culture was 
used to inoculate 50 ml LB. The culture was incubated at 37°C until it reached 0.3-0.5 OD/ml, 
transferred into a 50 ml Falcon tube, and centrifuged for 10 min at 2000 rpm in Megafuge 1.0R 
(Heraeus). Cells were resuspended in 25 ml cold 50 mM CaCl2 and centrifuged again. After 
resuspension in 3 ml of cold 50mM CaCl2, sterile glycerol was added to 10%, and the cells were kept 
at -80°C in 300 μl aliquots. Transformation was performed as described (Sambrook, Fritsch et al. 
1989): 10-50 ng of plasmid DNA were mixed with 50 μl of competent cells and incubated on ice for 
30 min. Heat-shock was performed for 1 min at 42°C and cells were immediately chilled on ice for 1 
min. Subsequently, 800 μl of LB- medium were added and incubated for 1 h at 37°C. Cells were 
centrifuged briefly in a microfuge and the cell pellet was resuspended in 50 μl of 10 mM Tris/HCl, 
pH 7.5. Cells were plated on the selection media and incubated overnight at 37°C. The isolation of 
the plasmid DNA from the transformed strain was carried out using QIAGEN Plasmid Mini and Maxi 
Kits according to the manufacturer’s instructions.  
3.2.1.2 Generation of templates for run-off in vitro transcriptions  
DNA plasmids encoding the MINX or PM5-10 pre-mRNA were extracted from E. coli DH5α cells using 
the QIAGEN Plasmid Maxi Kit (Qiagen) according to the manufacturer’s protocol. Plasmid DNA was 
eluted in mQ H2O and linearized by restriction digestion to generate templates for run-off in vitro 
transcriptions. The reactions were performed with the respective restriction endonuclease (NEB) 
according to the instructions of the manufacturer. Briefly, 10 units of enzyme were used to cut 1 μg 
of plasmid DNA by incubating for 1 h at 37 °C.  
Agarose gel-electrophoresis was then performed to ensure linearization of the DNA after restriction. 
Samples were supplemented with 6x DNA loading dye. Gels were prepared using 1% (w/v) agarose 
and 0.4 μg/ml ethidium bromide in 1x TBE buffer. Gels were run at 100 V for approximately 1 h. 
3.2.1.3 In vitro transcription 
RNA in vitro transcription was carried out using DNA templates derived from linearized 
plasmids (3.2.1.2). Uniformly 32P-labeled m7G(5’)ppp(5’)G-capped pre-mRNA was synthesized in vitro 
by T7 (MINX) or SP6 (PM5-10) run-off transcription. The composition of a standard reaction is shown 
in Table 1:  
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Table 1: Standard in vitro transcription reaction 
 
Volume (μl)  Final concentration  
5X T7 (SP6) transcription buffer  20 1X  
0.1 M ATP  7.5 7.5 mM  
0.1 M CTP  7.5 7.5 mM  
0.1 M UTP  1.5 1.5 mM  
0.1 M GTP  1.5 1.5 mM  
0.15 M m7G(5’)ppp(5’)G-cap  3.3 5 mM  
RNase inhibitor (40 U/μl)  3.7 1.5 U/ml  
SP6 (T7) RNA polymerase (20 U/μl)  10 2.0 U/ml  
DNA template (250 ng/μl)  10 25 ng/ml  
α-[32P]-labelled UTP (10 mCi/ml, 3000 Ci/mmol)  5 
 
H2O  30 
 
Total  100 
 
 
The transcription was carried out at 37 °C for 3 h. The DNA template was digested by addition of 2 µl 
RQ1 DNase (1U/µl, NEB) and further incubation at 37 °C for 30 min. In order to purify the pre-mRNA 
from unincorporated NTPs, the synthesized RNA was passed through a ProbeQuant G-50 column 
(GE Healthcare) according to the manufacturer’s protocol, followed by ethanol precipitation (3.2.1.5). 
3.2.1.4 PCI extraction 
Phenol-chloroform-isoamyl alcohol (PCI) extraction was used to separate nucleic acids from proteins. 
During extraction, proteins remain in the organic phase, while nucleic acids stay in the aqueous 
phase. Reactions were first adjusted to 200 µl final volume if not stated otherwise. Subsequently an 
equal volume of PCI was added and samples were thoroughly mixed on a shaker for 10 min at room 
temperature. The resulting suspension was centrifuged for 10 min at room temperature at 
13000 rpm in a microfuge in order to separate the aqueous from the organic phase. Nucleic acids in 
the aqueous phase were precipitated in ethanol (3.2.1.5). 
3.2.1.5 Ethanol Precipitation 
Nucleic acids in aqueous solutions were precipitated by addition of 0.1 volume 3 M NaOAC, pH 4.7 
and 3 volumes absolute ethanol. Samples were kept at -20 °C for at least 30 min and precipitated by 
centrifugation for 30 min at 4 °C and 13000 rpm in a microfuge. The pellet was washed once with 
70% (v/v) ethanol, vacuum dried and finally resuspended in the desired solution.  
3.2.1.6 Nucleic acid quantification 
The concentration of nucleic acids was determined by measuring their absorption in an aqueous 
solution at a wavelength of 260 nm and 280 nm in comparison to the corresponding buffer without 
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nucleic acids. The purity of a nucleic acid solution was determined by the ratio of OD260/OD280: 
2.0 corresponded to pure RNA or oligonucleotides and 1.8 to pure DNA. Lower ratios idnicate 
contamination with proteins or phenol, which requires an additional PCI extraction (3.2.1.4). 
1 OD260 was considered to be equal to: 
 50 µg/ml of double-stranded DNA 
 33 µg/ml of single-stranded DNA 
 40 µg/ml of single-stranded RNA 
3.2.1.7 Proteinase K digestion 
To facilitate RNA recovery from protein rich samples, proteinase K treatment was performed prior to 
PCI extraction.  Samples were incubated in 1x PK buffer in the presence of 0.2 µg/µl proteinase K for 
15 min at 45 °C. The RNA was recovered by PCI extraction (3.2.1.4) followed by ethanol precipitation 
(3.2.1.5). 
3.2.1.8 Denaturing polyacrylamide gel-electrophoresis 
Denaturing polyacrylamide gel electrophoresis (PAGE) in the presence of 8 M urea was mainly used 
to separate snRNAs or intermediates and products of pre-mRNA in vitro splicing. Depending on the 
size of the RNAs, the gels contained 10-14% (v/v) polyacrylamide, 8 M urea and 1x TBE. 
Polymerization of the gels was initiated by addition of 300 µl 10% (w/v) APS and 30 µl TEMED to 
50 ml of gel solution. The RNA samples were dissolved in RNA loading dye, denatured by incubating 
for 5 min at 96 °C and briefly chilled on ice before loading. The electrophoresis was performed at 
15 W in 1x TBE buffer. The RNA was then visualized by SYBR Gold staining or autoradiography. 
Alternatively RNA was separated on a denaturing 4-12% NuPAGE gel (Invitrogen), run in 1x MOPS 
buffer (Invitrogen) according to the manufacturer’s protocol, and then visualized by SYBR Gold 
staining or autoradiography. 
3.2.1.9 SYBR Gold staining 
SYBR Gold staining of RNA was performed after fixation of SDS denaturing gels in 40% (v/v) 
methanol / 10% (v/v) acetic acid. RNA was stained according to manufacturer’s protocol and 
visualized with Fujifilm FLA-7000 laser scanner at a wavelength of 495 nm.  
3.2.2 Protein-biochemistry standard methods 
3.2.2.1 Protein quantification 
To measure the concentration of proteins, a BCATM Protein Assay Kit (Pierce) was used according to 
the manufacturer’s protocol. This assay is a detergent-compatible method based on bicinchoninic 
acid (BCA) for the colorimetric detection. Quantification of total protein was analysed at an 
absorption maximum of 562 nm. 
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3.2.2.2 Denaturing SDS polyacrylamide gel-electrophoresis (SDS-PAGE) 
Proteins were resolved on denaturing 4-12% NuPAGE gels (Invitrogen), run in 1x MOPS buffer 
(Invitrogen) according to the manufacturer’s protocol.  
3.2.2.3 Coomassie staining 
Coomassie staining of proteins was performed after fixation of SDS denaturing gels in 40% (v/v) 
methanol / 10 % (v/v) acetic acid. Proteins were stained with coomassie staining solution overnight 
at room temperature and were subsequently destained in water until protein bands were clearly 
visible.  
3.2.2.4 Purification of MS2-MBP 
The fusion protein, which was used for affinity-purification of spliceosomal complexes, was 
expressed in E. coli containing the plasmid encoding the MS2-MBP protein. Cells were grown to an 
OD600 of 0.3-0.6 in LB medium supplemented with ampicillin. The expression of the MS2-MBP protein 
was then induced by adding 0.1 M IPTG. The culture was further incubated for 2.5 h at 37 °C. The 
cells were pelleted by centrifugation in a Megafuge 1.0R (Heraeus) for 10 min at 2000 rpm. The 
supernatant was discarded and the cell pellet was washed with 40 ml of washing buffer (20 mM Tris-
HCl, pH 7.6, 0.2 M NaCl) supplemented with one complete EDTA-free protease inhibitor cocktail 
tablet. Then, the cells were resuspended in 25 ml of washing buffer and subsequently lysed by 
sonification. The lysate was centrifuged in a FiberLite F14-14 × 50 rotor for 30 min at 16000 g. The 
supernatant was transferred into a MBPTrap HP column (GE Healthcare) and the amylose resin was 
washed with 10 column volumes of MBP150 buffer followed by 5 column volumes of 5 mM Na2HPO4, 
pH 7.0. The MS2-MBP protein was then eluted with 5 mM Na2HPO4, pH 7.0 containing 20 mM 
maltose and the eluate was subsequently loaded onto a pre-equilibrated HiTrap Heparin HP column 
(GE Healthcare). The column was washed with 10 volumes of 5 mM Na2HPO4, pH 7.0 and the protein 
was eluted fraction-wise with elution buffer (20 mM HEPES-KOH, pH 7.9, 100 mM KCl, 15 % (v/v) 
glycerol, 0.5 mM DTT). Peak fractions were pooled, shock frozen in liquid nitrogen and finally stored 
at -80 °C. The protein concentration was determined using the BCATM Protein Assay Kit (3.2.2.1). 
3.2.3 Special methods 
3.2.3.1 Cell culture 
HeLa S3 cells (Computer Cell Culture Center, Belgium) were grown in suspension in S-MEM media 
supplemented with 5% (v/v) newborn calf serum, 50 μg/ml penicillin and 100 μg/ml streptomycin to 
a density of 2.5-5x 105 cells/ml. Cultivation and harvesting of the cells was essentially performed as 
previously described in (Kastner 1998). 
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3.2.3.2 Preparation of splicing active HeLa nuclear extract 
Splicing active nuclear extract was prepared from HeLa cells as described in (Dignam, Lebovitz et al. 
1983). Six to eight liters of HeLa cells were grown to a density of 2.5-5 x 105 cells/ml (Kastner 1998). 
The cells were pelleted by centrifugation in a Megafuge 1.0R (Heraeus) for 10 min at 2000 rpm. The 
supernatant was discarded and the cells were washed three times with ice-cold 1x PBS, pH 7.4. Then, 
the cell pellet was resuspended in 1.25 volumes of 1x MC buffer supplemented with two complete 
EDTA-free protease inhibitor cocktail tablets per 50 ml of buffer. After an incubation of 5 min on ice, 
the cells were lysed with 18 strokes of a Dounce homogenizer at 4 °C. The mixture was transferred to 
50 ml tubes and the nuclei were pelleted by centrifugation in a FiberLite F14-14 × 50 rotor for 5 min 
at 13000 g. Afterwards the supernatant was discarded and nuclei were treated in one of the 
following ways: 
 According to the general procedure, the nuclei were resuspended in 1.3 volumes of 
1x Roeder C buffer containing 0.5 mM DTE and 0.5 mM PMSF. For lysis of the nuclei the 
suspension was again subjected to 20 strokes of a Dounce homogenizer at 4 °C. The lysate 
was stirred for 40 min at 4 °C, followed by centrifugation in a FiberLite F14-14 × 50 rotor at 
16000 rpm for 30 min to pellet particulate material. The supernatant was recovered and 
dialyzed against 50 volumes of 1x Roeder D buffer at 4 °C for 5 h with one change of buffer 
after 2.5 h. The dialyzed nuclear extract was recovered and centrifuged in a 
FiberLite F14-14 × 50 rotor at 10000 rpm for 10 min at 4 °C. The supernatant was aliquoted, 
frozen in liquid nitrogen and stored at -80 °C. 
 According to the optimized for cryo-EM procedure, the nuclei were resuspended in 
1.3 volumes of 1x Roeder D or 1x Roeder C buffer and homogenized with 20 strokes of a 
Dounce homogenizer at 4 °C. The lysate was stirred for 40 min at 4 °C, followed by 
centrifugation in a FiberLite F14-14 × 50 rotor at 16000 rpm for 30 min to pellet particulate 
material, if not stated otherwise. The supernatant was immediately used in an in vitro 
splicing reaction.  
3.2.3.3 In vitro splicing reactions 
A typical splicing reaction was carried out in the presence of 10 nM pre-mRNA and 40 % (v/v) HeLa 
nuclear extract in a buffer containing 20 mM HEPES-KOH, pH 7.9, 3 mM MgCl2, 65 mM KCl, 2 mM ATP 
and 20 mM creatine phosphate. Alternatively, splicing was carried out in the presence of 5 nM 
pre-mRNA and 20% (v/v) HeLa nuclear extract (optimized procedure) in a splicing mixture containing 
20 mM HEPES-KOH, pH 7.9, 3 mM MgCl2, 65 mM KCl or 50 mM NaCl, 2 mM ATP and 20 mM creatine 
phosphate. Spliceosomal complexes were allowed to form by incubating at 30 °C. Bact complexes 
were assembled on PM5-10 pre-mRNA by incubating at 30 °C for 0-3 h. A 30-fold molar excess of 
DNA oligonucleotides complementray to nucleotides -6 to -18 and -12 to -24 relative to the 5’ss (M6 
and M12 oligos, respectively) was added and the reaction was incubated at 30°C for an additional 
20 min. After splicing, the reactions were chilled on ice. 
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3.2.3.4 Analysis of splicing complexes by native agarose gel-electrophoresis 
Spliceosomal complexes A, B and C are formed in sequentially and show decreased mobility on a 
native agarose gel (Lamond, Konarska et al. 1987, Kent and MacMillan 2002). To resolve spliceosomal 
complexes, 20 µl splicing reactions were incubated at 30 °C for different time points. Heparin was 
added to 18 μl aliquots of the splicing reaction to a final concentration of 0.125 mg/ml and the 
mixtures were incubated for another 1 min at 30°C before addition of 2 μl of 4X agarose loading 
buffer. The samples were loaded onto a native agarose gel (26 cm x 15 cm) containing 1.5% (w/v) of 
low melting point agarose (Invitrogen) in 0.5 x TBE buffer. Electrophoresis was performed by applying 
100 V for 5 h at room temperature. The gels were dried at 60 °C for 5 h and bands were visualized by 
exposing to a phosphoimager screen. 
3.2.3.5 MS2 affinity-selection of splicing complexes 
Spliceosomal complexes were isolated by MS2 affinity-selection as previously described (Bessonov, 
Anokhina et al. 2010). Pre-mRNA was incubated with a 20-fold molar excess of purified MS2-MBP 
fusion protein for 30 min at 4 °C prior to splicing. After performing in vitro splicing the reaction was 
equilibrated with HEPES-KOH, pH 7.9 and then loaded onto a MBPTrap HP column (GE Healthcare) 
equilibrated with 1x G-150 buffer (20 mM HEPES-KOH, pH 7.9, 1.5 mM MgCl2, 150 mM NaCl). The 
column was washed with 40 volumes of 1x G-150 buffer and complexes were eluted with 1x G-150 
buffer containing 1 mM maltose. Eluted complexes were loaded onto a 36 ml linear 10-30% (v/v) 
glycerol gradient containing G-150 buffer (20 mM HEPES- KOH, pH 7.9, 1.5 mM MgCl2, 150 mM NaCl), 
centrifuged at 23000 rpm for 15 h at 4 °C in a Surespin 630 (Thermo Scientific) rotor and gradient 
fractions were harvested from the bottom. The distribution of 32P-labeled pre-mRNA across the 
gradient was determined by Cherenkov counting. Fractions were analysed on denaturing 4-12% 
NuPAGE gels (Invitrogen), followed by autoradiography or fixation and staining (3.2.1.9 and 3.2.2.3). 
Peak fractions containing the activated spliceosomal complexes were pooled, concentrated by 
centrifugation with an Amicon Ultra concentration unit (Merck), diluted to decrease the glycerol 
concentration and reloaded on a second gradient with or without glutaraldehyde as fixative (for EM 
analysis and for biochemical sample validation, respectively). The RNA and protein compositions of 
purified complexes were analysed on denaturing 4-12% NuPAGE gels (Invitrogen). 
3.2.3.6 ProteoPlex 
A ProteoPlex screen, to identify the optimal buffer conditions for spliceosomal complex stability, was 
performed in 20 μl reactions in a 96-well plate (Bio-Rad) (Chari, Haselbach et al. 2015). Each 
individual 20 μl reaction was composed of 16 μl of the isolated complex at a concentration of 
0.1 - 1 μM, 2 μl of SYPRO orange (Life Technologies) at a final concentration of 1x and 2 μL of the 
buffer/chemical under investigation. Buffer substance screens at various pH values were performed 
with a custom made buffer screen, where individual stock solutions were 1 M (Table 2). Each plate 
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contained control wells, which contained the purification buffer of the spliceosome complex and 
wells without complex. Unfolding transitions were recorded in a CFX connect real-time PCR machine 
(Bio-Rad). A reader program was utilized, where the entire plate was equilibrated to 30°C for 2 min 
followed by fluorescence measurement. Subsequently, the samples were incrementally heated in 1°C 
steps, equilibrated for 30 s and fluorescence was measured. Finally, the sample was held at 95°C for 
2 min, followed by a final fluorescence measurement. 
Table 2: Composition of custom made buffer screen  
All individual stock solutions were 1 M. Column 12 is intentionally left blank for controls 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 
SPG1) 
pH 5.6 
MMT2) 
pH 5.6 
PCB3) 
pH 5.6 
MES4) 
pH 5.5 
Na Citrate 
pH 5.5 
BisTris5) 
pH 5.8 
Na/K Phosphate 
pH 5.8 
ADA6) 
pH 6.0 
HEPES7) 
pH 6.8 
Imidazole 
pH 6.2 
Tris8) 
pH 7.5  
B 
SPG1) 
pH 6.0 
MMT2) 
pH 6.0 
PCB3) 
pH 5.0 
MES4) 
pH 5.7 
Na Citrate 
pH 5.75 
BisTris5) 
pH 6.0 
Na/K Phosphate 
pH 6.1 
ADA6) 
pH 6.2 
HEPES7) 
pH 7.0 
Imidazole 
pH 6.45 
Tris8) 
pH 7.7  
C 
SPG1) 
pH 6.4 
MMT2) 
pH 6.4 
PCB3) 
pH 6.4 
MES4) 
pH 5.9 
Na Citrate 
pH 6.0 
BisTris5) 
pH 6.2 
Na/K Phosphate 
pH 6.4 
ADA6) 
pH 6.4 
HEPES7) 
pH 7.2 
Imidazole 
pH 6.7 
Tris8) 
pH 7.9  
D 
SPG1) 
pH 6.8 
MMT2) 
pH 6.8 
PCB3) 
pH 6.8 
MES4) 
pH 6.1 
Na Citrate 
pH 6.25 
BisTris5) 
pH 6.4 
Na/K Phosphate 
pH 6.7 
ADA6) 
pH 6.6 
HEPES7) 
pH 7.4 
Imidazole 
pH 6.95 
Tris8) 
pH 8.1  
E 
SPG1) 
pH 7.2 
MMT2) 
pH 7.2 
PCB3) 
pH 7.2 
MES4) 
pH 6.3 
Na Citrate 
pH 6.5 
BisTris5) 
pH 6.6 
Na/K Phosphate 
pH 7.0 
ADA6) 
pH 6.8 
HEPES7) 
pH 7.6 
Imidazole 
pH 7.2 
Tris8) 
pH 8.3  
F 
SPG1) 
pH 7.6 
MMT2 
pH 7.6 
PCB3) 
pH 7.6 
MES4) 
pH 6.5 
Na Citrate 
pH 6.75 
BisTris5) 
pH 6.8 
Na/K Phosphate 
pH 7.3 
ADA6) 
pH 7.0 
HEPES7) 
pH 7.8 
Imidazole 
pH 7.45 
Tris8) 
pH 8.5  
G 
SPG1) 
pH 8.0 
MMT2) 
pH 8.0 
PCB3) 
pH 8.0 
MES4) 
pH 6.7 
Na Citrate 
pH 7.0 
BisTris5) 
pH 7.0 
Na/K Phosphate 
pH 7.6 
ADA6) 
pH 7.2 
HEPES7) 
pH 8.0 
Imidazole 
pH 7.7 
Tris8) 
pH 8.8  
H 
SPG1) 
pH 8.4 
MMT2) 
pH 8.4 
PCB3) 
pH 8.4 
MES4) 
pH 6.9 
Na Citrate 
pH 7.25 
BisTris5) 
pH 7.2 
Na/K Phosphate 
pH 7.9 
ADA6) 
pH 7.4 
HEPES7  
pH 8.2 
Imidazole 
pH 7.95 
Tris8) 
pH 9.0  
1) 1M SPG Buffer contains: 0.125M Succinic Acid, 0.5M NaH2PO4, 0.375M Glycine adjusted to the appropriate pH with 10M NaOH. 
2) 1M MMT Buffer contains: 0.2M DL-Malic Acid, 0.4M MES monohydrate, 0.4M Tris adjusted to the appropriate pH with either 10M HCl or 10M NaOH 
3) 1M PCB Buffer contains: 0.4M Sodium Propionate, 0.2M Sodium Cacodylate trihydrate, 0.4M Bis-Tris Propane adjusted to the appropriate pH with 10M HCl  
4) MES(2-(N-morpholino)ethanesulfonicacid)monohydrate  
5) Bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane  
6) N-(2-Acetamido)iminodiaceticacid  
7) 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonicacid  
8) 2-Amino-2-hydroxymethyl-propane-1,3-diol 
3.2.4 Electron microscopy 
The structure of isolated spliceosomal complexes was analyzed by electron microscopy (EM). Cryo 
EM experiments were performed in collaboration with Dr. David Haselbach (Department of 
Structural Dynamics, MPI-BPC). Carbon films and grids for cryo EM were kindly prepared by Frank 
Würriehausen (Department of Structural Dynamics, MPI-BPC). 
3.2.4.1 Preparation of continuous carbon film and holey carbon grids  
For continuous carbon films, mica (Plano G250- 1, 25x75 mm) was used as the coating carrier. To 
obtain a smooth surface that does not have beforehand any direct air contact, the mica was freshly 
split. The fresh side was indirectly exposed to carbon in an Edwards E12E vacuum coating unit (BOC 
Edwards, Kirchheim) by conducting electric current through two carbon rods (Ringsdorff Werke 
GmbH, Bonn). 
Low-cost grids with irregular holes were made to evaluate sample quality. Copper grids were covered 
with self-made triafol film containing holes. Then carbon was directly sputtered onto the triafol film. 
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To dissolve and remove the triafol film between the carbon layer and copper grids, the grids were 
incubated in ethyl acetate overnight and air dried. In order to record images that were used for cryo 
EM analysis and 3D reconstruction, copper EM grids with a holey carbon film (R3.5/1) (Quantifoil 
Micro Tools GmbH, Jena) were used.  
3.2.4.2 Sample preparation 
For EM investigations, affinity-purified complexes were subjected to a second glycerol gradient 
centrifugation under mild-fixating GraFix conditions (Kastner, Fischer et al. 2008). Briefly, 6-30 pmol 
of spliceosomes were loaded onto a linear 5-20% sucrose and 0-0.1% (v/v) glutaraldehyde gradient 
containing G-150, if not stated otherwise. Gradients were centrifuged at 60000 rpm for 110 min in a 
TH660 rotor or at 23000 rpm for 15 h in TST 41.14 rotor at 4°C and harvested from the bottom in 200 
or 500 µl fractions, respectively. The distribution of 32P-labeled RNA across the gradient was 
determined by Cherenkov counting and peak fractions were used for EM studies. The purified 
spliceosomal complexes were allowed to adsorb on a thin carbon film prior to negative staining or 
rapid plunge freezing into liquid ethane at 100% humidity and 4°C.  
3.2.4.3 Negative stain EM analysis 
Negative staining provides high contrast with a relatively simple preparation procedure. Therefore, it 
was mostly used for a quick sample quality estimation. As a staining solution for the negative stain 
EM, we used saturated (~5% w/v) uranyl formate, dissolved in double distilled water. The solution 
was thoroughly mixed and then centrifuged at 13000 rpm for 20 min at 4°C in Biofuge pico (Heraeus) 
in order to pellet excess of uranyl formate. To adsorb isolated complexes, a piece of carbon coated 
mica was floated on the surface of the sample well in a custom made teflon block. Then, carbon film 
with absorbed sample was covered with a copper EM grid, transferred to the uranyl formate staining 
solution and incubated for 1 min.  
For visualization of structural features, images were recorded at a magnification of 88000x, 
corresponding to a pixel size of 2.5 Å2/pixel with a CM200 FEG electron microscope 
(Philips, Netherlands) equipped with a 4kx4k charge-coupled (CCD) camera (TVIPS) and a room 
temperature holder (Philips, Netherlands). For each data set 10000-15000 individual single-particle 
images were collected. Repeating rounds of image processing of these images were performed using 
the in-house software package (coweyes). After a reference-free alignment, images were subjected 
to multivariate statistical analysis and classification (van Heel and Frank 1981, van Heel and Harauz 
1988, Dube, Tavares et al. 1993). The resulting class averages were used as reference images in 
subsequent rounds of alignment until the class averages were stable. 
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3.2.4.4 Cryo EM image acquisition and analysis 
Cryo EM images were recorded at -193°C in a Titan Krios electron microscope (FEI Company, The 
Netherlands) on a Falcon 3EC direct electron detector at a nominal 59,000x magnification, resulting 
in a calibrated pixel size of 1.16 Å2/pixel on the specimen level. 20 frames were recoded for each 
micrograph with an average dose of 2 e- per frame per Å2. Motion correction and spatial frequency 
weighed frame sum was achieved using the unblur software suite (Campbell, Cheng et al. 2012). Ctf 
parameters were determined with Gctf (Zhang 2016). Summed micrograph images were then 
evaluated based on CTF parameters. Gautomatch (http://www.mrc-lmb.cam.ac.uk/kzhang/) 
software was used to pick particles. As a reference I used 40° projections of the yeast Bact model 
(EMD-9524) filtered to 60 Å. In total ~0.52 million particles from the pre-sorted cryo-micrographs 
were collected and cleaned by 3D classification in RELION. The remaining ~0.48 million particles were 
subsequently applied to three separate rounds of 3D classification in RELION (Scheres 2012) resulting 
in two different forms of the human Bact complex. Best classes were further refined to achieve the 
final structures. Part of the lower resolution density of one of the forms was excluded with a soft 
mask with a cut-off of 7 voxel in the final rounds of the refinement. Resolution was determined by 
Fourier shell correlation that was calculated from two independent data sets with a threshold of 
0.143. A local resolution estimation was made in ResMap (Kucukelbir, Sigworth et al. 2014). 
3.2.4.5 Model fitting and building 
Structures were visualized in UCSF Chimera (Pettersen, Goddard et al. 2004). Available X-ray or 
homology models of proteins were placed into the EM density mostly using Chimera. Individual 
models of substructures (e.g. domains or structural motifs) were further docked as rigid bodies by 
Coot (Emsley, Lohkamp et al. 2010). After visual inspection, the models were adjusted manually in 
the density. The U2/U6 helix II was refined by rigid-body fitting of an idealized double-stranded RNA 
helix. Final visualization was carried out with Chimera.  
3.2.5 Mass spectrometry 
3.2.5.1 Protein identification by mass spectrometry 
For protein identification via mass spectrometry, proteins recovered from affinity-purified 
spliceosomal complexes were separated on 4-12% NuPAGETM gradient gels (Invitrogen) and stained 
with Coomassie. Entire lanes were cut into 23 slices and proteins were digested in-gel with trypsin 
and extracted as described by Shevchenko et al. (Shevchenko, Wilm et al. 1996). The extracted 
peptides were analyzed on a LTQ-Orbitrap Velos or Q Exactive Mass Spectrometers (Thermo 
Scientific) under standard conditions. Proteins were identified by searching fragment spectra against 
the NCBI non-redundant database using Mascot as a search engine. 
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3.2.5.2 Crosslinking and crosslink identification by mass spectrometry 
All crosslinking experiments were performed in collaboration with Dr. Olexandr Dybkov (Dep. of 
Cellular Biochemistry; MPI-BPC).  
Purified Bact complexes were cross-linked with 150 μM BS3 for 40 min at 20°C and purified further by 
a second density gradient centrifugation step. Approximately 15 pmol of Bact complexes were 
pelleted by ultracentrifugation and analyzed essentially as described before (Leitner, Walzthoeni et 
al. 2014) with the following modifications: precipitated material was dissolved in a buffer containing 
4 M urea and 50 mM ammonium bicarbonate, reduced with DTT, alkylated with iodoacetamide, 
diluted to 1 M urea and digested with trypsin (Promega) (1:20 w/w). Peptides were reverse-phase 
extracted and fractionated by gel filtration on a Superdex Peptide PC3.2/30 column (GE HealthCare). 
50 μl fractions corresponding to an elution volume of 1.2–1.8 ml were analyzed on a Orbitrap Fusion 
Lumos Tribrid and Q Exactive HF Mass Spectrometer (Thermo Scientific). Protein-protein crosslinks 
were identified by pLink 1.23 search engine and filtered at FDR 1% (pfind.ict.ac.cn/software/pLink) 
according to the recommendations of the developer (Yang, Wu et al. 2012).  
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4 Results 
4.1 Experimental strategy to isolate human activated spliceosomes 
For the purification of activated (Bact) spliceosomes, I used a pre-mRNA substrate, termed PM5-10, 
that contains a single 5’ exon, an intron with a branch site and an additional 10 nucleotides (nts) 
downstream of the BS, but lacking a 3’ splice site (ss) and 3' exon. It has previously been shown that 
the PM5-10 construct allows the assembly of the Bact complex but that due to the short 
polypyrimidine tract (PPT) it cannot be catalytically activated (Bessonov, Anokhina et al. 2008). The 
PM5-10 construct contained at its 5’ end three MS2 stem loops, which were co-transcriptionally 
added to allow affinity purification of the Bact complex on amylose agarose using a fusion protein of 
MS2 coat protein and maltose-binding protein (MBP).  
 
 
 
 
Figure 4.1: General strategy to isolate human 
spliceosomal complexes using an MS2-tagged 
pre-mRNA substrate 
PM5-10 pre-mRNA tagged at its 5’ end with three 
binding sites of the MS2 virus coat protein was 
preincubated with a MS2-MBP fusion protein (step I). 
Subsequently, nuclear extract was added and 
spliceosomes were allowed to form (step II). 
Complexes were then affinity selected using amylose 
beads (step III) and subsequently eluted with maltose 
(step IV). Eluted spliceosomal complexes were 
fractionated by size on a linear glycerol or sucrose 
gradient (step V). 
 
 
 
 
The Bact purification scheme is illustrated in Figure 4.1. Briefly, MS2-PM5-10 pre-mRNA was incubated 
with a 20-fold molar excess of MS2-MBP fusion protein. Then, a standard splicing reaction was 
performed for 180 min. A 30-fold molar excess of DNA oligonucleotides, which are complementary to 
nts -6 to -18 and -12 to -24 (relative to the 5’ss) of the PM5-10 substrate was added and the reaction 
was incubated at 30°C for additional 20 min. During the latter incubation step, endogenous RNaseH 
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cleaves only pre-mRNA in assembly steps earlier than Bact, which allows the purification of Bact 
complexes largely uncontaminated by H, A or B complexes. Bact complexes are then purified by 
affinity chromatography using amylose beads and eluted from the amylose column under native 
conditions with an excess of maltose. Eluted complexes are subsequently fractionated by 
centrifugation on a linear glycerol or sucrose gradient, which allows separation of the 40-45S 
Bact spliceosomes from smaller MS2-MBP containing RNP particles. 40-45S peak fractions were either 
pooled or analysed individually. 
4.2 Optimization of human Bact complex stability using a high-throughput 
buffer screen 
Spliceosomes are known to be structurally dynamic, a property, which often hinders the 
reconstruction of 3D cryo-electron microscopy (cryo-EM) structures at high resolution (Stark and 
Lührmann 2006). Therefore I first tested numerous buffer conditions with the intention to 
biochemically stabilize the spliceosome in order to minimize its conformational heterogeneity and 
flexibility. A convenient screening method to assess the effect of numerous conditions (e.g. buffers 
and small molecule additives) on the stability of a protein or RNP complex of interest in a high-
throughput format was recently established in the group of Prof. Stark (Dep. of Structural Dynamics, 
MPI-BPC) and was termed ProteoPlex (Chari, Haselbach et al. 2015). In the procedure, a hydrophobic 
dye (SYPRO Orange) interacts with exposed hydrophobic protein regions upon heat denaturation. 
Thus, the thermal stability of a protein complex is estimated at various temperatures by measuring 
the increase in fluorescent intensity as a result of binding of the fluorescent dye to unfolded proteins 
(Boivin, Kozak et al. 2013, Chari, Haselbach et al. 2015). For this purpose, Bact spliceosomes purified 
under standard splicing conditions were subjected to a Thermofluor screen under 88 different buffer 
conditions (Figure 4.2 A).  
The screen revealed that the hBact complex is stable under a variety of conditions from pH 6.4 to 8.2 
and the particles were as stable under standard buffer conditions as in any other conditions tested. 
Therefore, I decided to validate the quality of the Bact complexes, purified under different buffer 
conditions, using transmission electron microscopy (TEM). A monodisperse distribution of 
spliceosomal particles was observed in a range of different pH values (Figure 4.2 B) and no or only 
little fragmentation of spliceosomes had occurred. 
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Figure 4.2: ProteoPlex approach for identifying stabilizing buffer conditions 
(A) Normalized experimental melting curves for Bact complexes in all tested buffer conditions from a ProteoPlex pH screen. 
Standard buffer is shown in orange. One of the most optimal buffers as identified with ProteoPlex is indicated in blue. 
(B) Electron micrographs of the Bact complex under standard (left) and one of the most optimal conditions as determined by 
ProteoPlex (right). 
Then I varied the buffer conditions during the splicing reaction / Bact complex formation, first by 
changing the pH from 6 to 9 (Figure 4.3 A). In brief, the in vitro splicing mixture was complemented 
with buffer at the pH of interest to a final concentration of 50 mM. After 3 hours of incubation the 
efficiency of Bact complex formation was initially analysed on a native agarose gel in the presence of 
heparin. Under pH conditions close to neutral, I observed that assembly of all spliceosomal 
intermediates including Bact was most efficient, suggesting that the complexes were more stable at 
neutral pH. At slightly acidic buffer conditions, however, I observed accumulation of earlier 
spliceosome forms, which could indicate that spliceosome assembly was slowed down. However, 
when the affinity purified Bact type complexes, which were assembled in a buffer at pH 6.9, were 
separated by gradient centrifugation, the spliceosomes exhibited a bimodal sedimentation 
behaviour, indicating some heterogeneity of the sample (Figure 4.3 B). For comparison, spliceosomes 
assembled and purified under standard splicing conditions (pH 7.9) were also subjected to gradient 
centrifugation, and fractionated as a largely symmetrical peak.  
 
Figure 4.3: Optimization of reaction conditions 
(A) In vitro splicing reaction of 32P-labeled PM5-10 pre-mRNA performed in HeLa nuclear extract for 3 h. Spliceosomal 
complexes (positions indicated on the left) were analysed by agarose gel electrophoresis. Bands were visualized by 
autoradiography. (B) Sedimentation behaviour of spliceosomes formed under different buffer conditions on a 10-30% 
glycerol gradient.  
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RNA analysis of the gradient fractions showed that all peak fractions contain unspliced pre-mRNA 
and nearly equimolar amounts of U2, U5 and U6 snRNAs, but U1 and U4 snRNAs were largely absent, 
indicating that the vast majority of spliceosomes had undergone activation (Figure 4.4 A). Negative 
stain EM analysis of the spliceosomes from fractions 12/13 (low S value) and 16 (high S value), 
respectively, revealed that they displayed significantly different appearances. While faster 
sedimenting complexes contained largely round particles with an appearance similar to spliceosomes 
assembled and purified under standard conditions at pH 7.9, slower sedimenting particles displayed 
rather elongated shapes (Figure 4.4 B).  
 
Figure 4.4: Change of the reaction conditions leads to an increase in conformational heterogeneity 
(A) The peak gradient fractions of the complexes formed in an in vitro splicing reaction under neutral buffer conditions 
(HEPES pH 6.9) were analysed on a NuPAGE gel, followed by SYBR Gold staining. RNA identities are shown on the right. 
Fractions corresponding to faster and slower sedimenting particles are indicated in orange and blue boxes, respectively. 
(B) Negative stain electron micrographs of complexes from gradient fractions corresponding to lanes “A” and “B” of panel A 
compared to complexes assembled under standard conditions (ctrl, pH 7.9). Scale bar, 50 nm. 
As the Bact complexes obtained in the standard splicing reaction appeared to be optimal spliceosomal 
particles, which did not aggregate and exhibited a homogeneous appearance under negative stain 
EM conditions, I decided to proceed with these Bact preparations for unstained cryo-EM analysis. 
4.3 Structure determination of the activated human spliceosome 
4.3.1 Purification and characterisation of Bact spliceosomes.  
The final optimized purification strategy of Bact spliceosomes involved several steps. First, preparative 
amounts of Bact complex were assembled under standard splicing conditions in a 700 ml splicing 
reaction at pH 7.9 (Chapter 3.2.3.3). The affinity purified Bact complexes were fractionated on 38.6 ml 
5-20% linear sucrose gradients in G-150 buffer (20 mM HEPES-KOH, pH 7.9, 150 mM NaCl, 1.5 mM 
MgCl2). Peak fractions were split in two groups based on sedimentation behaviour (slower and faster 
sedimenting complexes). Particles in fractions 3-4 and 6-7, respectively, were pooled (Figure 4.5 A), 
concentrated by centrifugation with an Amicon 50kD cut-off unit and subjected separately to 
fractionation on a second sucrose gradient, which contained also 0 to 0.1% (v/v) 
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glutaraldehyde (Kastner, Fischer et al. 2008). Spliceomes from individual fractions from this gradient 
were concentrated by centrifugation with an Amicon 50kD cut-off unit and subjected to EM analysis.  
 
Figure 4.5: Purification and cryo-EM analysis of the human Bact complex 
(A) The affinity-purified sample was further fractionated by sucrose gradient centrifugation. The total RNA from each 
fraction was analysed on a NuPAGE gel, followed by SYBR Gold staining. Fractions 3-4 and 6-7 were concentrated and 
analysed separately. The asterisk shows the position of RNaseH degraded pre-mRNA. (B) Typical cryo-EM raw image of 
unstained human Bact spliceosomes (fractions 6-7) recorded with a Titan Krios (FEI Company) electron microscope at a 
nominal magnification of 59000x with a Falcon 3EC direct electron detector resulting in a pixel size of 1.16 Å2/pixel. 
As shown in Figure 4.5 A, purified spliceosomes sedimenting with an S value of about 45S contain U2, 
U5 and U6 snRNAs in addition to pre-mRNA, consistent with the RNA composition of Bact complexes. 
I decided to split the peak fractions in two groups. Although no difference could be found between 
particles from separated pools, I processed the pools for cryo-EM analysis separately. Negatively 
stained and cryo-grids were prepared as described in Chapter 3.2.4. The Bact complexes from both 
pools were monodisperse in negative stain EM, as well as under cryogenic imaging conditions. An 
example of a cryo micrograph is shown in Figure 4.5 B. 
Proteins present in isolated spliceosomes from corresponding fractions of non-fixed gradients were 
separated on a denaturing 4-12% NuPAGE gels (Invitrogen), followed by Coomassie staining. Proteins 
from a single lane were identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
in the Bioanalytical Mass Spectrometry Group as described in Chapter 3.2.5. The protein composition 
of purified spliceosomes is summarized in Figure 4.6. Mass-spectrometry identified more than 120 
proteins, including snRNP and non-snRNP proteins (data not shown). These include proteins 
associated with U2 snRNP, some of the U5 proteins (Prp8, Brr2, Snu114, 40K and Sm core proteins), 
the Prp19/CDC5L protein complex and related factors, proteins of the intron-binding complex, 
components of the human RES complex, components of the exon junction complex (EJC) and 
proteins associated with the activated spliceosome through the first catalytic cycle, as previously 
described (Bessonov, Anokhina et al. 2010). Additional proteins found in isolated spliceosomes 
include MS2-MBP fusion protein, cap-binding proteins, a number of hnRNP and SR proteins (data not 
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shown). Consistent with previous studies, U1 and U4/U6 snRNP proteins, including LSm proteins, as 
well as B complex specific proteins were not identified by MS analysis or were underrepresented 
(Bessonov, Anokhina et al. 2010, Agafonov, Deckert et al. 2011). 
 
Figure 4.6: Characterization of the protein composition of Bact spliceosomes 
Proteins isolated from purified Bact complexes were visualized on a NuPAGE gel by Coomassie blue staining (left).  
Proteins present in human Bact complexes and their molecular masses are summarized in the table. Proteins were identified 
by LC-MS/MS. Standard names for human proteins, as well as names of their homologues in yeast S. cerevisiae and 
S. pombe are indicated. Accession numbers for human proteins are shown in blue. 
4.3.2 Structure determination, model-building and overview of the Bact spliceosome 
structure 
Images were recorded using a Falcon 3EC direct electron detector with a calibrated pixel size of 
1.16 Å2/pixel on the specimen level. The defocus range was varied from ~1.0 to ~3.0 μm. A total of 
20 frames per stack were recorded with the total dose rate about 2 e-/Å2 for each frame. A total of 
7 494 cryo-EM micrographs were collected. Frames in each image were aligned and summed using 
the unblur software suite (Campbell, Cheng et al. 2012). The defocus values of each image were 
determined by Gctf (Zhang 2016). 
A total of ~520 000 particle images (henceforth termed particles) were autopicked using the 
reference-based particle picking routine in Gautomatch software 
(http://www.mrc-lmb.cam.ac.uk/kzhang/). As a template, I used 40° projections of the yeast 
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Bact complex map (EMD-9524) low-pass filtered to 60 Å.  All subsequent 2D and 3D classifications as 
well as 3D auto-refinement runs were performed in RELION using particles binned to a pixel 
size of 2.32 Å2/pixel. 
An initial dataset of 50 000 particles was processed to inspect sample quality and composition and to 
define the image processing strategy that was applied to the entire data set (data not shown). 
In order to remove false positive particles from the initial data set, I performed reference-free 
2D classification and subsequent 3D multi-reference refinement (unsupervised 3D classification) 
based on likelihood optimisation. The unsupervised 3D classification not only helps to remove 
junk-particles from a dataset, but was also shown to separate classes with large conformational 
differences (Scheres, Gao et al. 2007). Considering a high level of structural similarity between 
human and yeast spliceosomes, I started with the map of S. cerevisiae Bact complex filtered to 60 Å as 
an initial 3D reference (EMD-9524) (Yan, Wan et al. 2016). For the 3D classification I used 5 classes 
(K = 5) and performed 25 iterations of likelihood optimization using non-aligned particles. 
3D classification yielded one poorly defined class comprising mostly junk particles that were 
discarded (class 3) (Figure 4.7). The other four classes displayed reasonable similarity to the yeast 
Bact structure and showed common structural features, such as an elongated central body connected 
to a foot and a top domain together with shallow and steep slopes. However, they also exhibited 
significant differences in peripheral regions, which could be interpreted in terms of two different 
conformations, henceforth termed as form A and form B, respectively (Figure 4.7). Classes 1 and 2, 
comprising ~122 000 and ~115 000 particles, respectively, represent form A, which has a globular 
density at the top right corner as a characteristic feature. Classes 4 and 5, comprising ~122 000 
and ~123 000 particles, respectively, reflect the second form B, which has an elongated density 
element at the lower right side of the central body, as well as an additional globular density in the 
middle and at the top left corner, while density at the top right corner is, in contrast, much less 
visible (Figure 4.7).  
Although independent processing of these four classes helped to improve the above mentioned 
forms, the final resolution was restricted due to insufficient number of particles. Therefore, the four 
selected classes were merged, yielding ~480 000 particles that were read back to the original images 
and re-extracted based on their refinement centre using RELION. Relative orientations of the 
selected particles were determined with improved accuracy in 3D auto-refinement runs with 
respective references 1 and 2, representing forms A and B, (Figure 4.7). 
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Figure 4.7: Computational sorting scheme of the human Bact complex 
Using the particle picking software Gautomatch and 40° projections of the yeast Bact model (EMD-9524) filtered to 60 Å as a 
reference, I extracted ~520 000 particles from the pre-sorted cryo-micrographs and cleaned the dataset by 3D classification 
in RELION that resulted in separation of two conformationally different forms. Good classes comprising ~480 000 particles 
were merged and subsequently applied to three separate rounds of 3D classification in RELION featuring 5 or 20 classes 
each. (I) For the determination of the most complete form A, the 45 189 particles finally contributing to the best 3D class 
were used for the 3D auto-refinement revealing an 6.8 Å resolution structure (referred to as the unmasked EM density map 
of the form A). (II) For the highest resolution structure, I excluded part of lower resolved density representing the first 
conformational state in the final rounds of the refinement (form A with mask). A soft mask with a 7 voxel frame and an 
additional 7 voxel soft frame was used for the refinement and for the resolution determination. The final map was obtained 
with a resolution of 5.3 Å. (III) Exhaustive 3D classification targeting form B yielded a 3D class, consisting of 17 341 particles. 
Further refinement revealed an 8.1 Å resolution structure (form B). 
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First, I set out to resolve peripheral regions described above and to identify components of the 
corresponding densities. To obtain the most complete form A, a guided multi-reference classification 
procedure was applied again to all ~480 000 auto-refined particles. Two subsequent rounds of 
3D classification with K = 5 followed by selection and 3D auto-refinement of the best class were 
performed yielding an average resolution of 6.8 Å (Figure 4.7, red, dashed box I).  
For the highest resolution structure, ~480 000 particles, auto-refined with the reference 1 low-pass 
filtered to 40 Å were subjected to a 3D classification with K = 20 (Figure 4.7, violet, dashed box II). 
The best resulting class comprising ~81 000 particles yielded a ~10 Å resolution structure. While 
peripheral regions were somewhat lower resolved, I decided to mask them out and excluded part of 
the density referred to as the steep slope, applying a soft mask with a 7 voxel frame and an 
additional 7 voxel soft frame (Figure 4.7). Finally, I performed 3D auto-refinement resulting in a map 
with an average resolution of 5.3 Å. As can be seen in Figure 4.8 A, the angular distribution of 
particles used for the final reconstruction of the core Bact structure is reasonable. Resolution was 
determined by Fourier shell correlation calculated from two independent data sets with a threshold 
of 0.143 (Figure 4.8 B). Local resolution estimation using ResMap revealed that indeed peripheral 
regions are less well resolved but still at sub-nanometer resolution (Figure 4.9). 
 
Figure 4.8: Cryo-EM analysis of the human Bact complex 
(A) Two perpendicular orientations of the Bact complex are shown. Angular distribution of the particles used for the 
reconstruction of the spliceosomal Bact complex at 5.3 Å resolution. Each column represents one view and the height of the 
column is proportional to the number of particles for that view. Red columns indicate abundant views. (B) The resolution of 
the overall map of A and B forms and the core region of the A form is estimated to be 6.8 Å, 8.1 Å and 5.3 Å, respectively, 
on the basis of the FSC criterion of 0.143. 
The next aim was to obtain the highest possible resolution for the peripheral regions of the form B. 
Due to considerable heterogeneity, the main challenge was to distinguish particles belonging to 
different conformational variants. Iterative multi-reference 3D classification targeting only those 
classes that exhibited form-B appearance lead to a significant decrease in the particle population, 
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indicating that either too many good particles were discarded during classification or too many 
variations of this conformational state can be distinguished. Therefore, I performed independent 
3D auto-refinement for the entire dataset comprising ~480 000 particles with a low-pass filtered to 
40 Å reference 2, representing form B. Subsequently, I performed exhaustive 3D classification with 
K = 20 resulting in few classes, characterizing the second conformational state. The best subset 
containing 17 341 particles was subjected to 3D refinement giving a structure with an average 
resolution of 8.1 Å, according to the FSC 0.143 criterion (Figure 4.8, blue, dashed box III). As can be 
seen in Figure 4.9 C, local resolution of the core part is better than 8 Å. The resulting map showed 
clear features of the elongated side density and the globular density in the middle part, while the 
globular density at the top peripheral region above the shallow slope could not be resolved at 
sub-nanometer resolution. 
 
 
 
 
 
Figure 4.9: Local resolution 
plots of the Bact complexes 
Two perpendicular views of 
the complexes are shown. 
The local resolutions are 
color-coded for different 
regions of the Bact complex 
and reveal a resolution 
distribution from ca. 5 to 
10 Å with some less 
well-defined areas at the 
periphery of the complex. 
(A) Higher resolution regions 
(in blue, up to 5 Å) were 
obtained for the centrally-
located core of the form A 
refined with the soft mask. 
(B, C) Peripheral regions that 
still have sub-nanometer 
resolution represent less 
stable areas in forms A (B) 
and B (C). 
 
 
 
Results 
54 
 
4.4 Structural overview of form A of the Bact complex 
In the front view, the Bact spliceosome exhibits a mushroom-like shape with a central body connected 
to a foot and a top domain, as well as to a shallow and a steep slope (Figure 4.10). In the steep slope 
we distinguish a more elongated and a globular domains, termed UPD1 and 2 (unmasked peripheral 
domains 1 and 2). UPD1 is connected to the central domain by two massive density bridges 
(bridges 1 and 2), to the top domain by a thinner adjacent density bridge 3 and to a globular UPD2 by 
a bridge 4. Additionally, globular UPD2 is attached to the top domain by density bridges 5 and 6. 
Another unmasked domain, termed UPD3, is situated between bridges 2 and 3. Finally, a globular 
domain is attached to the lower part of the top domain (UPD4) and another one to the lower part of 
the central domain (UPD5). 
 
Figure 4.10: cryo-EM structure of the human Bact complex 
Different views of the Bact complex EM density map. Better resolved regions are shown in blue and five additional domains, 
termed unmasked peripheral domain UPD 1-5 are shown in grey. Density bridges B1-B6 connect UPD 1-3 to the central 
body and a top domain. Scale bar is located at the right side. 
4.4.1 Structural organisation of U5 snRNP proteins 
U5 snRNP proteins that remain associated with the human Bact complex include four large proteins, 
Prp8, Brr2, Snu114 and U5 40K, in addition to the U5 Sm core and the U5 snRNA. The domain 
organization of Prp8, Brr2 and Snu114 is shown in Figure 4.11. The U5 Sm core, including the 
3'-terminal U5 snRNA Sm site, is located at the foot of the 5.3 Å EM density map of Bact. 
The GTP-binding protein Snu114 shows a high degree of homology with the ribosomal elongation 
factor EF-2/EF-G (Fabrizio, Laggerbauer et al. 1997); it is located at the lower end of the main body 
(Figure 4.11, E). Domains D1 to D5 of Snu114 adopt the same compact structure as in the human (h) 
tri-snRNP and C* complex (Agafonov, Kastner et al. 2016, Bertram, Agafonov et al. 2017, Zhang, Yan 
et al. 2017). 
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Figure 4.11: Structures and positions of the U5 snRNP proteins 
(A) Fit and structural organisation of Prp8. Prp8 is comprised of the following domains: NTD1, NTD2: N-terminal domains 1 
and 2; NTDL, linker between NTD1 and 2; RT, reverse-transcriptase-like; En, endonuclease-like; RH, RNase H-like; Jab1, 
Jab1/MPN-like. (B) Location of Prp8, Brr2, Snu114, U5 40K and U5 Sm proteins. (C) Expanded view showing fit and 
structural organisation of Brr2 (NC/CC, N-terminal/C-terminal helicase cassettes) with the bound Prp8 Jab1 domain. (D) Fit 
of the U5 40K WD40 domain. (E) Fit and structural organisation of Snu114 (domains D1 to D5 homologous to EF-G/EF-2). 
The 274 kDa protein Prp8 is a major scaffolding protein situated at the heart of the spliceosome’s 
catalytic core RNP. The large central RT/En domain of Prp8 lies with its long axis almost perpendicular 
to the axis of the main structural domain of Bact, such that the RT domain lies above Snu114 (Figure 
4.11, B). The RH domain is closely associated with the “back side” of the En domain, whereby the RH 
RNA-binding β-sheet faces the En domain and the RH β-hairpin-loop points upwards. The Prp8 NTD1 
has essentially the same structure as in the S. cerevisiae cryo-EM models; it is in contact with the 
U5 snRNA and Snu114 in the lower part of the main domain of Bact (Figure 4.11, lower A and B). The 
Prp8 RT/En domain is found at different positions relative to the NTD1 in the Bact complex compared 
with the human tri-snRNP (Figure 4.12). While in the tri-snRNP Prp8 has an open conformation, in 
which the En domain is located ca. 5 nm away from the NTD1, in the Bact complex it adopts a closed 
conformation. That is, the En domain is very close to NTD1, leaving a narrow channel between the 
two domains that appear to accommodate the 5’ exon (see below). Thus, already at the Bact stage, 
Prp8 has undergone the major rearrangements that are required to create the pocket between the 
thumb/X, linker, NTD1 and NTD2, into which the catalytic RNA network docks (Figure 4.12, B). 
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Figure 4.12: Conformational differences in Prp8’s RT/En domains between the human tri-snRNP and Bact complex 
Protein surfaces of Prp8 domains (NTD1, NTD2: N-terminal domains 1 and 2; RT, reverse-transcriptase-like; 
En, endonuclease-like) and Snu114 together with snRNA models are shown. (A) Open conformation of Prp8 in the human 
tri-snRNP (PDB 3JCR) (Agafonov, Kastner et al. 2016), where the En domain is spatially separated from NTD1. SL, stem loop 
(B) In the Bact structure Prp8 adopts a closed conformation. The catalytic U2/U6 RNA network and U2/BS helix are docked 
into the active site pocket of the Prp8 protein. ISL, U6 internal stem loop; BS, branch site of the pre-mRNA. 
I was able to locate the complete 200 kDa helicase unit of Brr2 in complex with the Prp8’s Jab1 
domain in the shallow slope of the Bact structure, close to the tip of the Prp8’s En domain (Figure 
4.13). Although Brr2 contains two tandemly organised helicase cassettes, only the N-terminal 
cassette (NC) actively unwinds the U4/U6 duplex during spliceosome activation (Santos, Jovin et al. 
2012). Interestingly, the C-terminal tail of Prp8’s Jab1 domain, which regulates Brr2 helicase activity 
(Maeder, Kutach et al. 2009, Mozaffari-Jovin, Wandersleben et al. 2013), appears to be docked in the 
RNA-binding channel of the NC, as previously observed in the Brr2-Jab1 co-crystal (Mozaffari-Jovin, 
Wandersleben et al. 2013); thus, after U4/U6 unwinding, Brr2 appears to be once again repressed 
(Nguyen, Galej et al. 2015, Nguyen, Galej et al. 2016, Wan, Yan et al. 2016). 
Brr2 shares an interface with Prp8’s En domain via the helix-loop-helix (HLH) domain of its N-terminal 
helicase cassette (NC); this interaction appears to be stabilized by the PPIase domain of the 
Bact protein NY-CO-10 (hCwc27), which connects Brr2’s NC (via its HLH domain) and Prp8’s NTD1 and 
En domain (Figure 4.13, B and C), consistent with our crosslinking data (Supplementary Table S1). As 
in the human tri-snRNP Brr2 is located close to Prp8’s RT domain (Agafonov, Kastner et al. 2016), 
hBrr2 must undergo a dramatic repositioning after integration of the human tri-snRNP into the 
human spliceosome (see also below).  
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Figure 4.13: Location of the 
RNA helicase Brr2 in complex 
with Prp8’s Jab1 domain and 
its interaction with the Prp8 
and NY-CO-10 proteins 
(A) Overall structure of hBrr2 
in complex with Prp8’s Jab1 
domain. EM density map for 
the Jab1 domain is shown. 
(B) Brr2 is placed in the 
shallow slope of the Bact 
density, while Prp8, Snu114, 
U5 40K and NY-CO-10 are 
positioned in the central body, 
and U5 Sm proteins are 
located at the foot of the Bact 
density map. (C) Helix-loop-
helix (HLH) domain of hBrr2 
interacts with both Prp8’s 
En domain and the PPIase 
domain of the NY-CO-10 
protein.  
4.4.2 Organization of U5 snRNA and the catalytic U2-U6 RNA network 
in the Bact spliceosome 
Figure 4.14 shows the location of high density RNA helical elements within the Bact structure. The 
major stem-loop (SL) of U5 snRNA fits into the long RNA helical density element such that the 
3'-terminal U5 snRNA Sm site is located at the foot of the 5.3 Å EM density map of Bact, whereas 
loop 1 of the U5 snRNA is found in the upper region of the elongated main body. U5 snRNA has 
essentially the same structure as in the human C* complex and makes multiple contacts with Prp8’s 
NTD1 domain (Figure 4.14, C).  
 
Figure 4.14: Structure of catalytic core elements in the human Bact complex 
(A) Regions of the highest density within the central domain of the hBact 5.3 Å EM density map. BS-A, branch site adenosine. 
(B) An overview of the RNA architecture in the hBact. (C) A close-up view of the U5 snRNA surrounded by Prp8’s NTD1 and 
U6 snRNA elements including the extended U6 ACAGA/5’ss helix and U6 5’SL.  
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Close to U5 RNA loop I a tripartite RNA density element is located, into which the rearranged U2/U6 
catalytic RNA network can be placed. The ca. 5.3 Å resolution in this part of the Bact complex allows 
the unambiguous placement of the loop and kinked stem of the U6 snRNA internal stem loop (ISL), 
the two U2/U6 helices Ia and Ib (which are stacked on each other), and the sharp turn separating the 
ACAGA box helix of U6 snRNA and helix Ia of U2/U6 (Figure 4.15).  
 
Figure 4.15: RNA network of the human Bact complex 
(A) EM density map and fit of the U6 ISL, extended U6/5’ss helix, U2/U6 helix I and U5 stem I. (B) The helical stack of 
U2/U6 helix I. U6 snRNA nucleotides of the catalytic triplex are shown in purple. (C) Position of metal-coordinating 
U6 snRNA nucleotides A53, G54, G72 and U74. Putative catalytic Mg2+ ions (M1 and M2) positions are represented by red, 
dashed circles. 
The topography of the RNA density is consistent with the existence of the catalytic triplex, as found 
in the hC* complex. The topography of U6 nts U74 and G72, as well as of A53 and G54, is such that 
they could potentially coordinate Mg2+ ions 1 and 2, respectively (which I cannot discern at 5.3 Å 
resolution). This would be consistent with biochemical studies showing metal ion coordination of the 
corresponding nts in yeast U6 (Fica, Tuttle et al. 2013). It is interesting to note, however, that there is 
density for a possible location of only the second catalytic Mg2+ ion (M2) but not for M1. This is 
similar to the situation in the yeast Bact complex, where M2 is already in place while density for M1 is 
missing (Yan, Wan et al. 2016). Thus, while the catalytic RNA triplex appears to be established in the 
hBact complex, the catalytic centre is not yet in an active state. However, only minor rearrangements 
of the M1-coordinating nucleotides would be required to allow binding of M1 and catalysis of step 1 
of splicing. 
4.4.3 The 5’ss is located close to the catalytic centre, but is occluded by proteins Rnf113A 
and U2 SF3A2 
In the Bact model, the RNA helix formed by the interaction of the U6 ACAGA box and the 5' end of the 
intron is located in the vicinity of the U2/U6 snRNA network (Figure 4.16); thus the 5'ss is already 
positioned close to the catalytic centre in the Bact complex. A continuation of the intron sequence of 
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the U6/intron helix (towards the 5'ss) leads to a density element that makes a U-turn close to the 
U2/U6 catalytic triplex and along U5 snRNA loop 1 (Figure 4.14, A). This density accommodates well 
the kinked 5'ss RNA element from the yeast Bact cryo-EM structure (Rauhut, Fabrizio et al. 2016, Yan, 
Wan et al. 2016) with the scissile bond of the pre-mRNA 5’ss oriented towards the catalytic centre 
(Figure 4.16). Furthermore, the GU dinucleotide at the intron’s 5’ end is in close contact with a short 
protein density element as shown in Figure 4.16. In the yeast Bact spliceosome, the 5’-terminal GU nts 
of the intron are in close contact with aromatic amino acids of the C-terminal zinc finger (ZnF) of 
Cwc24 (Rnf113A) and with N-terminal residues of the U2 SF3A protein SF3A2 (Prp11). Additionally, 
these protein-RNA interactions appear to be stabilized by Prp8’s α-finger (Yan, Wan et al. 2016). 
 
Figure 4.16: Organisation of the 5’ss in the human Bact complex 
(A) EM density map of the RNA elements at the catalytic centre. The scissile phosphodiester bond is located close to 
the catalytic triplex of U6 snRNA, which is shown in purple. Putative location of the catalytic Mg2+ ions is indicated by red, 
dashed circles. (B) Fit of RNA and protein elements into EM density map. The 5ʹ exon of the pre-mRNA is anchored to 
U5 snRNA, whereas the 5ʹss is recognized by the ACAGA box of U6 snRNA. The GU dinucleotide of the 5’ss interacts with the 
Rnf113A and SF3A2 proteins. Prp8’s α-finger is located close to the 5'ss (C) A close-up view of the 5’ss at the catalytic 
centre.  
In the human Bact structure a homology model of the C-terminal ZnF of the evolutionarily conserved 
human Cwc24 protein (Rnf113A) can be fit into the density associated with the GU dinucleotide of 
the 5’ss. Major parts of SF3A2 are similarly organized as in the yeast Bact structure, and it is also 
possible to trace its N-terminal part in a corresponding density close to the 5’ss GU nts. Moreover, 
the α-finger of the human Prp8 protein is also located close to the ZnF of Rnf113A (Figure 4.16, B). 
Therefore, it is likely that also SF3A2 may contact the 5’ss in the human Bact structure. Taken 
together, the 5’ss GU nts of the pre-mRNA are located close to the catalytic centre of the human 
Bact structure but are occluded by interaction with the ZnF of Rnf113A (yCwc24) and probably also by 
residues of SF3A2, a situation which closely resembles that in the yeast Bact spliceosome. As these 
proteins not only spatially separate the 5’ss from the catalytic centre, but at the same time hinder 
access of the BS adenosine (the step 1 nucleophile) to the 5’ss, they must be rearranged to liberate 
the 5’ss for its final docking into the catalytic centre. Consistent with this idea, Cwc24 is dissociated 
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from the spliceosome during the Prp2-mediated catalytic activation, and SF3A proteins including 
SF3A2, are destabilized, i.e. structurally rearranged (Warkocki, Odenwälder et al. 2009, Lardelli, 
Thompson et al. 2010, Ohrt, Prior et al. 2012). 
While it is possible to trace an additional ca. 10 more N-terminally located amino acids of Rnf113A in 
a corresponding density extending from the ZnF region towards the top domain of the Bact structure, 
there is no density for the RING finger domain of Rnf113A, close to the U2 SF3B3 protein (where the 
homologous domain of yCwc24 is positioned in the yBact structure (Yan, Wan et al. 2016), presumably 
due to flexibility of this domain in the hBact structure. It is interesting to note, however, that this 
region of the protein is close to the top domain and to the Brr2 helicase domain, as indicated by 
multiple crosslinks of Rnf113A to the U2 SF3B and Brr2 proteins (Supplementary Table S1). 
It is also interesting to note that the N-terminal elongated part of NY-CO-10 is located adjacent to the 
part of Rnf113A (just N-terminal of its ZnF domain) and directly interacts with it, consistent with 
crosslinks between these protein regions, providing a possible molecular basis for the biochemical 
observation that NY-CO-10 dissociates from the spliceosome at the same time as Rnf113A (Bessonov, 
Anokhina et al. 2008). 
4.4.4 The U2/U6 catalytic RNA network interacts closely with Prp8 and numerous Bact 
proteins 
While the 3D structure of the rearranged U2/U6 RNA network in the spliceosome is very similar to 
the structure of the catalytic centre of the group II self-splicing intron, it can only form, and is only 
stable, in the presence of the closed form of Prp8 and numerous additional proteins of the 
Bact complex including the Prp19/CDC5 complex. Figure 4.17 shows how the U2/U6 RNA network fits 
tightly with one face into the active site of PRP8. For example, the NTD2 of PRP8 packs against 
the U2 snRNA part of U2/U6 helix Ib and is also in contact with the U6 ISL, and the linker between 
PRP8 NTD1 and 2 is located in the major groove of U6 ISL. 
 
Figure 4.17: Proteins that stabilize the 
U2/U6 RNA network 
(A) The catalytic U2/U6 RNA network 
docked in the active site pocket of 
Prp8 (shown as a space filling model) 
in the hBact structure. The conserved 
interaction of the linker between 
NTD 1 and 2 (NTDL) with the U6 ISL is 
shown. (B) Myb domain of Cdc5 
interacts with U2/U6 helices Ia and II. 
WD40 domain of Prl1 contacts the U5 
stem Ic and U6 ISL.  
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In addition to Prp8, the following Bact proteins also interact with the U2/U6 RNA network. The WD40 
domain of Prl1 interacts with U5 stem Ic and the U6 ISL loop (Figure 4.17, B; Figure 4.18, A). The 
N-terminal Myb domains of Cdc5 are attached to the Prp8 RT domain and interact with U2/U6 
helices Ia and II (Figure 4.17, B; Figure 4.18, B). Interestingly, an α-helix of Cdc5 located closer to 
the C terminus, which runs along the U6 ACAGA/5’ss helix in the human C* complex, is not visible 
and, therefore, is probably very flexible in the Bact complex. N-terminal parts of Skip (hPrp45) are also 
in contact with the U6 ISL, while other parts of this protein meander around the Prl1 WD40 domain 
(Figure 4.18, B and C). While in the human C* complex, the N-terminal amino acids ~100-130 of Skip 
could be found, in the Bact they appear to be flexible and thus not visible (Figure 4.18, D). More 
C-terminal regions of Ad002 are organized in a similar manner as in C*, indicating that this protein is 
correctly integrated into the hBact complex (Figure 4.18, A). Finally, the N-terminal HAT (Half a TPR) 
repeats of the HAT protein hSyf3 (Crnkl1) bind to the lower stem of the U6 ISL, while its HAT repeats 
1-2 are bound to Prp8’s NTD2 and HAT repeats 3-5 interact with U2/U6 helix II (Figure 4.18, C). 
 
Figure 4.18: EM density map of 
proteins interacting with the 
U2/U6 catalytic RNA network 
(A) A close-up view of Prl1’s WD40 
domain. The interactions of the 
Prl1’s WD40 domain with Skip and 
Ad002 and U5 stem Ic are shown. 
(B) Fit of proteins surrounding 
U2/U6 helix II. The meandering 
path of Skip is shown. (C) A close-
up view of the region between the 
U6 ACAGA/5’ss helix and U2/U6 
helix II, bound to HAT repeats of 
Crnkl1. Skip bridges Crnkl1 and the 
WD40 domain of Prl1. (D) Skip 
protein from the hC* complex, 
placed into EM density map of 
hBact (PDB 5XJC; Zhang, Yan et al. 
2017). Missing density for the 
N-terminal region of Skip in the 
hBact map suggests that this part of 
the protein is highly flexible. 
4.4.5 An extended U6 ACAGA/5’ss helix and a rearranged 5'-terminal region of U6 snRNA 
in the human Bact complex 
Interestingly, U6 nucleotides 30-40, which are immediately upstream of the ACAGA box, also form 
base pairs (including non-canonical ones) with additional intron nucleotides downstream of 
the 5'ss (Figure 4.19). This resulting helix is hereinafter termed the extended U6 ACAGA/5’ss helix. As 
an extended U6 ACAGA/5’ss helix is also present in the human C* complex (Bertram, Agafonov et al. 
2017, Zhang, Yan et al. 2017), but was not observed in yeast spliceosomes (Rauhut, Fabrizio et al. 
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2016, Yan, Wan et al. 2016, Fica, Oubridge et al. 2017, Plaschka, Lin et al. 2017, Yan, Wan et al. 2017), 
it may be a structural feature of the spliceosome in higher eukaryotes only. Such extended helical 
elements may help to stabilize short RNA helices, such as the human U6 ACAGA box/5'ss helix, which 
consists of only a few canonical base pairs. 
 
Figure 4.19: Structure and interaction partners of the U6 snRNA 5’-terminal region in hBact complex 
(A-B) Position and fit of the extended U6 ACAGA/5’ss helix and U6 5’SL in hBact complex compared to hC* (PDB 5XJC) 
(Zhang, Yan et al. 2017). (C) Close-up view of the G10 protein, which tightly interacts with the 5’SL of U6. (D) N-terminal ZnF 
domains of Rbm22 directly bind to the extended U6 ACAGA/5’ss helix and lock the intron in a channel. (E) C-terminally 
located RRM domain of Rbm22 is part of the bridge 1 (B1).  
In human Bact, the 5'-terminal SL of U6 is located in the lower part of the central domain in essentially 
the same position as in the human C* complex (Figure 4.19, A and B). Consistent with the similar 
position of the U6 snRNA 5’ end in the human Bact and C* complexes, the human G10 (Bud31) protein 
also interacts with U6 snRNA close to the U6 5'SL and anchors it to the Prp8 NTD1 domain (Figure 
4.19, C). The ZnF domains of Rbm22 also bind tightly to the single-stranded region of U6 snRNA on 
the opposite side of G10, close to the U6 5'SL (Figure 4.19, D). The C-terminally located RRM domain 
of Rbm22 reaches out to the UPD1 domain and is thus part of bridge 1 (B1) (Figure 4.19, E; and also 
below). 
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4.4.6 The 5' exon-binding channel and the location of the EJC-binding protein Cwc22 
While the first three 3’-terminal nts of the 5’ exon interact with nts of the U5 snRNA loop 1, I can 
trace an additional ca. 10 nts of the exon RNA that thread through a narrow channel; this channel 
connects the Prp8 En domain and the NTD1 (Figure 4.20, A). Consistent with it accommodating RNA, 
the channel contains many positively charged amino acids. The positioning of the Cwc22 protein at 
the end of the proposed exon-binding channel supports indirectly the postulated path of the 5' exon 
in the Bact complex. Cwc22 contains an N-terminal MIF4G-like domain, which in turn contains five 
HEAT repeats and a centrally positioned α-helical MA3 domain. Guided by crosslinks, the two 
domains of Cwc22 can be located on both sides of the exon channel (Figure 4.20 B and D). In the 
human spliceosome hCwc22's MIF4G domain binds the eIF4A3 helicase of the exon junction complex 
(EJC), and it therefore aids in the deposition of the EJC upstream of the spliced exon junction (Le Hir, 
Izaurralde et al. 2000). The position of the MIF4G domain at the end of the exon-binding channel is 
thus consistent with the function of this domain in depositing the EJC complex. Indeed, there is 
additional less well resolved density associated with the MIF4G domain, and this density may 
represent part of eIF4A3 of the EJC complex. At least it is possible to dock the RecA domains of 
eIF4A3 into this density (Figure 4.20, E). In the Bact model, the α-helical MA3 domain of Cwc22 is 
located next to the RT domain of Prp8 and thus lies on the opposite side of the exon-binding channel 
as the MIF4G domain. 
 
 
Figure 4.20: Organisation of proteins 
comprising the exon-binding channel 
(A) A close-up view of the 5’ss and 
surrounding regions of the pre-mRNA. Fit of 
the Prp8 domains forming the exon-binding 
channel. (B) An overview of proteins 
forming the exon-binding channel in the 
hBact structure. (C) A close-up view of the 
MA3 domain of Cwc22 and its fit in the Bact 
EM density. (D) Position of Cwc22 domains 
around the 5’ exon. Cwc22's MA3 domain is 
bound to the Prp8 RT/En domain and its C-
terminal MIF4G domain is attached to 
Snu114’s domain 1 (E) Location of the 
Cwc22 MA3 and MIF4G domains and the 
RecA domains of the EJC helicase eIF4A3 
(PDB 2XB2) (Buchwald, Ebert et al. 2010), 
placed in the UPD5 density element of the 
unmasked Bact model. Model of an extended 
5' exon RNA (red) positioned relative to the 
RecA domains of eIF4A3 in the Bact complex. 
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4.4.7 The U2/U6 helix II adopts a unique conformation in the human Bact complex and is 
sandwiched between proteins Crnkl1 and Ppil2 
Comparison of the conformation of the rearranged U2/U6 RNA network, the U2/U6 helix II and 
the 5’SL of U6 snRNA in the yeast (Bact, C, C*) and human (C*) cryo-EM models reveals that they are 
largely similar, except that the human C* complex has an extended U6 ACAGA helix (Zhang, Yan et al. 
2017). In stark contrast, the U2/U6 RNA helix II adopts a unique conformation in the human Bact 
complex. While in the human C* and all other yeast complexes mentioned above, the end of U2/U6 
helix II points upwards, in the hBact complex it is not only situated somewhat lower in the 
spliceosome, but in addition it is rotated by about 90˚, with the end of the helix lying in a plane 
roughly perpendicular to the long axis of the central body. Furthermore, the protein interactions of 
U2/U6 helix II also differ significantly in the hBact complex (Figure 4.21). 
 
Figure 4.21: Comparison of the position/orientation of the U2/U6 helix II in the human Bact and C* complexes 
Structural comparison of the U2/U6 helix II between the hBact (A) and hC* (B) complexes. Compared to C* (PDB 5XJC) 
(Zhang, Yan et al. 2017), the U2/U6 helix II in the Bact complex is rotated and situated at a lower position, interacting directly 
with Crnkl1 and, thus, leaving no space for integration of the hSyf2 protein. 
In the yeast Bact and all other later spliceosomal complexes, U2/U6 helix II is located close to the 
crossing point of the HAT proteins Clf1 (Syf3) and Syf1, but does not directly interact with these 
proteins. Instead, several α-helices of the Syf2 protein embrace U2/U6 helix II and are in direct 
contact with it (Figure 4.21, B). In contrast, in hBact the HAT repeats 3 to 5 of Crnkl1 (Syf3) preceding 
the crossing point of Crnkl1 with Xab2 (Syf1), interact directly with one side of U2/U6 helix II, forming 
part of the B2 bridge. The other side of U2/U6 helix II is in contact with a globular density, which also 
has a thin connection to bridge 3. The X-ray structure of the PPIase domain of Ppil2 (Davis, Walker et 
al. 2010) can be placed into this density element, consistent with protein-protein crosslinks 
(Supplementary Table S1) (Figure 4.22, A). 
In addition to the PPIase domain, Ppil2 contains two C-terminally located U box domains. 
Surprisingly, these are spatially separated from the PPIase domain by about 10 nm and are 
associated with domain IV of hSnu114 (U box 1) and an adjacent region of hPrp8 comprising α-helix 
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amino acids 1100 to 1120 (U box 2) (Figure 4.22); this is consistent with results from crosslinking 
(Supplementary Table S1). Unfortunately, the linker region of Ppil2 connecting its U boxes and PPIase 
domain cannot be traced in the hBact cryo-EM density. 
 
Figure 4.22: Location and interactions of Ppil2 in the hBact complex 
(A) The UPD3 PPIase domain of Ppil2 interacts with the upper side of the U2/U6 helix II. (B) Close-up view of the fit of the 
Ppil2 U box domains and their neighbouring proteins into the Bact EM density. (C) Overview of the location and interactions 
of spatially separated domains of Ppil2 in the Bact structure. 
Owing to the unique conformation of the U2/U6 helix II and its sandwich between Crnkl1 and the 
PPIase domain of Ppil2, there is no space left for the integration of hSyf2 (GCIP interacting protein 
p29, GCIPp29) into the hBact spliceosome. This explains, at least in part, why hSyf2 integrates into the 
human spliceosome not together with the other NTC proteins (as in yeast), but only concomitantly 
with or after catalytic activation of the hBact complex (Agafonov, Deckert et al. 2011). As in the 
human C* complex, hSyf2 and the U2/U6 helix II have adopted essentially the same structure as in 
the corresponding yeast Bact or C complexes, it is likely that the recruitment of hSyf2 may be 
coordinated with the structural rearrangement of U2/U6 helix II during the transformation of the 
hBact complex to the hC or hC* complex. 
Results 
66 
 
4.4.8 Organisation of the HAT proteins Crnkl1 and Xab2 and the RNA helicase Aquarius 
The Crnkl1 (hSyf3) protein has altogether 17 HAT repeats, of which the N-terminal 5 repeats are 
attached to the central domain of hBact and to U2/U6 helix II. HAT repeats 6 to 7 bind strongly to the 
HAT protein Xab2 (hSyf1). The C-terminal HAT repeats of Crnkl1 are not visible in the unmasked 
density of hBact (Figure 4.22, A). The Xab2 protein forms on both sides of the crossing with Crnkl1 
α-helical solenoids. While density for most of the N-terminal HAT repeats is present, it is visible only 
for a few of the HATs of the C-terminal wing of the curved solenoid (Figure 4.23). 
 
Figure 4.23: Organisation of the UPD1 
(A) Overview of the location of UPD1, made up by Aquarius (Aqr) and the N-terminal region of its interaction partner Xab2. 
(B-E) EM density fit of the RNA helicase Aqr in the UPD1 density in the unmasked Bact model. UPD1 is connected to the 
central domain by two bridges (B1 and B2), to the top domain by B3 and to a globular UPD2 by B4.  
The large elongated density element UPD1 is made up by the RNA helicase Aquarius (Aqr). The Xab2 
N-terminal HAT repeats 1 to 8 share a large interface with the Aquarius protein (Figure 4.23 A). 
Compared with the crystal structure of the isolated Aqr protein (De, Sessonov et al. 2015), several 
domains of Aqr are rearranged in the Bact structure. Most prominent is the repositioning of the 
β-barrel of Aqr by about 2 nm from its position in the crystal structure, in the direction of the pointer 
domain in the hBact structure (Figure 4.24). In the hBact complex, the β-barrel is part of the bridge 1 
and is probably in direct contact with the RRM of RBM22, consistent with protein crosslinks 
(Supplementary Table S1) (Figure 4.23, B and D). The massive ARM domain of Aqr is located at the 
opposite side of B4, which connects UPD1 and 2 and is partially comprised of the N-terminal region 
of Xab2 and the pointer that protrudes from the RecA1 domain of Aqr (Figure 4.23, C and E).  
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Figure 4.24: Comparison of the 
overall architecture of 
Aquarius in the human Bact 
complex and crystal structure  
(A-B) Ribbon representation of 
Aquarius, viewed from two 
different orientations (rotated 
perpendicularly) in the human 
Bact complex and (C-D) crystal 
structure (PDB 4PJ3) (De, 
Bessonov et al. 2015). 
 
4.4.9 The U2 SF3B protein complex is located at the top of hBact and bridges Prp8 and 
Brr2 
Major building blocks of the Bact spliceosome include the U2 snRNP SF3B and SF3A protein 
complexes, which are destabilized or entirely absent in later complexes of the catalytic cycle of the 
spliceosome. In human B and Bact spliceosomes, SF3A/B proteins are in contact with the pre-mRNA 
intron at or near the BS, and they stabilise the U2/BS helix. Of particular interest is the SF3B1 protein 
of the SF3B complex, which contains a C-terminal HEAT repeat domain and which can be crosslinked 
within spliceosomes to the BS, as well as to nucleotides upstream of the BS and along the entire 
3' end of the intron (Gozani, Potashkin et al. 1998, Will, Schneider et al. 2001). Thus, SF3B1 should be 
close to the U2/BS helix and its location in the Bact complex structure should also help to define the 
path of the end of the intron (see also BS-3'ss, below). As described below, a major portion of SF3B is 
located in the top domain of the 5.3 Å cryo-EM structure of Bact complex. In the recently solved 
crystal structure of a protease-resistant human SF3B core complex (Cretu, Schmitzová et al. 2016) 
(Figure 4.25 B), the C-terminal domain of human SF3B1 is composed of 20 HEAT repeats and is 
organised as a relatively relaxed, right-handed superhelix with a pitch of about 65 Å and a mean 
diameter of about 100 Å. In the Bact structure, there are 20 well-defined density elements arranged in 
a ring-like manner, located above the Prp8 RT/En domain, into which all 20 HEAT repeats of the 
human SF3B1 crystal structure fit. 
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Figure 4.25: Comparison of the 
overall architecture of the SF3B 
protein complex in human Bact and 
the crystal structure of a protease-
resistant human SF3B core complex 
A) Overview of the location of SF3B 
proteins in the human Bact structure. 
(B) Ribbon representation of the SF3B 
core complex, viewed from two 
perpendicular orientations in the 
crystal structure of the isolated SF3B 
protein complex (PDB 5IFE) (Cretu, 
Schmitzová et al. 2016). (C) A close-up 
of the fit of the SF3B1 HEAT domain 
and PHF5A. (D) A comparison of the 
overall arrangement of the SF3B1 
HEAT domain between the crystal 
structure of the human SF3B core 
complex and the hBact complex (right). 
However, the overall arrangement of the HEAT domain in the Bact complex differs significantly from 
the crystal structure; in Bact it appears much more condensed, with a lower pitch, such that the HEAT 
repeats form a ring-like structure with a diameter of ~60 Å. As the N-terminal HEAT repeats H1–H7 
are rotated downwards, the first and last HEAT repeats lie nearly on top of each other, and are 
separated by only 18 Å. The SF3B1 HEAT domain is in contact with the top of the Prp8 RT/En domain 
through HEAT repeats 13 and 14, and the top of the RT domain, through its C-terminal α-helices 
(Figure 4.25). 
 
Figure 4.26: Localization of the SF3B complex proteins in the hBact structure 
(A) A close-up view of the fit of SF3B3 in the hBact EM density map. Interface of SF3B3’s β-propeller BPB with RecA domains 
of Brr2’s NC cassette. (B) Front view of the hBact complex and location of SF3B proteins. (C) The SF3B1 HEAT domain is 
located on top of the Prp8 RT/En domain. SF3B5 tightly interacts with SF3B3. 
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In the human SF3B core complex crystal structure, SF3B3 adopts an intertwined three-propeller 
(WD40) cluster form, which contains two tightly coupled β propellers (BPA+BPC) with a large clam-
shaped pocket between them, into which the three-helix structure of SF3B5 (SF3B10) is tightly bound 
(Figure 4.26). Both SF3B3 and PHF5A have a main interface with SF3B1's C-terminal HEAT repeats, 
but they also contact N-terminal HEAT repeats (Figure 4.25; Figure 4.26). The intertwined 
β-propellers BPA und BPC of SF3B3 are located at the top of the Bact model and are aligned with the 
long axis of the main body. The bottom part of BPB faces Brr2's NC cassette and has a major interface 
with the RecA domain of the latter (Figure 4.26). In addition, BPA und BPC also contact Brr2's helicase 
domain. Thus, SF3B1’s's HEAT and SF3B3's WD40 β-propeller domains bridge Prp8 and Brr2 in the Bact 
complex. 
4.4.10 Path of the intron’s 3' region across the HEAT domain 
The PM5-10 construct, which was used for the assembly and purification of the human Bact complex, 
contains 10 nts downstream of the BS. The cryo-EM map of the Bact structure reveals the presence of 
a density element that could accommodate a single-stranded RNA, starting at the bottom part of 
PHF5A, where the 3'-terminal nucleotide of the U2/BS helix is positioned, along the concave side of 
HEAT repeats 3–5 and ending just short of the bottom of HEAT repeats 6 and 7 (Figure 4.27). The 
length of this density element is sufficient to accommodate 10 nts in a stretched conformation. If the 
intron RNA were continued it would pass along the RES protein CGI-79 (Snu17) (see below), very 
similar to the situation in the yeast Bact complex (Rauhut, Fabrizio et al. 2016, Yan, Wan et al. 2016) 
 
Figure 4.27: Location of the BS/U2 helix and path of the intron’s 3’ region 
(A) The BS/U2 helix could be placed into the density element located at the opening between the terminal HEAT repeats of 
SF3B1. (B) Upstream of the BS, the intron is base-paired to U2 snRNA, forming an extended BS/U2 RNA helix. (C) Close-up 
view of the intron path downstream of the BS. 
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4.4.11 The BS/U2 RNA helix is sequestered between the SF3B1 N- and C-terminal HEAT 
repeats, ca. 20 Å away from the RNA catalytic centre 
In the hBact model, the pre-mRNA BS/U2 helix (from human C*) could be placed into the density 
element located at the opening between the terminal HEAT repeats of SF3B1 (Figure 4.27). The BS 
RNA faces the C-terminal HEAT repeats and the density of the BS adenosine (BS-A) is clearly visible. 
The latter is flipped out of the branch helix and is located in a protein pocket built by the β-helices of 
HEAT repeats H15–H16 and capped by PHF5A (SF3B14b). The close contact of HEAT repeats H15–H16 
and PHF5A with the BS RNA is consistent with the inaccessibility of these nucleotides in 
the Bact complex (including the bulged-out adenosine residue) to chemical modification (P. Bao and K. 
Hartmuth, personal communication). On the other side of the BS/U2 helix, the HEAT repeats 1 and 2 
pack against the U2 snRNA. Upstream of the BS, ca. 10 nts of the intron are base-paired to U2 snRNA, 
including non-canonical base pairs, forming an extended BS/U2 RNA helix (Figure 4.27). 
The orientation of the BS/U2 helix is such that the 5'-terminal nt of U2 is ca. 20 Å above the 
3'-terminal U2 nt of U2/U6 helix Ia (Figure 4.28). This is the greatest distance that can be bridged by 
the 4-nt-long U2 linker that connects these two helices. The 2’-hydroxyl of the bulged BS-A is spatially 
separated from the scissile bond of the 5’ss by about 5 nm (Figure 4.28, B). The 3'-terminal U2 nt of 
the BS/U2 helix lies at the upper end of the HEAT repeat H1 and is connected through a 9-nts-long 
linker to the U2 stem-loop IIa (Figure 4.28, C). In summary, these results show that the BS/U2 RNA 
helix is held at the greatest possible distance from the catalytic RNA centre by the terminal repeats of 
SF3B1's HEAT domain. At the same time, the BS-A is occluded in a SF3B protein pocket and thus 
cannot attack the 5'ss at this stage. 
 
Figure 4.28: The BS/U2 helix is spatially separated from the active site 
(A) 5'-terminal nt of U2 is ca. 20 Å above the 3'-terminal U2 nt of U2/U6 helix Ia. (B) The BS-A is spatially separated from the 
scissile bond of the 5’ss by about 5 nm. (C) The 3'-terminal U2 nt of the BS/U2 helix is located at the upper end of the HEAT 
repeat H1 and is connected via a 9-nts-long linker to U2 SL IIa. 
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4.4.12 The U2 SF3B6 (p14) protein is spatially separated from the BS adenosine 
In spliceosomal A and B complexes the SF3B6 RRM domain protein has been shown to crosslink to 
the BS-A, suggesting that it is involved in the BS recognition in the early spliceosome (Will, Schneider 
et al. 2001). The SF3B6 was shown to bind to the N-terminal region of SF3B1, comprising amino acids 
(aa) 373-415; moreover, SF3B6 in complex with a corresponding SF3B1 peptide could be crystallized 
(Schellenberg, Edwards et al. 2006, Spadaccini, Reidt et al. 2006). In the Bact cryo-EM structure no 
density close to the U2/BS helix was found, which could accommodate the SF3B6 protein. Instead it 
is located at the convex side of SF3B1’s HEAT domain, close to the N-terminal HEAT repeats, where 
an α-helical region of SF3B1 bridges SF3B6 to the HEAT repeats 1 and 2, consistent with protein 
crosslinks (Supplementary Table S1). A short α-helix spanning aa Pro398 to Val414 of SF3B1 is firmly 
attached to the central part of the SF3B6 domain (Figure 4.29, B). The putative adenosine-binding 
region of SF3B6 (Schellenberg, Edwards et al. 2006) is spatially separated from the flipped-out BS-A 
by about 5 nm (Figure 4.29, D). Thus, if SF3B6 is indeed close to the BS in early spliceosomes, a major 
rearrangement of SF3B6 together with its SF3B1 binding region has to occur during the transition of 
the early spliceosome to the Bact complex.  
 
Figure 4.29: Localization of the SF3B6 protein 
(A) Overview of the SF3B6 position in the hBact complex. (B) A close-up of the fit of SF3B6 into the hBact EM density map. 
SF3B6 is attached to SF3B1 at the convex side of SF3B1’s HEAT domain. (C) EM density map and (D) ribbon representation 
of the SF3B protein complex, showing the adenosine-binding region (Ade) of SF3B6, spatially separated from the flipped-out 
BS-A by about 5 nm.  
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4.4.13 RES proteins and RNA helicase Prp2 are in contact with distinct regions of SF3B1's 
HEAT repeats on the side opposite of the BS/U2 RNA helix 
The S. cerevisiae proteins Snu17, Bud13 and Pml1 form a heteromeric complex (RES) that is 
important both for splicing and for the retention of unspliced pre-mRNA in the nucleus (Gottschalk, 
Bartels et al. 2001, Dziembowski, Ventura et al. 2004). Recently, a solution structure of the yeast RES 
core complex consisting of the RRM protein Snu17, the C-terminal region of Bud13 and the 
N-terminal region Pml1, was determined (Wysoczanski, Schneider et al. 2014). In view of the high 
evolutionary conservation of human RES proteins, it is likely that they are also similarly organized as 
a hetero-trimeric complex as the yeast counterpart. Indeed, guided by crosslinks, it was possible to 
fit the RES core structure below the SF3B1 HEAT ring, close to HEAT repeats H7 to H9, where RbmX2 
(hSnu17) interacts with the bottom edge of H6–H8 (Figure 4.30) (Supplementary Table S1). The RES 
core structure contains a short α-helix of hBud13, which in the Bact complex points downwards from 
RbmX2 toward the RT domain, and an additional region of hBud13 (aa 592-618), which was modelled 
as an α-helix, extends to the lower part of Prp8's RT domain (Figure 4.30). The C-terminal FHA 
domain of Snip1 (hPml1) also lies next to the RT domain (Figure 4.30). A long alpha-helical region of 
Skip is associated with Snip1. These observations are consistent with the idea that the RES complex 
plays a part in bridging the SF3B1 HEAT and Prp8 RT domains. 
 
 
 
Figure 4.30: The location of RES 
proteins 
(A) Overview of the position of 
the RES complex in the human 
Bact structure. (B) Density fit of 
the RES core complex on the 
convex side of SF3B1’s HEAT 
domain. (C) The hBud13 C-
terminal helix occupies a density 
element that continues down to 
Prp8’s RT/En domain. (D) A long 
alpha-helical region of Skip is 
associated with Snip1. 
 
Interestingly, in the hBact 3D model, the RNA helicase hPrp2 interacts closely (through its C-terminal 
OB fold domain) with the upper part of HEAT repeats H7–H9 of SF3B1, and its RecA domains point 
away from the HEAT domain, facing the RES complex (Figure 4.31). This is consistent with the 
C-terminal domain playing an essential role in mediating Prp2's interaction with the spliceosome 
(Edwalds-Gilbert, Kim et al. 2004). It is interesting to note that hPrp2 is stably bound to the HEAT 
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domain even in the absence of a long 3’-end of 
the intron, demonstrating that RNA-protein 
interactions are not essential for complex 
formation of hPrp2 with the human 
spliceosome. Similar findings have been made 
for the yeast spliceosome (Warkocki, 
Odenwälder et al. 2009). On the basis of 
protein-protein crosslinks, Prp2's cofactor 
GPKOW, appears to be located between Prp2 
and the RES complex (Supplementary Table S1). 
 
 
 
Figure 4.31: Location of the hPrp2 RNA helicase 
(A) Back view of the hBact complex and fit of hPrp2 in the 
UPD4 of the Bact model. (B) hPrp2 interacts closely with the 
upper part of HEAT repeats H7–H9 of SF3B1. Organisation 
of the 3’-domain of U2 snRNP and the intricate network of 
SF3A complex proteins with other parts of the spliceosome 
 
4.4.14 Organization and interactions of the U2 SF3A protein complex 
The 3’-terminal Sm core structure of U2 snRNP, with its associated A’ and B’’ heterodimer proteins, is 
spatially separated from the central SF3B protein complex and is located together with a large part of 
the SF3A protein complex in the UPD2 domain of the unmasked hBact cryo-EM model. It is connected 
by several bridges to the SF3B-containing top domain and to UPD1. Starting from the 3’-terminal 
U2 nt of the extended U2/BS helix, the U2 snRNA nts can be traced in a density close to the convex 
side of the HEAT domain that runs up to a density, which accommodates the U2 stem-loop IIa. 
U2 stem-loop IIb then forms the bridge B6, connecting the U2 Sm site. Proteins of the U2 SF3A 
complex, and the SF3B2 and SF3B4 proteins (hCus1 and hHsh49), form an intricate protein network, 
connecting numerous parts of the spliceosome including the U2 snRNP 3’ domain.  
Bridge B5 contains two RRM domains of the U2 B” protein, with RRM2 being close to the WD40-C 
domain of SF3B3. Thus, consistent with the finding of crosslinks between RRM2 of U2 B” and the 
C-terminal domain of SF3A3, which in turn crosslinks to SF3B3’s WD40-C domain, SF3A3’s C-terminal 
domain can be placed into the density between RRM2 of U2B” and the WD40-C domain of SF3B3 
(Figure 4.32, B; Figure 4.33, B).  
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Figure 4.32: Organization of U2 SF3A protein complex 
(A) Globular UPD2 is connected to the U2 SF3B complex located in the top domain via thin bridges B5 and B6 and to the 
UPD1, containing Aqr and Xab2, via B4. (B) Top view of the unmasked Bact model and density elements in UPD2 attributed 
to the U2 Sm core RNP and part of the SF3A protein complex. Main connections are provided between the 3’-terminal U2 
snRNP domain and the top domain of Bact through the SF3A proteins, and SF3B2 and SF3B4. 
Guided by crosslinks, a large part of the crystal structure of the SF3A core comprising the N-terminal 
region of SF3A3 and an α-helical domain of SF3A1 can be placed into a density element at the top of 
UPD2 (Figure 4.33). Here, one part of SF3A3 (aa 124 to 353) interacts with Sm proteins and stem-loop 
III of U2 snRNA, while the N-terminal part (aa 1 to 123) binds to the U2A’ protein and together with 
the helical region of SF3A1, is connected to the N-terminal HAT repeats of Xab2 in bridge B4 (Figure 
4.33). Evidence from crosslinks indicates that hIsy1 may possibly also be part of this bridge. 
Beneath bridge B4 runs an additional bridge B3, which connects the N-terminal HAT repeats 2-4 of 
Xab2, through protein CypE, to the RRM1 of SF3B4, whereby CypE’s PPIase domain is attached to 
Xab2 and its RRM domain interacts with RRM1 of SF3B4, which in turn also interacts with a 
C-terminally located domain of SF3B4 (Figure 4.33, A). As mentioned above, the PPIase domain of 
Ppil2 appears to interconnect bridge B3 via contacts with SF3B4’s RRM1 domain with U2/U6 helix II 
(Figure 4.22). A SF3A2 domain is also part of bridge B3 and is located close to the linker region 
between CypE’s PPIase and RRM domain (Figure 4.33). Finally, the central ZnF domain of SF3A2 is 
associated with the C-terminal HEAT repeats of SF3B1 and contacts closely the backbone of the 
extended U2/BS helix (Figure 4.33), while its N-terminal part reaches out to the 5’ss GU nts (see 
above), a setting which closely mirrors the organization and RNA contacts of its counterpart Prp11 in 
the yeast Bact complex (Yan, Wan et al. 2016). 
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Figure 4.33: SF3A/B proteins bridge 
UPD1 and 2 to the top domain and 
also to each other 
(A) A close-up view of the fit of 
proteins in bridge B3, connecting 
UPD1 to the top domain. B3 contains 
the CypE protein, whose PPIase 
domain is attached to Xab2, 
whereby its RRM domain interacts 
with the RRM domain of SF3B4. The 
C-terminally located region of SF3A2, 
which is also part of B3, is placed 
between domains of CypE, while its 
N-terminal domain interacts with 
SF3B1 and the extended U2/BS helix. 
(B) UPD2 is attached to the top 
domain via the 3’ end of U2 snRNA 
(B6) and the two RRM domains of 
U2 B”. (C) Organization of UPD2, 
comprised of the 3’ end of 
U2 snRNA, the U2 Sm ring, 
U2 proteins A’ and B”, as well as 
parts of the SF3A complex proteins 
SF3A1 and SF3A3. 
Similar to the yeast B complex structure, a large part of the SF3B2 protein forms an extended 
polypeptide domain that is associated with the C-terminal HEAT repeats of SF3B1 (Figure 4.34). 
A globular region of SF3B2 forms an intricate complex with the RRM1 domain of SF3B4 and an 
extended C-terminally located α-helical part of SF3A3 (Figure 4.34). 
 
Figure 4.34: A close-up view on the SF3B2 structure in the human Bact complex 
(A) SF3B2 forms an extended polypeptide region that folds onto SF3B1 HEAT repeats H16–H20 and the SF3B3 BPC domain. 
(B) A globular region of SF3B2 interacts with SF3B4’s RRM1 and nearby ZnF domains of SF3A2 and SF3A3. 
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4.5 Cryo-EM structure of form B of the Bact complex 
The final 3D classification of the hBact particles yielded a second major form of the hBact complex at an 
average resolution of 8.1 Å. Close inspection of this Bact form reveals that the structure of most of the 
central domains, the U2 SF3B core structure, hBrr2 and most of the 3’ domain of U2 snRNP is very 
similar to that in form A of hBact. This also applies to the organisation of the U2/U6 catalytic RNP core, 
including the missing density for the catalytic metal M1. 
However, forms A and B also show significant differences in other regions of the structure. The most 
striking difference is the presence of an elongated density element at the side of the hBact main body 
in form B, which is not visible in form A. This elongated density comprises a helical bundle, which is 
formed by the coiled-coil regions of the four copies of hPrp19, Spf27 and the C-terminal helical part 
of Cdc5. The four Prp19 WD40 domains are not visible, presumably because they are highly flexible 
(Figure 4.35). 
 
Figure 4.35: Two major conformationally different forms of the human Bact complex 
(A) Front view of the two major forms of hBact. (B) Comparison of the overall EM density of the two forms of Bact. The U2 Sm 
region (UPD2) is repositioned together with the Aqr-Xab2 protein complex (UPD1). Simultaneously, rearrangement of the 
U5 40K WD40 domain and Ppil2 domains occurs. Form B, which has an elongated density element at the lower right side of 
the central body, as well as an additional globular density in the middle, likely represents a later transition state of the 
spliceosome towards its activation. 
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In form B the Prp19 helical bundle is connected to the main body of the hBact complex by three major 
bridges. One attachment point is the WD40 domain of the U5 40K protein, which is associated with 
the lower end of the helical bundle, most probably through the Spf27 helix. Interestingly, the 
position of the WD40 domain of U5 40K has rearranged between the two forms of the 
hBact structure, such that in form B it has moved upwards, away from the U5 snRNA close to the foot 
of the main body (Figure 4.36). The second anchor point of the Prp19 helical bundle at the main body 
is a density bridge between a roughly spherical density element at the main body and the centre of 
the helical bundle (Figure 4.36). This spherical density element comprises the PPIase domain of Ppil1, 
the bridge that was also observed in the cryo-EM structure of the hC* complex (Bertram, Agafonov 
et al. 2017, Zhang, Yan et al. 2017).  
 
Figure 4.36: Overview of the organisation of additional density elements in form B of the human Bact complex. 
(A) Front view of the form B unmasked EM density map. Arrows indicate the location of protein domains that are either not 
visible in the form A (Prp17, Prp19, Spf27, Cdc5, Ppil1, Skip) or reorganised (U5 40K). (B, D) A close-up of the fit of the U5 
40K WD40 domain in forms A (B) and B (D) of hBact. (C) Overview of the structural architecture and interactions of the Prp19 
helical bundle with the central body and Aqr-Xab2 protein complex. 
Strikingly, density for the PPIase domain of Ppil1 is not present in form A of the hBact complex (Figure 
4.35). The absence of density for Ppil1 in form A raises the question of whether the protein is 
physically absent from the Bact particles representing form A, or whether it is already associated with 
the Bact particles but simply not stably bound and, therefore, not visible in the cryo-EM 
reconstruction. For the following reasons it is likely that Ppil1 is already bound to the form A 
Bact particles but is still in a flexible state. Ppil1 has previously been shown to bind stably to a region 
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of the Skip protein encompassing aa 59-79 (Wang, Zhang et al. 2010). Thus it is highly likely that in 
nuclear extracts Skip and Ppil1 form a complex, which is integrated into spliceosome as a 
heterodimer. Evidence for this idea was indeed provided recently by the protein composition of a 
purified human B complex that, in addition to the typical B complex proteins, also contained Skip and 
Ppil1 (Bertram, Agafonov et al. 2017, in press). A close inspection of the form A Bact structure 
revealed that the region of the Skip protein, which is presumably attached to Ppil1, is indeed also not 
visible, indicating that this part of Skip together with Ppil1 is flexible in form A. In contrast, in form B, 
not only is the density for Ppil1 well defined, but the density of the part of Skip that is attached to 
Ppil1 is also visible, at least to some extent (Figure 4.36). 
A third bridge between the helical bundle and the main body of Bact  is located at the top of the helical 
bundle (Figure 4.36) and probably comprises part of Cdc5. This bridge connects Cdc5's C-terminal 
helical region with its N-terminal Myb domains, which are associated with the Prp8 RT domain in 
form B as in form A of the Bact structure. 
The third significant difference between forms A and B is the absence of density for the PPIase 
domain of Ppil2 in form B (Figure 4.35). At the same time the N-terminal U box domains of Ppil2 are 
still well defined in form B and have not rearranged in comparison with form A. This indicates that 
Ppil2 is still present in the Bact particles representing form B of the Bact structure, but that Ppil2’s 
PPIase domain has become destabilized and flexible. It is interesting to note that in form B the 
conformation of U2/U6 helix II has changed slightly, with the end of the helix turned slightly 
upwards; such a rearrangement is probably only possible as a result of destabilization of Ppil2’s 
PPIase domain in form B. Moreover, bridge B3 is slightly rearranged in form B as compared with 
form A (Figure 4.37). 
 
Figure 4.37: Comparison of the 
structural organization of 
U2/U6 helix II in the two major 
forms of Bact and the human C* 
complex 
(A-B) Close-up views of the fit of 
U2/U6 helix II and its interaction 
partner Crnkl1 in forms A (A) 
and B (B) of the hBact complex. 
(C) Ribbon representation of the 
superimposed structures of 
U2/U6 helix II in the two major 
forms of hBact. Components of 
the form A are shown in light 
brown. (D) Comparison of the 
U2/U6 helix II structure between 
form A of Bact and the C* 
complex. 
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As in form A the Ppil2 PPIase domain is also connected to bridge B3, the rearrangement of bridge B3 
may be caused by the destabilization of Ppil2’s PPIase domain in form B. 
The Aqr/Xab2 protein complex has also slightly rearranged in form B, while all other bridges and the 
3’ domain of U2 appear to be organised in a very similar way in the two forms of the Bact structure. 
Finally, these two forms of the Bact structure differ significantly with respect to the visibility of 
the WD40 domain of hPrp17; in form A density for this domain is missing, while in form B it is well 
defined (Figure 4.38).  
In the human C* complex, the C-terminal part of hPrp17 forms several short α-helical elements and 
meanders through the peripheral part of the main domain, connecting several proteins, including 
Skip and CypE (Bertram, Agafonov et al. 2017, Zhang, Yan et al. 2017). In form B of the hBact 
structure, it is possible to trace the path of hPrp17 and to place several α-helices by rigid-body 
docking into corresponding densities of the hBact structure.  
 
Figure 4.38: The location of the step II splicing factor Prp17 in form B of the human Bact complex 
(A) Overview of the structure of the form B. (B) A close-up view of the location of Prp17 in the EM density map of form B. 
The C-terminal WD40 doman of Prp17 is placed in the globular density between the central and top domains. The N-
terminal portion of Prp17 adopts an extended conformation. 
In summary, the presence and absence of certain densities in the two forms of the cryo-EM 
Bact structure, is in all probability not due to the physical presence and absence of the respective 
proteins or protein domains. Instead, the two forms very probably represent two forms of the 
Bact complex, which differ in the conformational state of several proteins or domains thereof. 
Interestingly, the rearrangement of some of the protein domains appears to be coordinated. This is 
most likely to be the case for the movement of the U5 40K WD40 domain, and for the stable docking 
of Ppil1 and the Prp19 helical bundle, both to each other and to the central domain of 
the Bact structure.
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5 Discussion 
In this work the cryo-EM structure of the human activated spliceosome was determined for the first 
time. Following exhaustive 3D classifications two major populations of images were finally obtained, 
forms A and B, at resolutions of 5.3 Å and 8.1 Å, respectively. While the overall structures of the two 
major populations were largely very similar, several proteins or protein domains exhibited distinct 
conformational states in these two populations; this is probably due to the differential 
conformational flexibility of these proteins. In the following discussion I will first discuss the main 
features of the hBact structure, which are shared by both populations. In the last part I will discuss the 
conformational dynamics of the human Bact complex. 
5.1 The catalytic U2/U6 RNP core structure of the hBact complex is 
evolutionarily highly conserved 
For many years it was debated whether, during activation of the human spliceosome, initially a 4-way 
U2-U6 RNA junction forms at the catalytic centre, rather than a 3-way junction as observed in the 
yeast spliceosome (Madhani and Guthrie 1992, Sun and Manley 1995, Sashital, Cornilescu et al. 
2004). The cryo-EM structure of the human Bact complex shows clearly that the catalytic U2/U6 RNA 
network forms a U2/U6 3-way junction and adopts a 3-dimensional structure that not only closely 
resembles the 3D structure of group II self-splicing introns, but also the 3D structure of the catalytic 
RNA network found in the S. cerevisiae Bact spliceosome. For example, the topology of the EM density 
map of the catalytic core RNA elements of the hBact structure is entirely consistent with the 
formation of the catalytic triplex in the human activated spliceosome (Figure 4.15). 
For catalysis of the first (and second) steps of splicing, two Mg2+ ions have to be positioned ca. 4 Å 
apart within the catalytic RNA network (Steitz and Steitz 1993), a process that is accomplished by 
their coordination through nucleotides of the U6 ISL bulged loop and the catalytic triad of U6 snRNA 
in U2/U6 helix 1b (Fica, Tuttle et al. 2013). This arrangement of the two catalytic metal ions was 
indeed observed in the 3D cryo-EM structure of the yeast C complex and the human and yeast 
C* complexes (Fica, Oubridge et al. 2017, Yan, Wan et al. 2017, Zhang, Yan et al. 2017). In the human 
Bact structure, however, density was only observed for the catalytic metal ion M2 at the catalytic 
centre, but not for M1 (Figure 4.15 C; Figure 4.16 A) – even though the nucleotides that would 
coordinate M1 appeared to be largely positioned in the correct conformation. Interestingly, the same 
situation was also observed in the cryo-EM structure of the yeast Bact complex, which likewise 
showed density for the catalytic Mg2+ M2, but not for M1 (Yan, Wan et al. 2016). As in both 
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Bact complexes an N-terminal region of the SF3A2/Prp11 protein is located close to the nucleotides 
that would coordinate M1, this protein may possibly hinder the correct positioning of M1. Consistent 
with this idea, SF3A2/Prp11 is rearranged during the catalytic activation of the yeast and human Bact 
spliceosomes (Bessonov, Anokhina et al. 2008, Warkocki, Odenwälder et al. 2009, Lardelli, Thompson 
et al. 2010). 
The catalytic U2/U6 RNA network of the human Bact spliceosome is embedded in the same protein 
environment as it is in the yeast Bact spliceosome. The proteins that surround it include Prp8, Cdc5, 
Prl1, Crnkl1 and Skip. Indeed, the same conserved protein regions are in contact with equivalent RNA 
sites/regions of the U2/U6 RNA network in these two spliceosomes (Figure 5.1) (Rauhut, Fabrizio et 
al. 2016, Yan, Wan et al. 2016). The only difference between them concerns the N-terminal region of 
Ad002/Cwc15, which in the yeast Bact complex is in contact with the U6 ISL (Yan, Wan et al. 2016), 
but in the human Bact complex appears to be flexible. However, as it is in contact with U6 ISL in the 
human C* complex (Bertram, Agafonov et al. 2017), it seems very likely that the Ad002 N-terminal 
region will be stably positioned at the U6 ISL during catalytic activation of the Bact complex for step 1 
catalysis. In summary, the structure of the catalytic U2/U6 RNP core is strikingly conserved between 
yeast and human. Moreover, the intricate protein-RNA network at the catalytic RNP core also clearly 
indicates that catalytic U2/U6 RNA network will only form in the presence of the spliceosomal 
proteins, which in turn explains why previous attempts to reconstitute an RNA-only catalytic 
pre-mRNA network largely failed (Valadkhan and Manley 2001, Valadkhan and Manley 2003). 
 
 
Figure 5.1: The U2/U6 catalytic RNA network closely interacts with proteins in the hBact structure 
The catalytic U2/U6 RNA network docked in the active site pocket of Prp8 (shown as a space filling model) interacts with 
Cdc5, Prl1, Skip (A) and Crnkl1 (B) proteins. (C) Ad002 does not interact with the U6 ISL 
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5.2 The first-step reactants are spatially separated in the human Bact 
complex and are occluded by proteins in an evolutionarily conserved 
manner 
Consistent with earlier biochemical crosslinking studies (Sontheimer and Steitz 1993), the 3’ end of 
the 5’ exon and the ACA nts of the U6 ACAGA box are base-paired to U5 snRNA loop 1 and the 5’ end 
of the intron, respectively (Figure 5.2). This induces a U-turn conformation at the 5’ss 
GU di-nucleotide and positions these two nucleotides close to the catalytic centre. The 5’ss, however, 
is occluded by interactions of the GU nucleotides with the N-terminal ZnF region of Rnf113A/hCwc24 
(Figure 4.16 B and C). In the yeast Bact complex the 5’ terminal GU nucleotides are in contact with the 
side chains of protein Cwc24 and the N-terminus of protein Prp11 (Yan, Wan et al. 2016). As the 
N-terminus of SF3A2 (the human homologue of Prp11) is also visible, at least in part, close to the 5’ss 
in the human Bact structure, it is likely that it interacts with the 5’ss nucleotides in a similar manner as 
Prp11 in the yeast Bact structure (Yan, Wan et al. 2016). 
 
Figure 5.2: RNA secondary structure in the Bact spliceosome 
Schematic representation of the RNA network. The complete secondary structure of the U5 snRNA is shown on the left. 
Tertiary interactions are indicated by grey, dotted lines. 
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While the conformation of the 5’ss and its base-pairing interactions, as well as interactions with 
proteins are highly conserved between yeast and human Bact complexes, the first ca. 10 nts of the 
intron downstream of the U6 ACAGA/5’ss helix are involved in the formation of an extended helix in 
the human Bact, but not in the yeast spliceosome. As such, an extended ACAGA/5’ss helix was not 
observed in the cryo-EM structures of other yeast assembly stages, but was present in both human B 
(Bertram et al. 2017, in the press) and C* complexes (Bertram, Agafonov et al. 2017), despite the fact 
that they were assembled on distinct pre-mRNAs. This suggests that an extended U6 ACAGA/5’ss 
helix may be specific for spliceosomes of higher eukaryotes. 
The BS region of the pre-mRNA is organised in the human Bact structure in a manner very similar to its 
organisation in the yeast Bact complex. Thus, in both complexes the BS is base-paired to U2 snRNA in 
an extended BS/U2 RNA helix and the BS/U2 helix itself is clamped between the terminal HEAT 
repeats of the superhelical HEAT domain of SF3B1 (Figure 5.2; Figure 4.27), with the BS-A occluded in 
a protein pocket comprised of the C-terminal HEAT repeats and the PFH5 protein. Moreover, the 
distance between the BS-A and the catalytic centre is ca. 5 nm in both spliceosomes. Finally, the 
C-terminal ZnF domains of SF3A2/Prp11 make contact with the extended part of the U2/BS helix in a 
structurally homologous manner. 
In summary, the human and yeast spliceosomes follow structurally the same strategy in generating a 
pre-catalytic activated spliceosome. In both spliceosomes (i) a catalytic U2/U6 RNP core is assembled 
whose 3D structure resembles closely the RNP core of a catalytically active spliceosome, except that 
the catalytic M1 metal is not yet stably coordinated at the catalytic centre, (ii) the 5’ss is already 
positioned close to the catalytic centre but is occluded by homologous proteins (Rnf113A/Cwc24 and 
SF3A2/Prp11) and (iii) the BS-A is bulged out from the U2/BS helix, but is occluded by U2 SF3B 
proteins and is spatially separated by ca. 5 nm from the catalytic centre. Together, these structural 
features contribute synergistically to a “safeguard” system, which prevents premature nucleophilic 
attack on the scissile bond of the 5’ss at this stage of the spliceosome's assembly. 
5.3 Similarities and possible differences in the catalytic activation pathways 
between human and yeast spliceosomes 
For the catalytic activation of the Bact complex, several major structural rearrangements have to 
occur in the spliceosome. First, the catalytic metal ion M1 has to be stably bound at the catalytic 
U2/U6 RNA centre at a distance of about 4 Å from metal ion M2. Second, Rnf113A/Cwc24 and 
SF3A2/Prp11 have to be rearranged to make the 5’ss available for nucleophilic attack by 
the 2’-hydroxyl group of the BS-A. Finally, for the latter attack to happen, SF3B1/Hsh155 has to be 
rearranged such as to liberate the U2/BS helix; at the same time SFA2/Prp11 has to be displaced 
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from the extended U2/BS helix to allow the latter to swing into the U2/U6 catalytic RNA centre for 
step I catalysis. In the yeast system, it is clear that the only driving force for these events is the 
ATP-dependent action of the RNA helicase Prp2 in co-operation with its co-factor Spp2 (Warkocki, 
Odenwälder et al. 2009). Also in human, hPrp2 together with its co-factor GPKOW is essential for the 
catalytic activation of the spliceosome (Silverman, Maeda et al. 2004). However, there is evidence 
that Prp2 action may not be sufficient. For example, it was recently shown that the ATPase activity of 
the RNA helicase Aqr, which is absent in yeast, is also required to activate catalytically the human 
spliceosome (De, Bessonov et al. 2015). Whether Prp2 and Aqr act co-ordinately or sequentially, is 
currently not clear. Moreover, at least two additional RNA helicases, DHX35 and Abstrakt, which are 
also not present in yeast, have been identified in human C complexes, and these could also play a 
part in the catalytic activation process.  
With the caveat in mind that Aqr and, perhaps, additional RNA helicases contribute to the final 
catalytic activation of the human spliceosome, it is nevertheless reasonable to assume that the 
human Prp2 may trigger the same or similar structural rearrangements of the hBact spliceosome as 
yeast Prp2. In yeast, Prp2 not only displaces Cwc24 and Cwc27 and a fraction of the RES proteins 
from the spliceosome, but also rearranges the U2 SF3B and SF3A proteins, such that their binding to 
the spliceosome becomes salt-sensitive (Warkocki, Odenwälder et al. 2009, Lardelli, Thompson et al. 
2010). How can these dramatic events be triggered by a single RNA helicase? An unexpected scenario 
opened up when the cryo-EM structure of the yeast Bact complex revealed that Prp2 was bound to 
the convex side of the Hsh155 HEAT domain, close to the exit site of the 3’-end of the intron from 
the HEAT domain, but opposite the point where the BS/U2 helix is located within the HEAT domain 
(Rauhut, Fabrizio et al. 2016, Yan, Wan et al. 2016). As this architectural design precluded the 
possibility that Prp2 could access the BS/U2 helix directly, the more likely scenario is that Prp2 binds 
to the intron’s 3’-end and induces, in an ATP-dependent manner, a structural change in the HEAT 
domain, such that the terminal HEAT repeats liberate the BS/U2 RNA helix. Moreover, as Cwc24, 
Prp11 and RES proteins – as well as other U2 SF3A and SF3B proteins, including Cus1 and Prp9 – 
contact the HEAT domain at distinct HEAT repeats, the Prp2-mediated conformational change of the 
HEAT domain may also destabilize the binding of the abovementioned proteins to Hsh155 and thus 
lead to their dissociation from the spliceosome.  
Thus, in summary, the Hsh155 HEAT domain is a major scaffolding domain, which not only occludes 
the U2/BS helix, but is also indirectly connected to the 5’ss by an intricate protein-protein network, 
such that a Prp2-mediated structural change within the HEAT domain would liberate the first-step 
reactants in a highly coordinated manner and pave the way for the docking of the BS-A into the 
catalytic centre. For the following reasons it is reasonable to assume that a similar scenario as 
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depicted for the yeast spliceosome may also apply to the Prp2-mediated part of the catalytic 
activation pathway in the human spliceosome. First of all, all the protein-protein and protein-RNA 
interactions associated with the 5’ss and the U2/BS helix and their interconnectivity with the HEAT 
domain is highly conserved between the yeast and human Bact spliceosomes. Secondly, the human 
and yeast Prp2 RNA helicases are both bound to the homologous HEAT repeats 7 and 8 on the 
convex side of the HEAT domain of the SF3B1/Hsh155 protein in the human and yeast Bact 
complexes. In the yeast spliceosome the intron end leaves the HEAT domain and passes along the 
RbmX2 (hSnu17) RRM domain, and is finally bound by the helicase domain of Prp2 (Schneider, 
Agafonov et al. 2015, Rauhut, Fabrizio et al. 2016, Yan, Wan et al. 2016). The human Bact complex was 
assembled onto a pre-mRNA that contained only 10 nucleotides downstream of the BS – an RNA 
stretch just long enough to transverse the inner part of the HEAT domain close to the HEAT repeats 5 
to 7. In the human Bact structure, RbmX2 is bound at a site equivalent to that in the yeast complex, 
and the distance and orientation of RbmX2 and the HEAT domain-bound hPrp2 are highly similar to 
those in yeast Bact. Therefore, we may reasonably infer that in human Bact a wild-type intron 3’ end 
would be accommodated by RbmX2 and hPrp2 in the same way. Thus hPrp2 may also rearrange the 
SF3B and SF3A proteins, as well as Rnf113A and NY-CO-10 (hCwc27), as it does in the yeast 
spliceosome. 
5.4 Rearrangement of the U2/U6 helix II and recruitment of hSyf2 as a 
prerequisite for catalytic activation of the human spliceosome? 
The question remains why, in the human system, the RNA helicase Prp2 is not sufficient to activate 
the hBact complex catalytically, instead requiring at least also the ATPase activity of Aqr. In this 
context it is important to note that the yeast and human Bact structures differ significantly in respect 
of the conformation of the U2/U6 helix II. Moreover, the human homologue of the yeast NTC 
protein Syf2 is not integrated into the human Bact complex; this is probably due to the peculiar 
conformation of U2/U6 helix II in the human Bact complex, which simply leaves no space to bind hSyf2 
stably (Figure 4.21) (Rauhut, Fabrizio et al. 2016, Yan, Wan et al. 2016). The observations (i) that in 
the yeast Bact complex the U2/U6 helix II has adopted the canonical upright conformation and (ii) that 
Syf2 is present in the Bact spliceosome and binds close to the bottom of the U2/U6 helix together 
suggest that in the human spliceosome the U2/U6 helix II has to be rearranged in order to allow the 
integration of the human Syf2. Indeed, in the human C* complex U2/U6 helix II has adopted the 
conventional conformation and hSyf2 is bound to the bottom of the helix in a manner very similar to 
that in the yeast Bact complex (Bertram, Agafonov et al. 2017, Zhang, Yan et al. 2017). At present it is 
not known exactly when hSyf2 is recruited to the spliceosome. Therefore, it is possible that 
the rearrangement of the U2/U6 helix II and the incorporation of hSyf2 may occur before – or 
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concomitantly with – catalytic activation and may require the coordinated action of the Aqr and 
hPrp2 RNA helicases (and perhaps even an additional RNA helicase such as DHX35). Consistent with 
this scenario is the observation that in form B of the Bact complex the PPIase domain of Ppil2 is 
already dissociated from its binding site at the U2/U6 helix II. A rearranged U2/U6 helix II and a stably 
bound hSyf2 at the base of the helix could in turn also cause a rearrangement of other proteins of 
the central domain of the Bact complex.  
In summary, the structure of the human Bact complex indicates that the catalytic activation pathway 
of the human spliceosome is more sophisticated and more highly regulated than in yeast. The 
absence of hSyf2 from the hBact complex and the different conformations of the HAT proteins Xab2 
(hSyf1) and Crnkl1 (hClf1) in the human and yeast Bact structures explain, at least in part, why in 
human cells these proteins are organised differently as compared with yeast. While in yeast they are 
all recruited to the spliceosome as part of the large NTC complex, in human Syf2 and Crnkl1 exist as 
single proteins, while Xab2 is part of the IBC. Therefore, in human spliceosomes these proteins can 
be sequentially recruited, allowing staggered assembly and thus the possibility of additional steps of 
regulation, as discussed for the integration of hSyf2. 
5.5 Residues in human SF3b155's HEAT repeats whose mutation is linked to 
cancer are close to RES, Prp2 and the 3' end of the intron 
Mutations in certain amino acids of the HEAT repeats of human SF3B1 are associated with various 
cancers (Bonnal, Vigevani et al. 2012, Darman, Seiler et al. 2015, Alsafadi, Houy et al. 2016). Most of 
those mutations that occur very frequently in patients (i.e. "hot spot" mutations) are located close to 
or within the intra-repeat loops of HEAT repeats H4–H7. Thus, cancer-related hot-spot mutations are 
located close to the likely binding region of the intron’s 3' end and the binding sites for the RES core 
complex and Prp2 in the human Bact complex (Figure 5.3).  
Figure 5.3: Cancer-related mutations 
in the human SF3b155 
(A) hPrp2 interacts closely with the 
upper part of HEAT repeats H7–H9 of 
SF3B1. (B) Cancer-related mutations in 
the human SF3B1. The mutated amino 
acids are shown as pink space-filling 
spheres. The amino acids shown in red 
correspond to hot spot mutations that 
map close to the exit site of the BS-
3ʹss RNA from the HEAT domain and 
to the binding sites of RES and Prp2.  
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Mutations in SF3B1 HEAT repeats lead, by an unknown mechanism, to the selection of alternative 
branch sites and consequently to the use of cryptic pre-mRNA 3' splice sites and thus aberrantly 
spliced mRNAs (Alsafadi, Houy et al. 2016). Hot-spot mutations have been proposed to lead to a 
change in the curvature of the HEAT solenoid (Darman, Seiler et al. 2015). Although we do not know 
whether the spatial organization is different at earlier stages of spliceosome assembly (i.e. during 
A complex formation, when BS selection is thought to take place), based on the yeast Bact EM model, 
a structural change in the HEAT domain could indirectly destabilize the binding of the BS/U2 helix 
through the terminal HEAT repeats. Hot-spot mutations could potentially also alter binding of the 
3' end of the intron to the HEAT domain, and thereby directly influence the choice of the BS. 
Alternatively, or in addition, these mutations could affect the interaction of RES proteins, and alter 
splicing efficiency – and thus the levels of certain mRNAs – in cancer cells. 
5.6 The role of the U2 SF3B complex protein p14/SF3B6 remains enigmatic 
While six of the seven subunits of the U2 SF3B protein complex are conserved between human and 
yeast, the RRM domain protein p14/SF3B6 is absent in yeast, while being conserved among higher 
eukaryotes (Will, Schneider et al. 2001). The SF3B6 protein has been crosslinked to the BS-A in early 
human spliceosomal complexes (Query, Moore et al. 1994, Will and Luhrmann 2001). Therefore, it 
was surprising that in the human Bact structure SF3B6 is located on the convex side of the SF3B1 HEAT 
domain, close to the N-terminal HEAT repeats, but separated from the BS-A by ca. 5 nm (Figure 4.29). 
Indeed, the BS-A is nested into a protein pocket composed of the C-terminal HEAT repeats and 
PHF5A/hRds3 in such a way that it is impossible for the BS-A to crosslink to SF3B6, even if it was 
flexible in solution. The U2/BS helix is occluded by the hHsh155 HEAT domain and Rds3, in a very 
similar manner, in the yeast B complex (Plaschka, Lin et al. 2017), and it is likely that it is also similarly 
organised already in the A complex. However, the crystal structure of the isolated human SF3B core 
protein complex (lacking SF3B6) revealed an open, more relaxed left-handed superhelical HEAT 
domain (Cretu, Schmitzová et al. 2016). It is likely that in the 17S U2 snRNP the HEAT domain may 
also adopt the open conformation, as the U2 snRNA will have to engage first with the BS of the 
pre-mRNA intron during the E complex state of the spliceosome, while the BS-A is still recognised by 
splicing factor SF1 (Wahl, Will et al. 2009). After formation of the U2/BS helix and concomitant 
displacement of SF1, probably by the action of UAP56 (Staley and Guthrie 1998), the SF3B1 HEAT 
domain will have to adopt the closed conformation so as to clamp the U2/BS helix tightly. This may 
possibly occur during the Prp5 RNA-helicase-mediated structural change that is required to form a 
stable A complex. It is possible that in higher eukaryotes, where the selection of the correct BS by the 
spliceosome is regulated, the SF3B6 subunit may play a part in this process and contact the BS-A 
during the transition from the E to the A complex. Concomitantly with formation of a stable 
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A complex, SF3B6 may rearrange and adopt its position on the convex side of the HEAT domain. 
Cryo-EM structures of the A complex should soon reveal whether this model is correct. 
5.7 An intricate protein-protein interaction network comprising U2 SF3A 
proteins and peptidyl-prolyl isomerases 
The 3’ domain of the U2 snRNP, comprising the Sm core structure and the U2 A’ and B’’ proteins, is 
spatially separated from the core of the SF3B complex by an intricate network of protein-protein 
interactions in which the SF3A proteins play a major part (Figure 4.33). This is reminiscent of the 
organisation of the 17S U2 snRNP, where the SF3A protein complex also bridges the 3’-domain of 
U2 snRNP and the SF3B protein complex; the latter is bound to the 5’-terminal part of U2 snRNA 
(Kramer, Gruter et al. 1999). In addition, several SF3A and SF3B proteins are involved in forming 
bridges between the 3’-domain of the U2 snRNA, the core domain of the SF3B protein complex and 
the Aqr/Xab2 protein complex (Chapter 4.4.14). 
The published cryo-EM structures of the yeast Bact complex are not well resolved in the peripheral 
domains containing the 3’ domain of U2 and the Xab2/Crnkl1 protein basket. Therefore, it is difficult 
to compare these parts between the yeast and human Bact structures. In yeast, Xab2 appears to be 
primarily connected to the main body of Bact by its binding to the proteins Crnkl1 and hSyf2. In 
contrast, in the human Bact complex, a more sophisticated protein interaction network exists, which 
appears to stabilize the peripheral Aqr/Xab2 protein complex through several protein bridges to the 
main body of the Bact complex. These bridges contain, among other components, a class of proteins 
that is largely missing in the yeast spliceosome, i.e. PPIases. Altogether, the proteome of the human 
splicing machinery comprises at least eight PPIases, only one of which, NY-CO-10, has a counterpart 
in S. cerevisiae spliceosome (Cwc27) (Fabrizio, Dannenberg et al. 2009). The human PPIases are 
conserved in higher eukaryotes; nevertheless, their roles in pre-mRNA splicing have remained largely 
enigmatic. Four out of the eight PPIases (CypE, Ppil1, Ppil2 and NY-CO-10) are present in the human 
Bact complex. Strikingly, all of these are engaged in numerous protein-protein interactions. For 
example, CypE, which contains an RRM in addition to the PPIase domain, is part of the bridge B3, 
whereby its PPIase domain is bound to the N-terminal HATs of Xab2 and its RRM domain interacts 
with the RRM1 of SF3B4 and possibly also with the C-terminal domain of SF3A2. The PPIase domain 
of Ppil2 connects bridge B3 with the U2/U6 helix II, a case where a PPIase domain is in direct contact 
with RNA. The N-terminal U box domains of Ppil2 are spatially separated from its PPIase domain by 
about 10 nm and bind to hSnu114 and a nearby region of the hPrp8 RT domain.  
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Ppil1 anchors the Prp19 helical bundle to the main body of the Bact complex in form B of Bact and the 
PPIase domain of NY-CO-10 connects the NTD1 domain to the Prp8 RT domain in a manner similar to 
the way in which Cwc27 does this in the yeast Bact complex. Thus, one obvious function of the 
numerous PPIases in the human Bact complex appears to be of serving as bridges between various 
protein modules within the spliceosome. Whether the PPIase domains also fulfil enzymatic functions 
by isomerizing proline-peptide bonds is not clear at all. Inspection of the catalytic centres of the 
various PPIases suggests that at least Ppil1 and CypE may be active enzymes and could act as 
molecular switches; however, this remains to be investigated. It is also unclear whether the U boxes 
of Ppil2 play a part in ubiquitination reactions, in addition to their function as protein interaction 
modules. 
5.8 Protein dynamics in the human Bact structure 
An interesting structural feature of the second major form B of the Bact complex is that it differs from 
form A in respect of the presence and absence of several protein domains, mostly in the peripheral 
regions of the Bact structure. The structure of the central domain, including the catalytic U2/U6 RNP 
core, is largely similar in both forms. The most dramatic difference is the absence of density for the 
large elongated Prp19 helical bundle in form A and the presence of its well defined density in form B 
of the Bact structure (Figure 4.35). At the same time, density for Ppil1 appears in form B, forming a 
bridge between the centre of the helical bundle and the central body of Bact. Moreover, the U5 40K 
WD40 domain has moved away from its site close to the lower stem of U5 snRNA in form A and 
engages in interactions with the lower end of the helical bundle. It is highly likely that the 
rearrangements of U5 40K and Ppil1 are coordinated with the stable docking of the helical bundle on 
the lower side of the central domain of Bact. It is not clear whether the rearrangements of the PPIase 
domain of Ppil2 (which is absent in form B) and the WD40 domain of the hPrp17 (which is present in 
form B but absent in form A of Bact) are also somehow coordinated with each other and/or with the 
other rearrangements discussed above, or whether they occur sequentially. 
In Chapter 4.5, I provided several pieces of evidence to indicate that the absence or presence of the 
above-mentioned protein domains in the two forms of the cryo-EM Bact structure is not due to the 
physical presence/absence of the respective proteins. Instead, in all likelihood, the differences 
indicate conformational flexibility of the protein domains. If we consider the conformational states in 
the cryo-EM structure of the human C* complex of those proteins which differ between forms A and 
B of hBact, it is striking that there is a significant similarity in these conformations between form B of 
Bact and that of the hC* structure. This is best illustrated for the stable docking of the Prp19 helical 
bundle to the main body of hBact and C* through interactions with U5 40K and Ppil1 proteins at 
almost equivalent positions (Figure 4.36). Therefore, it is reasonable to assume that form A is a 
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precursor to form B of the Bact structure and not just a dead-end complex. Thus, excitingly, it was 
possible to capture by cryo-EM analysis two conformational states of the human Bact complex that 
differ in their degree of conformational maturation towards the catalytic activation step. Consistent 
with the idea that form B is closer to the mature state of the Bact spliceosome than form A, is the 
finding that Ppil2 is dissociated from the spliceosome during the catalytic activation or step 1 
formation, as it is absent in the purified C complex (Bessonov, Anokhina et al. 2008). Thus we may 
speculate that Ppil2 becomes destabilized in the spliceosome in at least two steps. First the PPIase 
domain in the last stage of Bact complex maturation (as observed in form B), followed by the 
dissociation of the interaction of the Ppil2 U boxes with the central Bact domain during catalytic 
activation (Figure 4.35).  
To the best of our present-day knowledge, no ATP-requiring steps are involved in the transition of 
the Bact complex from form A to form B. This would mean that the observed conformational changes 
of the various protein domains are facilitated ("catalysed") simply by the thermal energy of the 
system. This, in turn, would suggest further that the dissociation of certain protein-protein interfaces 
would require the formation of new protein-protein interactions, which is exactly what one observes 
when comparing the structures of the two forms of the Bact spliceosome. 
For all these reasons, it is reasonable to assume that by capturing the two states of the Bact structure 
by 3D classification, I have visualized conformational dynamics of some protein domains of the Bact 
complex. It is likely that these represent only a small window at the end of a long trajectory on which 
the B complex is transformed into a Bact complex. Following the dissociation of the U4/U6 duplex of 
the B complex by Brr2 RNA helicase, an exchange of more than 40 proteins occurs to form the 
mature Bact structure and it is likely that this exchange is also facilitated largely by thermal energy. By 
exhaustive 3D classification of intermediate assembly steps (between the B to Bact transition), it may 
thus be possible in the near future to obtain insight into the myriad of conformational changes that 
the numerous Bact proteins have to undergo to finally produce a mature Bact complex structure, as 
reconstructed in the work described here. 
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7 Appendix 
7.1 Abbreviations 
3’ss      3‘splice site 
5’ss      5‘splice site 
A      Adenosine  
aa      Amino acid 
Amp     Ampicillin 
APS      Ammonium peroxodisulfate 
ATP      Adenosine triphosphate 
bp      Base pair 
BS      Branch site 
BSA      Bovine serum albumin 
BS-A     Branch site adenosine 
°C      Degree celsius 
C      Cytosine 
CTP      Cytosine triphosphate 
Ci      Curie 
cpm      Counts per minute 
Da      Dalton 
dd      Double distilled 
DExD/H     Consensus sequence of helicases 
DMSO      Dimethyl sulfoxide 
DNA      Desoxyribonucleic acid 
DTT      Dithiothreitol 
E. coli      Escherichia coli 
EDTA      Ethylendiamintetraacetate 
EJC     Exon junction complex 
EM      Electron microscopy 
ESE      Exonic splicing enhancer 
ESS      Exonic splicing silencer 
et al.      Et alii 
G      Guanosine 
g      Gram / centrifugal force 
GTP      Guanosine triphosphate 
H. sapiens    Homo sapiens 
h      Hour / human 
HCl      Hydrochloric acid 
HEPES      N-2-Hydroxyethylpiperazin-N-2-ethansulfonic acid 
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hn      Heterogenous nuclear 
IBC     Intron binding complex 
ILS     Internal-stem loop 
ISE     Intronic splicing enhancer 
ISS     Intronic splicing silencer 
k      Kilo 
kDa      Kilodalton 
l      Liter 
LB     Luria Bertani 
LC      Liquid chromatography 
Lsm      Like-Sm 
M      Molar 
m      Milli  
μ      Micro 
min      Minutes 
mM      Millimolar 
mRNA      Messenger RNA 
MS      Mass spectrometry 
MW      Molecular weight 
nm     nanometer 
NTC     NineTeen complex 
NTP      Nucleoside triphosphate 
nts      Nucleotides 
OD      Optical density 
P      Phosphate 
PAGE      Polyacrylamide gel-electrophoresis 
PCI      Phenol-chloroform-isoamyl alcohol 
pH      Preponderance of hydrogen ions 
PMSF      Phenylmethylsulfonylfluoride 
PPT     Polypyrimidine tract 
Pre-mRNA     Precursor-mRNA 
%      Percent  
Py      Pyrimidine base 
R      Purine base 
RES     Retention and splicing 
RNA      Ribonucleic acid 
RNase      Ribonuclease 
RNP      Ribonucleoprotein 
rpm      Revolutions per minute 
RRM      RNA recognition motif 
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RT      Room temperature 
S      Svedberg unit 
s      Second 
S. cerevisiae     Saccharomyces cerevisiae 
SDS      Sodium dodecylsulfate 
Sm      ‘Smith’, patient in which Sm proteins were first discovered 
snRNA      Small nuclear ribonucleic acid 
snRNP      Small nuclear ribonucleoparticle 
SR      Serine arginine rich 
TEMED     N, N, N’, N’-Tetramethylethylendiamine 
Tris      Tris-(hydroxymethyl)-aminomethane 
tRNA      Transfer RNA 
U      Uridine / unit 
U snRNA     Uridine rich small nuclear RNA 
U snRNP     Uridine rich small nuclear ribonucleoparticles 
UTP      Uridine triphosphate 
UV      Ultraviolet 
V      Volt 
Vol     Volume 
v/v      Volume per volume 
W      Watts 
w/v      Weight per volume 
Y      Pyrimidine base 
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7.5 Supplementary materials 
Supplementary Table S1: BS3-crosslinks between known structured regions of human Bact 
Statistics (Spectral Counts and Scoremax) of the CX-MS data for the proteins of the purified human Bact. Numbers in the 
Residue 1 and 2 columns indicate the position of the crosslinked lysine or N-terminal methionine residue. Samples were 
analysed on Orbitrap Fusion Lumos Tribrid (Lumos) and Thermo Scientific Q Exactive HF (QExHF) mass spectrometers. Only 
intermolecular (Inter) protein-protein crosslinks are shown. Proteins are named according to UniProt Entry names. 
Type Protein 1 Protein 2 Residue 1 Residue 2 
Spectral count Scoremax Total spec. 
count 
Best 
Scoremax Lumos QExHF Lumos QExHF 
Inter AQR CRNL1 524 175 1 1 4,32 3,50 2 4,32 
    
 
604 175 1   5,93   1 5,93 
    
  
182   3   5,66 3 5,66 
    CWC22 550 530 1   0,36   1 0,36 
    ISY1 604 101   1   3,08 1 3,08 
    
 
762 179 2 4 14,97 18,53 6 18,53 
    PPIL1 558 80 1   5,94   1 5,94 
    PRP19 667 192 2   5,42   2 5,42 
    
 
759 192   1   0,95 1 0,95 
    
  
200   4   2,05 4 2,05 
    RBM22 604 229 1 1 4,79 4,10 2 4,79 
    SF3A2 662 42   2   2,80 2 2,80 
    SYF1 950 2 3 3 11,71 11,71 6 11,71 
    
 
954 2 12 16 6,32 8,25 28 8,25 
    
 
1002 2 5 1 6,34 5,28 6 6,34 
    ZN830 201 339 2   5,02   2 5,02 
    
  
343 5 1 9,34 6,06 6 9,34 
Inter BUD13 CRNL1 558 460 1 1 3,71 2,03 2 3,71 
    DHX16 417 389 2 2 3,70 3,97 4 3,97 
    
 
418 733 2   5,60   2 5,60 
    GPKOW 14 334   1   4,01 1 4,01 
    
 
104 334 1   3,16   1 3,16 
    
 
466 201 2 3 3,46 3,21 5 3,46 
    
 
474 299 2   3,11   2 3,11 
    PHF5A 596 108   1   5,72 1 5,72 
    PLRG1 558 41 1   2,88   1 2,88 
    PRP8 560 1514   1   3,73 1 3,73 
    RBMX2 483 119 11 9 16,25 18,46 20 18,46 
    
 
486 119   1   2,82 1 2,82 
    SF3B1 499 816 3   6,12   3 6,12 
    SF3B2 339 326   1   1,38 1 1,38 
    SNW1 474 503 1 1 2,71 3,47 2 3,47 
    
 
604 441 2 2 5,54 5,35 4 5,54 
    
 
605 441 7 5 14,66 17,06 12 17,06 
    U520 68 975 1   8,76   1 8,76 
Inter BUD31 CWC27 28 35 25 18 6,78 6,48 43 6,78 
    PRP8 9 218   2   10,33 2 10,33 
    
 
125 36 1 2 7,01 6,39 3 7,01 
    SPF27 42 177 1   0,43   1 0,43 
Inter CDC5L CRNL1 60 229 1   0,47   1 0,47 
    
 
174 229   4   8,41 4 8,41 
    
 
200 229 7 12 8,91 12,49 19 12,49 
    
 
255 388 1 1 4,96 2,20 2 4,96 
    
 
466 568 3 5 6,38 5,72 8 6,38 
    
  
569   1   3,47 1 3,47 
    
 
522 602   1   8,57 1 8,57 
    CTBL1 174 458   1   5,33 1 5,33 
    
 
219 31   1   7,53 1 7,53 
    
 
294 534   2   6,34 2 6,34 
    
 
685 56 2 1 6,87 5,91 3 6,87 
    CWC27 165 340   1   3,61 1 3,61 
    ISY1 187 55 1 2 6,75 8,61 3 8,61 
    PLRG1 576 19 2 1 5,38 5,95 3 5,95 
    PPIL2 70 226 2   3,17   2 3,17 
    
 
312 507 2 2 5,01 4,32 4 5,01 
    
 
466 507 7 8 11,57 8,58 15 11,57 
    
  
508 5 2 8,80 7,99 7 8,80 
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Type Protein 1 Protein 2 Residue 1 Residue 2 
Spectral count Scoremax Total spec. 
count 
Best 
Scoremax Lumos QExHF Lumos QExHF 
    
  
509 3 3 8,66 6,16 6 8,66 
    PRCC 487 139 1 2 4,89 4,02 3 4,89 
    
 
522 216   2   10,98 2 10,98 
    PRP17 187 333 9 8 9,06 9,56 17 9,56 
    
 
200 333 13 13 13,19 8,36 26 13,19 
    
  
551   1   5,67 1 5,67 
    PRP19 522 179 2 3 6,70 6,95 5 6,95 
    
  
192 1 3 3,60 5,50 4 5,50 
    
  
244 2 1 7,59 4,25 3 7,59 
    
 
570 122 26 21 11,62 10,10 47 11,62 
    
 
631 122   4   8,06 4 8,06 
    
  
244 2 1 8,69 5,97 3 8,69 
    
 
685 179 4 6 7,23 7,71 10 7,71 
    
  
266 2 2 3,30 6,55 4 6,55 
    
 
686 179   1   6,48 1 6,48 
    
 
771 244   2   6,66 2 6,66 
    
 
782 179 1 1 4,39 4,09 2 4,39 
    
  
192   1   2,39 1 2,39 
    
  
244 11 9 10,80 11,86 20 11,86 
    
  
261   4   9,75 4 9,75 
    
  
266 4 1 9,38 5,73 5 9,38 
    
 
795 244 1 4 5,11 6,77 5 6,77 
    PRP8 7 892 29 19 10,16 8,77 48 10,16 
    
 
28 727 1   5,79   1 5,79 
    
 
291 533   1   4,41 1 4,41 
    
 
539 85 1 2 5,32 5,37 3 5,37 
    RBMX2 187 243   1   2,12 1 2,12 
    SF3B2 174 577   1   2,47 1 2,47 
    
 
187 543 1 2 4,15 7,04 3 7,04 
    
  
570   1   1,76 1 1,76 
    SF3B6 106 29 1 2 3,04 5,82 3 5,82 
    SMD1 291 86 2   8,38   2 8,38 
    SMD2 264 98 1   1,02   1 1,02 
    
 
782 118   1   9,25 1 9,25 
    SMD3 201 104   1   2,93 1 2,93 
    SNR40 771 18 7 6 6,41 7,68 13 7,68 
    
  
275   2   6,92 2 6,92 
    
 
782 270 2 2 2,95 6,68 4 6,68 
    
  
275   8   10,60 8 10,60 
    
 
795 270 17 11 9,39 5,90 28 9,39 
    SNW1 28 258 1   5,25   1 5,25 
    
  
266 3 9 8,05 9,99 12 9,99 
    
 
124 311 1   5,37   1 5,37 
    SPF27 312 168 3   5,87   3 5,87 
    
 
685 97 11 6 5,63 4,70 17 5,63 
    
 
771 177 69 69 15,74 16,94 138 16,94 
    
 
782 191 12 10 10,53 10,17 22 10,53 
    
 
795 218 2 2 4,79 4,37 4 4,79 
    
 
799 218   2   3,49 2 3,49 
    SYF1 290 654 7 9 5,96 11,85 16 11,85 
    
 
294 654 31 23 22,28 18,10 54 22,28 
    
 
312 677 1 1 8,19 11,57 2 11,57 
    
 
522 532 12 11 6,94 7,18 23 7,18 
    U5S1 466 446 4 6 4,12 4,94 10 4,94 
    ZN830 255 137 1   4,97   1 4,97 
    
  
149 1 2 3,25 3,74 3 3,74 
Inter CRNL1 AQR 175 524 1 1 4,32 3,50 2 4,32 
    
  
604 1   5,93   1 5,93 
    
 
182 604   3   5,66 3 5,66 
    BUD13 460 558 1 1 3,71 2,03 2 3,71 
    CDC5L 229 60 1   0,47   1 0,47 
    
  
174   4   8,41 4 8,41 
    
  
200 7 12 8,91 12,49 19 12,49 
    
 
388 255 1 1 4,96 2,20 2 4,96 
    
 
568 466 3 5 6,38 5,72 8 6,38 
    
 
569 466   1   3,47 1 3,47 
    
 
602 522   1   8,57 1 8,57 
    CWC27 730 462 1   4,13   1 4,13 
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Type Protein 1 Protein 2 Residue 1 Residue 2 
Spectral count Scoremax Total spec. 
count 
Best 
Scoremax Lumos QExHF Lumos QExHF 
    ISY1 213 127 2 2 7,46 8,08 4 8,08 
    KIN17 229 33   1   5,10 1 5,10 
    PLRG1 397 173   2   7,99 2 7,99 
    
  
180 3 6 9,36 8,12 9 9,36 
    
 
602 62   2   4,25 2 4,25 
    
  
68   1   2,60 1 2,60 
    PPIL2 445 454   3   7,57 3 7,57 
    
  
460 1 2 4,62 5,74 3 5,74 
    
  
462 10 11 7,95 11,37 21 11,37 
    
 
460 462   3   5,38 3 5,38 
    
 
475 462   2   3,97 2 3,97 
    
 
485 462 1 3 3,88 14,03 4 14,03 
    
 
531 507   2   4,22 2 4,22 
    
 
568 490 1   11,43   1 11,43 
    
 
569 490 7 10 11,20 8,61 17 11,20 
    
 
574 490   1   1,68 1 1,68 
    
 
602 490 20 13 17,22 14,25 33 17,22 
    PRCC 229 434   1   4,15 1 4,15 
    
  
437   1   2,42 1 2,42 
    
  
442 1   8,40   1 8,40 
    
  
443 2 2 8,26 10,53 4 10,53 
    
 
357 193 1 1 7,80 6,74 2 7,80 
    
 
388 193   2   4,62 2 4,62 
    
  
207   9   12,28 9 12,28 
    
  
216 1   7,19   1 7,19 
    
 
397 193 8 10 9,89 7,82 18 9,89 
    
 
427 193 3 7 12,94 13,17 10 13,17 
    
 
724 137   4   4,98 4 4,98 
    PRP17 182 541   1   4,90 1 4,90 
    
 
213 547   3   4,95 3 4,95 
    
  
551 4 7 13,42 8,92 11 13,42 
    PRP19 832 179   1   3,59 1 3,59 
    
  
192   1   3,46 1 3,46 
    RBM22 224 114   1   8,39 1 8,39 
    RSMB 607 57   1   2,67 1 2,67 
    SF3A2 175 118 1 1 4,00 1,27 2 4,00 
    
 
680 194 1   0,89   1 0,89 
    SF3B2 175 570 2 2 3,94 3,93 4 3,94 
    
 
178 570   1   1,57 1 1,57 
    
 
182 570 5 4 8,03 11,74 9 11,74 
    SNW1 229 217   2   3,02 2 3,02 
    
 
357 48   1   5,04 1 5,04 
    
 
397 108 5 5 9,26 8,29 10 9,26 
    
  
110 8 5 8,54 9,53 13 9,53 
    
  
115 3 3 10,11 5,18 6 10,11 
    SYF1 427 482 15 9 9,90 6,95 24 9,90 
    
 
460 482   1   7,93 1 7,93 
    
 
461 482 4 9 5,37 7,04 13 7,04 
    
 
787 794 4 2 6,49 7,70 6 7,70 
    ZN830 445 216 2 2 5,16 5,44 4 5,44 
    
  
228 5 8 9,15 7,06 13 9,15 
    
  
234 18 20 10,46 13,76 38 13,76 
    
 
460 234 11 16 12,03 10,60 27 12,03 
    
 
475 228 2 1 3,24 3,04 3 3,24 
    
  
234 8 6 11,26 11,79 14 11,79 
    
 
485 234 1   2,84   1 2,84 
    
 
771 83   2   6,42 2 6,42 
Inter CTBL1 CDC5L 31 219   1   7,53 1 7,53 
    
 
56 685 2 1 6,87 5,91 3 6,87 
    
 
458 174   1   5,33 1 5,33 
    
 
534 294   2   6,34 2 6,34 
    CWC15 95 183 3 1 5,31 5,10 4 5,31 
    
 
102 183   4   5,70 4 5,70 
    
 
252 18   2   7,24 2 7,24 
    
 
347 91 1 2 4,93 4,75 3 4,93 
    
 
372 91   1   3,16 1 3,16 
    
 
527 28   1   3,28 1 3,28 
    
 
534 18   3   6,77 3 6,77 
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Type Protein 1 Protein 2 Residue 1 Residue 2 
Spectral count Scoremax Total spec. 
count 
Best 
Scoremax Lumos QExHF Lumos QExHF 
    DHX16 16 69   3   5,39 3 5,39 
    
 
27 69   2   9,40 2 9,40 
    
 
31 69 8 8 7,46 6,27 16 7,46 
    
 
56 69 1   2,95   1 2,95 
    
 
57 69   1   6,35 1 6,35 
    
 
91 69 2   7,24   2 7,24 
    
 
102 69 4   6,46   4 6,46 
    
 
297 1028 1   4,56   1 4,56 
    GPKOW 447 299   1   1,29 1 1,29 
    KIN17 56 297   1   3,79 1 3,79 
    PPIL2 56 82   1   4,82 1 4,82 
    PRP19 534 192 2   5,45   2 5,45 
    PRP8 91 2070 1   2,53   1 2,53 
    RBM22 554 170   1   0,44 1 0,44 
    RU2B 83 1   1   2,36 1 2,36 
    
 
84 1 1   3,22   1 3,22 
    SF3B1 31 6 2 2 6,24 5,44 4 6,24 
    
 
56 6 2 2 10,60 11,18 4 11,18 
    
 
57 6   1   14,05 1 14,05 
    
 
83 6 16 21 19,29 17,06 37 19,29 
    
 
84 6 10 7 10,38 11,45 17 11,45 
    
 
91 6 9 6 9,13 6,39 15 9,13 
    
  
21 5 5 8,40 5,87 10 8,40 
    
 
95 6 10 8 8,97 6,16 18 8,97 
    
  
21 2   6,69   2 6,69 
    ZN830 31 117   1   4,87 1 4,87 
    
  
149   1   4,97 1 4,97 
    
 
56 78 5 7 8,63 8,82 12 8,82 
    
  
104   7   18,19 7 18,19 
Inter CWC15 CTBL1 18 252   2   7,24 2 7,24 
    
  
534   3   6,77 3 6,77 
    
 
28 527   1   3,28 1 3,28 
    
 
91 347 1 2 4,93 4,75 3 4,93 
    
  
372   1   3,16 1 3,16 
    
 
183 95 3 1 5,31 5,10 4 5,31 
    
  
102   4   5,70 4 5,70 
    ISY1 183 260 1   2,08   1 2,08 
    PLRG1 18 363 3 4 12,71 9,86 7 12,71 
    PPIL2 92 82 1   4,29   1 4,29 
    
 
183 72 3 3 12,12 9,24 6 12,12 
    
 
195 188   1   6,52 1 6,52 
    
 
199 72 1   11,72   1 11,72 
    
  
180   3   10,65 3 10,65 
    
  
188 1 2 3,60 4,65 3 4,65 
    
 
221 418   1   2,04 1 2,04 
    PRP8 91 1144 5 8 7,47 11,71 13 11,71 
    
 
92 1144   1   4,10 1 4,10 
    
 
205 1158 1   4,23   1 4,23 
    
 
226 1132   3   7,91 3 7,91 
    RBM22 18 76 11 8 19,88 18,51 19 19,88 
    
 
28 40   2   4,60 2 4,60 
    SF3B2 91 556 2   7,23   2 7,23 
    SNW1 18 153 21 24 11,11 11,74 45 11,74 
    
 
152 311   3   11,67 3 11,67 
    ZN830 40 272 1   0,60   1 0,60 
    
 
147 26 3 3 5,54 5,95 6 5,95 
    
 
183 28 1   2,89   1 2,89 
Inter CWC22 AQR 530 550 1   0,36   1 0,36 
    CWC27 235 366 13 1 10,34 5,05 14 10,34 
    
 
243 429 1   4,36   1 4,36 
    
  
455   2   5,77 2 5,77 
    
 
250 434   2   10,55 2 10,55 
    
 
330 432 1 1 3,92 5,30 2 5,30 
    
  
434 11 13 10,02 12,87 24 12,87 
    
  
455 1   5,12   1 5,12 
    
 
397 364   1   6,00 1 6,00 
    DHX16 604 93   2   3,88 2 3,88 
    
 
648 93 16 19 13,10 13,52 35 13,52 
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Type Protein 1 Protein 2 Residue 1 Residue 2 
Spectral count Scoremax Total spec. 
count 
Best 
Scoremax Lumos QExHF Lumos QExHF 
    IF4A3 116 374 1 3 6,09 10,71 4 10,71 
    
 
118 252   2   7,15 2 7,15 
    
 
119 252 2 1 9,22 7,95 3 9,22 
    
 
243 374   1   3,10 1 3,10 
    
 
250 60 10 4 9,65 7,62 14 9,65 
    
  
374 3 2 9,48 10,91 5 10,91 
    
 
330 60 2 3 11,12 7,87 5 11,12 
    
  
152   1   5,98 1 5,98 
    PRP8 330 366 19 20 11,47 13,57 39 13,57 
    
 
584 1392   1   1,86 1 1,86 
    RUXE 745 80   1   2,02 1 2,02 
    SMD2 149 8 1   0,50   1 0,50 
    
 
250 50   1   0,20 1 0,20 
    SNW1 648 376 1   9,05   1 9,05 
    SPF27 598 155   2   3,80 2 3,80 
    SYF1 330 654 1   5,83   1 5,83 
    U520 584 1146   1   1,41 1 1,41 
    U5S1 330 359 1   6,22   1 6,22 
Inter CWC27 BUD31 35 28 25 18 6,78 6,48 43 6,78 
    CDC5L 340 165   1   3,61 1 3,61 
    CRNL1 462 730 1   4,13   1 4,13 
    CWC22 364 397   1   6,00 1 6,00 
    
 
366 235 13 1 10,34 5,05 14 10,34 
    
 
429 243 1   4,36   1 4,36 
    
 
432 330 1 1 3,92 5,30 2 5,30 
    
 
434 250   2   10,55 2 10,55 
    
  
330 11 13 10,02 12,87 24 12,87 
    
 
455 243   2   5,77 2 5,77 
    
  
330 1   5,12   1 5,12 
    IF4A3 432 374 2 1 8,45 10,24 3 10,24 
    
 
434 60 3 8 9,18 8,02 11 9,18 
    
  
70   3   3,84 3 3,84 
    
  
374 13 13 14,06 10,87 26 14,06 
    
 
455 19   1   6,90 1 6,90 
    
  
70 2 9 7,59 8,08 11 8,08 
    
  
74 2 4 6,07 8,28 6 8,28 
    
  
242   3   6,75 3 6,75 
    PPIE 372 83 1   4,24   1 4,24 
    R113A 192 107 1   3,03   1 3,03 
    RSMB 183 50 4 2 6,76 6,56 6 6,76 
    
 
184 50 17 16 11,34 8,20 33 11,34 
    
 
186 50 5 2 8,01 8,26 7 8,26 
    SF3A1 192 115   2   4,67 2 4,67 
    SF3A2 184 103 1 1 4,88 3,44 2 4,88 
    SYF1 180 539 1 1 4,39 3,50 2 4,39 
    U5S1 393 352 6 2 14,28 5,73 8 14,28 
    
  
359   1   5,13 1 5,13 
Inter DHX16 BUD13 389 417 2 2 3,70 3,97 4 3,97 
    
 
733 418 2   5,60   2 5,60 
    CTBL1 69 16   3   5,39 3 5,39 
    
  
27   2   9,40 2 9,40 
    
  
31 8 8 7,46 6,27 16 7,46 
    
  
56 1   2,95   1 2,95 
    
  
57   1   6,35 1 6,35 
    
  
91 2   7,24   2 7,24 
    
  
102 4   6,46   4 6,46 
    
 
1028 297 1   4,56   1 4,56 
    CWC22 93 604   2   3,88 2 3,88 
    
  
648 16 19 13,10 13,52 35 13,52 
    GPKOW 860 201   3   7,39 3 7,39 
    
 
1019 50 1   2,70   1 2,70 
    
  
61 4 6 7,74 9,03 10 9,03 
    PPIL2 73 90 16 9 10,56 9,37 25 10,56 
    
  
95 21 23 14,23 13,94 44 14,23 
    PRP19 1032 192   1   0,77 1 0,77 
    R113A 1027 21   2   4,28 2 4,28 
    RBMX2 93 246   1   4,56 1 4,56 
    
 
860 72 1   4,73   1 4,73 
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Type Protein 1 Protein 2 Residue 1 Residue 2 
Spectral count Scoremax Total spec. 
count 
Best 
Scoremax Lumos QExHF Lumos QExHF 
    SF3B1 69 6 21 14 10,16 6,71 35 10,16 
    
  
21 5 2 8,24 6,29 7 8,24 
    
  
22 2 7 4,67 6,28 9 6,28 
    
 
73 22   1   8,12 1 8,12 
    
 
860 733 2 3 11,31 11,23 5 11,31 
    SF3B3 1019 126 12 8 12,64 11,21 20 12,64 
    
  
296 3 1 5,58 9,21 4 9,21 
    
 
1027 126 34 48 11,86 11,97 82 11,97 
    SMD2 228 98 1   1,71   1 1,71 
    SNIP1 860 216 3 2 9,62 9,69 5 9,69 
    SRRM2 69 130   3   5,97 3 5,97 
    
  
131   1   3,77 1 3,77 
Inter GPKOW BUD13 201 466 2 3 3,46 3,21 5 3,46 
    
 
299 474 2   3,11   2 3,11 
    
 
334 14   1   4,01 1 4,01 
    
  
104 1   3,16   1 3,16 
    CTBL1 299 447   1   1,29 1 1,29 
    DHX16 50 1019 1   2,70   1 2,70 
    
 
61 1019 4 6 7,74 9,03 10 9,03 
    
 
201 860   3   7,39 3 7,39 
    PRP8 192 2244   2   2,22 2 2,22 
    
 
334 1831   1   4,97 1 4,97 
    
 
349 2108   1   4,16 1 4,16 
    SF3A1 349 210   1   2,09 1 2,09 
    U520 50 14   1   3,05 1 3,05 
    
  
60 1 3 4,91 6,76 4 6,76 
    
 
61 695   2   6,13 2 6,13 
    
 
192 14   1   3,71 1 3,71 
    
  
46 3 1 6,91 4,54 4 6,91 
    
  
73 4 5 5,89 5,80 9 5,89 
    
  
83 3 6 4,73 6,77 9 6,77 
    
 
346 155 1 1 3,67 3,87 2 3,87 
    
 
372 1049   1   9,98 1 9,98 
Inter IF4A3 CWC22 60 250 10 4 9,65 7,62 14 9,65 
    
  
330 2 3 11,12 7,87 5 11,12 
    
 
152 330   1   5,98 1 5,98 
    
 
252 118   2   7,15 2 7,15 
    
  
119 2 1 9,22 7,95 3 9,22 
    
 
374 116 1 3 6,09 10,71 4 10,71 
    
  
243   1   3,10 1 3,10 
    
  
250 3 2 9,48 10,91 5 10,91 
    CWC27 19 455   1   6,90 1 6,90 
    
 
60 434 3 8 9,18 8,02 11 9,18 
    
 
70 434   3   3,84 3 3,84 
    
  
455 2 9 7,59 8,08 11 8,08 
    
 
74 455 2 4 6,07 8,28 6 8,28 
    
 
242 455   3   6,75 3 6,75 
    
 
374 432 2 1 8,45 10,24 3 10,24 
    
  
434 13 13 14,06 10,87 26 14,06 
    SMD3 15 99 2 1 5,81 3,26 3 5,81 
    U5S1 152 244 4 7 11,23 12,38 11 12,38 
    
  
694 1 1 4,58 3,56 2 4,58 
Inter ISY1 AQR 101 604   1   3,08 1 3,08 
    
 
179 762 2 4 14,97 18,53 6 18,53 
    CDC5L 55 187 1 2 6,75 8,61 3 8,61 
    CRNL1 127 213 2 2 7,46 8,08 4 8,08 
    CWC15 260 183 1   2,08   1 2,08 
    PPIE 92 218   3   11,00 3 11,00 
    
 
101 218   1   9,28 1 9,28 
    PRP19 7 192 1   3,85   1 3,85 
    
  
244   4   6,46 4 6,46 
    RBM22 92 199 1   1,09   1 1,09 
    RU2A 259 205   2   6,82 2 6,82 
    
 
260 192 1   5,06   1 5,06 
    
  
193 1   16,77   1 16,77 
    
  
205 20 16 8,98 8,82 36 8,98 
    
  
221 2   4,90   2 4,90 
    
 
266 56 10 10 17,92 11,80 20 17,92 
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Type Protein 1 Protein 2 Residue 1 Residue 2 
Spectral count Scoremax Total spec. 
count 
Best 
Scoremax Lumos QExHF Lumos QExHF 
    
  
179 1   3,95   1 3,95 
    
  
191 12 6 10,33 8,40 18 10,33 
    
  
192   1   7,19 1 7,19 
    
  
193 46 48 16,71 22,31 94 22,31 
    
  
221 29 28 19,59 20,12 57 20,12 
    SF3A1 7 2 1 1 6,62 5,50 2 6,62 
    
 
55 115 4 4 8,45 6,34 8 8,45 
    
 
84 2   1   4,80 1 4,80 
    
  
30 1   3,78   1 3,78 
    
  
37 1 1 3,99 4,08 2 4,08 
    
  
115 5 5 7,39 7,41 10 7,41 
    
 
101 37 1   4,45   1 4,45 
    
 
105 37 6 3 7,82 5,61 9 7,82 
    
  
115 2 2 5,94 4,29 4 5,94 
    
 
121 2   1   5,27 1 5,27 
    
  
115   1   7,04 1 7,04 
    
  
131 1   3,26   1 3,26 
    
 
127 30 2   6,59   2 6,59 
    
  
37 1 1 5,55 5,21 2 5,55 
    
 
260 30 1 1 2,57 1,77 2 2,57 
    SF3A3 266 69 2 1 23,89 5,77 3 23,89 
    SF3B2 41 556   1   1,94 1 1,94 
    SMD2 259 98 2   3,99   2 3,99 
    
 
260 98 3 3 5,24 4,86 6 5,24 
    SNW1 121 317   1   1,68 1 1,68 
    SRRM2 259 169   1   1,87 1 1,87 
    SYF1 7 794 1   4,32   1 4,32 
    
 
41 794   4   8,69 4 8,69 
    
 
44 794   2   3,17 2 3,17 
    
 
84 257   1   3,12 1 3,12 
    
 
138 257 11 8 11,39 12,61 19 12,61 
    
 
188 83 5 3 5,37 4,77 8 5,37 
    
 
190 2 5 3 5,76 6,21 8 6,21 
    
 
260 2 10 11 10,22 12,04 21 12,04 
    
 
266 2 2 1 4,43 5,57 3 5,57 
    U520 260 2091   1   3,02 1 3,02 
Inter KIN17 CRNL1 33 229   1   5,10 1 5,10 
    CTBL1 297 56   1   3,79 1 3,79 
    PRP8 129 2   1   1,80 1 1,80 
    
 
171 609   1   0,53 1 0,53 
    SF3A2 157 48   1   2,23 1 2,23 
    SF3B3 231 26 11 5 12,74 9,88 16 12,74 
    
  
296   3   9,47 3 9,47 
    SMD1 33 9 1   0,01   1 0,01 
    U520 272 1169   1   3,73 1 3,73 
    
 
293 1146   2   3,19 2 3,19 
    U5S1 10 341 1 3 3,79 3,53 4 3,79 
Inter PHF5A BUD13 108 596   1   5,72 1 5,72 
    PRP8 108 853 1 1 4,16 7,98 2 7,98 
    SF3B3 13 137   1   4,82 1 4,82 
    
 
95 137   1   4,86 1 4,86 
Inter PLRG1 BUD13 41 558 1   2,88   1 2,88 
    CDC5L 19 576 2 1 5,38 5,95 3 5,95 
    CRNL1 62 602   2   4,25 2 4,25 
    
 
68 602   1   2,60 1 2,60 
    
 
173 397   2   7,99 2 7,99 
    
 
180 397 3 6 9,36 8,12 9 9,36 
    CWC15 363 18 3 4 12,71 9,86 7 12,71 
    PPIL1 66 80   2   6,55 2 6,55 
    
 
68 80 1 1 4,82 4,25 2 4,82 
    
 
135 80   3   6,41 3 6,41 
    PPIL2 505 462 2 5 4,74 7,58 7 7,58 
    PRCC 173 193   1   4,76 1 4,76 
    PRP19 1 122 4 9 9,20 9,50 13 9,50 
    
 
180 32   2   4,66 2 4,66 
    PRP8 271 1132   1   0,66 1 0,66 
    RUXE 47 80   1   2,44 1 2,44 
    SF3A2 320 118   1   2,42 1 2,42 
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Type Protein 1 Protein 2 Residue 1 Residue 2 
Spectral count Scoremax Total spec. 
count 
Best 
Scoremax Lumos QExHF Lumos QExHF 
    SNW1 173 110   1   4,48 1 4,48 
    
 
180 110 3 5 8,32 9,25 8 9,25 
    
 
181 110 1   3,51   1 3,51 
    
 
320 158 18 15 14,27 12,23 33 14,27 
    
 
363 153   1   6,44 1 6,44 
    
  
158 4 4 8,96 4,65 8 8,96 
    
  
217   2   3,31 2 3,31 
    SYF1 135 420 1 1 5,77 5,48 2 5,77 
    
 
237 2   1   1,77 1 1,77 
    U520 487 453   1   2,88 1 2,88 
Inter PPIE CWC27 83 372 1   4,24   1 4,24 
    ISY1 218 92   3   11,00 3 11,00 
    
  
101   1   9,28 1 9,28 
    PPIL1 185 158 2 1 3,97 2,97 3 3,97 
    RU2A 114 193 1   4,11   1 4,11 
    
 
123 172 2 4 6,97 6,56 6 6,97 
    
 
134 172 4 2 11,41 5,01 6 11,41 
    
  
179 1   4,45   1 4,45 
    
  
193 1 1 4,64 3,79 2 4,64 
    SF3A1 88 210 7 2 9,14 12,51 9 12,51 
    
 
104 131   3   4,62 3 4,62 
    
  
210 9 5 8,65 8,89 14 8,89 
    
  
223 1 2 3,84 7,60 3 7,60 
    
 
108 223 2 3 5,30 3,69 5 5,30 
    
  
230 2   7,92   2 7,92 
    
  
231 4 3 10,01 7,41 7 10,01 
    
  
251 1   5,99   1 5,99 
    
 
114 223 1 4 2,88 4,01 5 4,01 
    
  
230 1   6,53   1 6,53 
    
  
231   2   5,50 2 5,50 
    
 
123 230 4 1 10,80 4,93 5 10,80 
    
  
231 3 3 11,17 8,80 6 11,17 
    
 
134 231 1 4 11,97 6,50 5 11,97 
    
 
218 2 8 5 10,00 9,59 13 10,00 
    SF3A2 284 42   1   3,99 1 3,99 
    SF3A3 134 219 5 1 6,68 2,68 6 6,68 
    SF3B2 88 275   2   6,70 2 6,70 
    
 
104 275 1   7,39   1 7,39 
    SYF1 104 76 1 1 3,93 5,43 2 5,43 
    
 
108 36 3 4 5,59 7,83 7 7,83 
    
  
76 5 9 4,14 5,19 14 5,19 
    
  
212 1   3,66   1 3,66 
    
 
114 36 1 1 5,93 3,81 2 5,93 
    
  
212   1   4,71 1 4,71 
    
 
123 76 1 1 3,11 2,68 2 3,11 
    
 
134 76 3   6,00   3 6,00 
    
 
218 2 3 11 6,32 10,13 14 10,13 
Inter PPIL1 AQR 80 558 1   5,94   1 5,94 
    PLRG1 80 66   2   6,55 2 6,55 
    
  
68 1 1 4,82 4,25 2 4,82 
    
  
135   3   6,41 3 6,41 
    PPIE 158 185 2 1 3,97 2,97 3 3,97 
    PRP17 37 63 1   6,01   1 6,01 
    RBM22 80 286   3   6,71 3 6,71 
    SF3A3 52 97   1   2,39 1 2,39 
    SNR40 80 1 5 6 5,97 7,97 11 7,97 
    
  
8   1   6,01 1 6,01 
    
  
18 3 1 4,39 3,94 4 4,39 
    
 
161 18 1   3,56   1 3,56 
    SNW1 52 193 1   2,66   1 2,66 
    
 
58 81 1   12,15   1 12,15 
    
 
80 193 3 11 6,74 7,82 14 7,82 
    
 
158 97 28 20 14,71 12,35 48 14,71 
    SPF27 80 168 10 12 9,74 8,90 22 9,74 
Inter PPIL2 CDC5L 226 70 2   3,17   2 3,17 
    
 
507 312 2 2 5,01 4,32 4 5,01 
    
  
466 7 8 11,57 8,58 15 11,57 
    
 
508 466 5 2 8,80 7,99 7 8,80 
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Type Protein 1 Protein 2 Residue 1 Residue 2 
Spectral count Scoremax Total spec. 
count 
Best 
Scoremax Lumos QExHF Lumos QExHF 
    
 
509 466 3 3 8,66 6,16 6 8,66 
    CRNL1 454 445   3   7,57 3 7,57 
    
 
460 445 1 2 4,62 5,74 3 5,74 
    
 
462 445 10 11 7,95 11,37 21 11,37 
    
  
460   3   5,38 3 5,38 
    
  
475   2   3,97 2 3,97 
    
  
485 1 3 3,88 14,03 4 14,03 
    
 
490 568 1   11,43   1 11,43 
    
  
569 7 10 11,20 8,61 17 11,20 
    
  
574   1   1,68 1 1,68 
    
  
602 20 13 17,22 14,25 33 17,22 
    
 
507 531   2   4,22 2 4,22 
    CTBL1 82 56   1   4,82 1 4,82 
    CWC15 72 183 3 3 12,12 9,24 6 12,12 
    
  
199 1   11,72   1 11,72 
    
 
82 92 1   4,29   1 4,29 
    
 
180 199   3   10,65 3 10,65 
    
 
188 195   1   6,52 1 6,52 
    
  
199 1 2 3,60 4,65 3 4,65 
    
 
418 221   1   2,04 1 2,04 
    DHX16 90 73 16 9 10,56 9,37 25 10,56 
    
 
95 73 21 23 14,23 13,94 44 14,23 
    PLRG1 462 505 2 5 4,74 7,58 7 7,58 
    PRP8 26 1132 23 42 10,77 12,63 65 12,63 
    
 
166 1144   1   4,98 1 4,98 
    
 
180 1144   1   4,70 1 4,70 
    
 
226 727 31 32 16,31 9,03 63 16,31 
    
 
231 727 5 4 5,91 4,06 9 5,91 
    
 
232 727 2   3,60   2 3,60 
    SF3A2 392 101   1   4,79 1 4,79 
    
 
393 101   3   9,76 3 9,76 
    
 
418 91 10 20 11,08 9,21 30 11,08 
    
 
423 107 7 16 7,66 8,46 23 8,46 
    SF3B1 82 6   1   3,27 1 3,27 
    
 
90 6 1   4,32   1 4,32 
    
 
198 496   1   2,70 1 2,70 
    SMD2 230 98 1   3,66   1 3,66 
    SNW1 277 240 7 3 8,35 11,94 10 11,94 
    SYF1 418 50 1   3,79   1 3,79 
    ZN830 277 262   1   7,82 1 7,82 
    
 
312 234 1   4,53   1 4,53 
    
 
313 182 4   7,49   4 7,49 
    
  
190 5 14 11,12 11,80 19 11,80 
    
  
216   2   7,50 2 7,50 
    
  
228 12 14 10,15 8,92 26 10,15 
    
  
234 29 33 13,86 14,99 62 14,99 
    
 
450 190   2   4,28 2 4,28 
    
  
228 8 15 7,97 7,69 23 7,97 
    
  
234 4 7 5,51 7,02 11 7,02 
    
 
454 228 2 4 4,88 9,32 6 9,32 
    
  
234 10 8 8,24 8,84 18 8,84 
    
 
460 234 4   7,98   4 7,98 
    
 
462 182 1   8,86   1 8,86 
    
  
190 2 1 5,23 3,06 3 5,23 
    
  
228 7 7 10,95 10,98 14 10,98 
    
  
234 13 9 12,81 12,31 22 12,81 
Inter PRCC CDC5L 139 487 1 2 4,89 4,02 3 4,89 
    
 
216 522   2   10,98 2 10,98 
    CRNL1 137 724   4   4,98 4 4,98 
    
 
193 357 1 1 7,80 6,74 2 7,80 
    
  
388   2   4,62 2 4,62 
    
  
397 8 10 9,89 7,82 18 9,89 
    
  
427 3 7 12,94 13,17 10 13,17 
    
 
207 388   9   12,28 9 12,28 
    
 
216 388 1   7,19   1 7,19 
    
 
434 229   1   4,15 1 4,15 
    
 
437 229   1   2,42 1 2,42 
    
 
442 229 1   8,40   1 8,40 
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Spectral count Scoremax Total spec. 
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Scoremax Lumos QExHF Lumos QExHF 
    
 
443 229 2 2 8,26 10,53 4 10,53 
    PLRG1 193 173   1   4,76 1 4,76 
    RBM22 428 78 2   8,00   2 8,00 
    
  
104   2   4,89 2 4,89 
    
 
437 149   1   5,77 1 5,77 
    
 
442 286   1   3,25 1 3,25 
    
 
479 149 1 1 5,49 4,18 2 5,49 
    SF3A2 414 121   1   1,89 1 1,89 
    SNW1 137 48 4   3,86   4 3,86 
    
 
139 48 2   3,32   2 3,32 
    
 
193 97   2   9,21 2 9,21 
    
  
110   2   7,98 2 7,98 
    
 
207 110   1   5,50 1 5,50 
    
 
414 193 3 10 9,29 8,51 13 9,29 
    SYF1 193 423   2   7,77 2 7,77 
    
  
458 13 10 10,82 11,29 23 11,29 
    
 
207 420 3 5 7,47 7,31 8 7,47 
    
  
458 5 2 8,55 7,76 7 8,55 
    
 
216 420 2 2 9,41 7,17 4 9,41 
    
  
458 1 1 4,41 3,41 2 4,41 
    
 
223 420 1 3 5,40 8,12 4 8,12 
Inter PRP17 CDC5L 333 187 9 8 9,06 9,56 17 9,56 
    
  
200 13 13 13,19 8,36 26 13,19 
    
 
551 200   1   5,67 1 5,67 
    CRNL1 541 182   1   4,90 1 4,90 
    
 
547 213   3   4,95 3 4,95 
    
 
551 213 4 7 13,42 8,92 11 13,42 
    PPIL1 63 37 1   6,01   1 6,01 
    PRP8 161 36   1   5,69 1 5,69 
    
 
399 50   1   2,62 1 2,62 
    
 
551 162 1   2,71   1 2,71 
    SF3B2 440 570 4 4 9,59 5,60 8 9,59 
Inter PRP19 AQR 192 667 2   5,42   2 5,42 
    
  
759   1   0,95 1 0,95 
    
 
200 759   4   2,05 4 2,05 
    CDC5L 122 570 26 21 11,62 10,10 47 11,62 
    
  
631   4   8,06 4 8,06 
    
 
179 522 2 3 6,70 6,95 5 6,95 
    
  
685 4 6 7,23 7,71 10 7,71 
    
  
686   1   6,48 1 6,48 
    
  
782 1 1 4,39 4,09 2 4,39 
    
 
192 522 1 3 3,60 5,50 4 5,50 
    
  
782   1   2,39 1 2,39 
    
 
244 522 2 1 7,59 4,25 3 7,59 
    
  
631 2 1 8,69 5,97 3 8,69 
    
  
771   2   6,66 2 6,66 
    
  
782 11 9 10,80 11,86 20 11,86 
    
  
795 1 4 5,11 6,77 5 6,77 
    
 
261 782   4   9,75 4 9,75 
    
 
266 685 2 2 3,30 6,55 4 6,55 
    
  
782 4 1 9,38 5,73 5 9,38 
    CRNL1 179 832   1   3,59 1 3,59 
    
 
192 832   1   3,46 1 3,46 
    CTBL1 192 534 2   5,45   2 5,45 
    DHX16 192 1032   1   0,77 1 0,77 
    ISY1 192 7 1   3,85   1 3,85 
    
 
244 7   4   6,46 4 6,46 
    PLRG1 32 180   2   4,66 2 4,66 
    
 
122 1 4 9 9,20 9,50 13 9,50 
    RSMB 32 57   1   2,84 1 2,84 
    SF3A1 179 2 2 1 8,21 9,01 3 9,01 
    SF3A2 425 103 1   3,41   1 3,41 
    SF3B1 266 816 1   3,87   1 3,87 
    SMD2 192 51 3 1 3,33 3,10 4 3,33 
    SNR40 32 18 1 1 3,35 3,58 2 3,58 
    
 
122 1 2 8 8,37 12,84 10 12,84 
    
  
8   2   5,93 2 5,93 
    
  
18 2 1 8,17 6,13 3 8,17 
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270 1 7 2,13 7,02 8 7,02 
    
  
275 32 30 13,41 10,74 62 13,41 
    
  
322 1   3,68   1 3,68 
    
 
179 1   2   5,34 2 5,34 
    
  
270   2   2,35 2 2,35 
    
 
192 270 1   3,37   1 3,37 
    
  
275 8 5 12,96 12,89 13 12,96 
    
 
244 275 1 6 3,79 8,32 7 8,32 
    SPF27 122 168   2   9,89 2 9,89 
    
 
179 47 1 1 3,43 5,71 2 5,71 
    
  
168 3 5 11,24 11,35 8 11,35 
    
 
244 47 2 3 4,13 6,97 5 6,97 
    
  
168 5 6 9,50 9,97 11 9,97 
    
  
177   1   3,56 1 3,56 
    
  
218   4   5,22 4 5,22 
    
 
266 168   2   5,50 2 5,50 
    SYF1 192 708 2 2 5,70 8,37 4 8,37 
    
 
244 708 1 1 3,48 4,26 2 4,26 
    
 
266 708   6   12,79 6 12,79 
    ZN830 122 104 1   3,81   1 3,81 
    
  
149 2 2 8,36 7,80 4 8,36 
    
 
425 149 1 2 3,63 3,56 3 3,63 
Inter PRP8 BUD13 1514 560   1   3,73 1 3,73 
    BUD31 36 125 1 2 7,01 6,39 3 7,01 
    
 
218 9   2   10,33 2 10,33 
    CDC5L 85 539 1 2 5,32 5,37 3 5,37 
    
 
533 291   1   4,41 1 4,41 
    
 
727 28 1   5,79   1 5,79 
    
 
892 7 29 19 10,16 8,77 48 10,16 
    CTBL1 2070 91 1   2,53   1 2,53 
    CWC15 1132 226   3   7,91 3 7,91 
    
 
1144 91 5 8 7,47 11,71 13 11,71 
    
  
92   1   4,10 1 4,10 
    
 
1158 205 1   4,23   1 4,23 
    CWC22 366 330 19 20 11,47 13,57 39 13,57 
    
 
1392 584   1   1,86 1 1,86 
    GPKOW 1831 334   1   4,97 1 4,97 
    
 
2108 349   1   4,16 1 4,16 
    
 
2244 192   2   2,22 2 2,22 
    KIN17 2 129   1   1,80 1 1,80 
    
 
609 171   1   0,53 1 0,53 
    PHF5A 853 108 1 1 4,16 7,98 2 7,98 
    PLRG1 1132 271   1   0,66 1 0,66 
    PPIL2 727 226 31 32 16,31 9,03 63 16,31 
    
  
231 5 4 5,91 4,06 9 5,91 
    
  
232 2   3,60   2 3,60 
    
 
1132 26 23 42 10,77 12,63 65 12,63 
    
 
1144 166   1   4,98 1 4,98 
    
  
180   1   4,70 1 4,70 
    PRP17 36 161   1   5,69 1 5,69 
    
 
50 399   1   2,62 1 2,62 
    
 
162 551 1   2,71   1 2,71 
    R113A 442 180 2   9,88   2 9,88 
    
 
609 126 6 2 12,06 8,48 8 12,06 
    
 
623 139 2 3 9,02 5,64 5 9,02 
    RBM22 68 301 1   3,65   1 3,65 
    RUXE 267 72 2   0,28   2 0,28 
    SF3B1 1505 943 14 7 5,51 3,95 21 5,51 
    SF3B2 609 770   1   1,97 1 1,97 
    
 
1636 323 1   2,74   1 2,74 
    SF3B3 68 942 3 1 4,89 3,32 4 4,89 
    
 
1732 2 1   1,43   1 1,43 
    SNR40 29 286 3 14 6,07 8,40 17 8,40 
    
 
36 286 1 2 8,50 6,65 3 8,50 
    
 
43 286 3 2 6,84 4,94 5 6,84 
    
 
48 349   2   3,99 2 3,99 
    
 
50 349 3 2 10,85 6,83 5 10,85 
    SNW1 666 158 5 7 7,07 6,94 12 7,07 
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Type Protein 1 Protein 2 Residue 1 Residue 2 
Spectral count Scoremax Total spec. 
count 
Best 
Scoremax Lumos QExHF Lumos QExHF 
    
 
702 236 3 2 6,90 7,33 5 7,33 
    
 
727 266 1 1 2,73 4,97 2 4,97 
    
 
796 266 1 3 3,95 3,63 4 3,95 
    
 
847 416 4 6 7,92 6,30 10 7,92 
    
 
1505 441 7 2 9,55 11,45 9 11,45 
    
 
1801 476 3 3 6,63 6,48 6 6,63 
    
  
503 2 2 6,07 6,16 4 6,16 
    
 
1838 503 6 5 6,75 5,33 11 6,75 
    
 
1984 441   1   3,00 1 3,00 
    
 
1993 452   2   5,75 2 5,75 
    
  
468 8 10 6,00 6,42 18 6,42 
    
 
1994 468   2   3,96 2 3,96 
    
 
2031 468   2   5,19 2 5,19 
    
 
2049 468 1   3,33   1 3,33 
    
  
476 1   4,12   1 4,12 
    
 
2113 158   1   2,30 1 2,30 
    SPF27 1516 155   1   2,03 1 2,03 
    SRRM2 1831 1467   1   2,96 1 2,96 
    U520 1210 14 2   7,73   2 7,73 
    
 
1300 1557   1   3,59 1 3,59 
    
 
1306 14 2 3 6,62 6,62 5 6,62 
    
 
1344 14 15 14 14,63 16,45 29 16,45 
    
 
1636 1146 4 2 6,86 10,16 6 10,16 
    
 
1649 14 4   17,94   4 17,94 
    
 
1993 105 3 2 7,46 3,35 5 7,46 
    
  
144 5   7,11   5 7,11 
    
  
147   1   2,33 1 2,33 
    
 
1994 73 29 24 19,19 11,51 53 19,19 
    
 
2031 60 1   3,77   1 3,77 
    
  
107 1 1 6,25 7,19 2 7,19 
    
  
177 3 1 5,59 8,71 4 8,71 
    
  
178 1 1 4,54 7,63 2 7,63 
    
  
733 6 6 8,07 8,06 12 8,07 
    
  
1039 3 1 9,00 4,87 4 9,00 
    
  
1049   2   3,88 2 3,88 
    
 
2034 60 6 7 14,84 13,43 13 14,84 
    
  
177 8 6 11,94 8,73 14 11,94 
    
  
178 2   10,24   2 10,24 
    
  
733 9 6 7,20 6,80 15 7,20 
    
  
770 2 3 6,56 8,85 5 8,85 
    
  
1039 15 14 8,48 8,07 29 8,48 
    
  
1049 4 6 5,89 10,30 10 10,30 
    
 
2049 60 11 8 17,24 17,13 19 17,24 
    
  
107 1 1 5,90 4,04 2 5,90 
    
  
177 2 2 7,92 5,21 4 7,92 
    
  
178 1 1 2,78 1,98 2 2,78 
    
  
770 10 13 13,07 11,70 23 13,07 
    
  
1034   1   8,06 1 8,06 
    
  
1039 17 19 14,60 12,83 36 14,60 
    
  
1049 9 7 18,15 20,74 16 20,74 
    
  
1134 2 2 5,37 7,43 4 7,43 
    
  
1142 4 9 5,86 6,97 13 6,97 
    
  
1146 6 7 9,53 10,28 13 10,28 
    
 
2070 1034 1   4,40   1 4,40 
    
  
1039 12 14 13,61 14,76 26 14,76 
    
  
1049 3 5 9,54 13,06 8 13,06 
    
  
1145   1   4,63 1 4,63 
    
 
2244 256 1   5,36   1 5,36 
    
 
2249 14 1 3 5,80 7,57 4 7,57 
    U5S1 218 405 50 45 18,31 15,17 95 18,31 
    
  
409 33 18 13,05 10,81 51 13,05 
    
 
366 359 37 33 14,67 13,05 70 14,67 
    
 
1210 712   1   1,29 1 1,29 
    ZN830 477 102 1   3,62   1 3,62 
Inter R113A CWC27 107 192 1   3,03   1 3,03 
    DHX16 21 1027   2   4,28 2 4,28 
    PRP8 126 609 6 2 12,06 8,48 8 12,06 
    
 
139 623 2 3 9,02 5,64 5 9,02 
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Spectral count Scoremax Total spec. 
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180 442 2   9,88   2 9,88 
    SF3B3 276 1206 30 15 15,80 9,30 45 15,80 
    
  
1207   3   9,26 3 9,26 
    SF3B4 311 2   1   1,74 1 1,74 
    SNR40 164 349 1   2,60   1 2,60 
    U520 25 2026 6 5 7,69 6,44 11 7,69 
    
  
2087 4 4 4,70 4,95 8 4,95 
    
 
319 557 3 5 5,79 4,99 8 5,79 
    
  
770 12 6 6,29 3,97 18 6,29 
Inter RBM22 AQR 229 604 1 1 4,79 4,10 2 4,79 
    CRNL1 114 224   1   8,39 1 8,39 
    CTBL1 170 554   1   0,44 1 0,44 
    CWC15 40 28   2   4,60 2 4,60 
    
 
76 18 11 8 19,88 18,51 19 19,88 
    ISY1 199 92 1   1,09   1 1,09 
    PPIL1 286 80   3   6,71 3 6,71 
    PRCC 78 428 2   8,00   2 8,00 
    
 
104 428   2   4,89 2 4,89 
    
 
149 437   1   5,77 1 5,77 
    
  
479 1 1 5,49 4,18 2 5,49 
    
 
286 442   1   3,25 1 3,25 
    PRP8 301 68 1   3,65   1 3,65 
    SMD2 185 88   2   2,41 2 2,41 
    SNW1 40 153 2 1 4,22 3,40 3 4,22 
    
 
76 193 2 1 4,41 4,37 3 4,41 
    
 
114 193 1 1 5,63 7,06 2 7,06 
    
 
139 193   4   5,63 4 5,63 
    
 
286 81 8 8 12,64 21,62 16 21,62 
Inter RBMX2 BUD13 119 483 11 9 16,25 18,46 20 18,46 
    
  
486   1   2,82 1 2,82 
    CDC5L 243 187   1   2,12 1 2,12 
    DHX16 72 860 1   4,73   1 4,73 
    
 
246 93   1   4,56 1 4,56 
    SF3B1 8 120   1   4,28 1 4,28 
    
  
786 1 3 5,29 7,54 4 7,54 
    
 
77 700   1   3,48 1 3,48 
    
  
741 19 12 12,12 9,04 31 12,12 
    
 
101 120 1 5 4,07 8,28 6 8,28 
    
  
121   1   6,48 1 6,48 
    
 
119 741 1   8,55   1 8,55 
    
 
204 741 1   2,06   1 2,06 
    SNIP1 71 216 2   5,03   2 5,03 
    
 
72 216 3 1 6,18 4,84 4 6,18 
    SRRM2 101 228   1   3,23 1 3,23 
    U5S1 197 609   1   2,67 1 2,67 
    
 
263 352 1   4,35   1 4,35 
Inter RSMB CRNL1 57 607   1   2,67 1 2,67 
    CWC27 50 183 4 2 6,76 6,56 6 6,76 
    
  
184 17 16 11,34 8,20 33 11,34 
    
  
186 5 2 8,01 8,26 7 8,26 
    PRP19 57 32   1   2,84 1 2,84 
    SF3A3 54 175 3   4,98   3 4,98 
    SF3B2 57 320   1   7,58 1 7,58 
    SMD1 5 41 6 9 8,10 7,27 15 8,10 
    
  
86   2   5,65 2 5,65 
    
 
8 41 3 8 12,27 11,47 11 12,27 
    SMD3 5 87 3   4,40   3 4,40 
    
 
88 78 1 2 3,23 5,23 3 5,23 
    
  
84   3   5,63 3 5,63 
    
  
87   1   3,28 1 3,28 
    SNR40 57 1 1 1 4,10 4,65 2 4,65 
Inter RU2A ISY1 56 266 10 10 17,92 11,80 20 17,92 
    
 
179 266 1   3,95   1 3,95 
    
 
191 266 12 6 10,33 8,40 18 10,33 
    
 
192 260 1   5,06   1 5,06 
    
  
266   1   7,19 1 7,19 
    
 
193 260 1   16,77   1 16,77 
    
  
266 46 48 16,71 22,31 94 22,31 
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205 259   2   6,82 2 6,82 
    
  
260 20 16 8,98 8,82 36 8,98 
    
 
221 260 2   4,90   2 4,90 
    
  
266 29 28 19,59 20,12 57 20,12 
    PPIE 172 123 2 4 6,97 6,56 6 6,97 
    
  
134 4 2 11,41 5,01 6 11,41 
    
 
179 134 1   4,45   1 4,45 
    
 
193 114 1   4,11   1 4,11 
    
  
134 1 1 4,64 3,79 2 4,64 
    RU2B 30 101   1   3,90 1 3,90 
    
  
111 2 4 9,04 15,53 6 15,53 
    SF3A1 67 264   1   1,49 1 1,49 
    
 
193 316   2   8,13 2 8,13 
    
 
205 223 3 3 5,52 4,84 6 5,52 
    
 
221 188 3   7,24   3 7,24 
    SF3A3 56 69   1   5,33 1 5,33 
    
 
172 64 1 1 5,84 3,43 2 5,84 
    
  
69 4 4 5,87 4,42 8 5,87 
    
 
179 64   1   9,27 1 9,27 
    
  
69 11 21 15,81 11,99 32 15,81 
    
 
221 64   3   10,20 3 10,20 
    
  
69   5   11,00 5 11,00 
    SF3B1 191 175 4 4 4,88 5,22 8 5,22 
    
  
177 2   4,32   2 4,32 
    
 
192 175   1   4,31 1 4,31 
    
  
177 1   3,34   1 3,34 
    SF3B2 179 280 1 4 3,71 4,03 5 4,03 
    SYF1 205 2 39 20 11,40 8,14 59 11,40 
Inter RU2B CTBL1 1 83   1   2,36 1 2,36 
    
  
84 1   3,22   1 3,22 
    RU2A 101 30   1   3,90 1 3,90 
    
 
111 30 2 4 9,04 15,53 6 15,53 
    SF3A3 103 463 3 3 11,65 9,14 6 11,65 
    
 
111 463 2 1 4,12 4,46 3 4,46 
    
 
224 496 8 5 10,73 11,11 13 11,11 
    
 
225 496 1 1 11,23 10,13 2 11,23 
    SF3B2 85 352   1   2,95 1 2,95 
    
 
93 352   1   3,52 1 3,52 
    
 
101 352   1   6,45 1 6,45 
    
 
103 352   1   4,32 1 4,32 
    
 
111 352 8 3 9,25 6,22 11 9,25 
    SF3B3 111 1074 7 7 13,76 13,15 14 13,76 
    SMD3 101 31   1   4,43 1 4,43 
    SNIP1 111 79   1   3,11 1 3,11 
Inter RUXE CWC22 80 745   1   2,02 1 2,02 
    PLRG1 80 47   1   2,44 1 2,44 
    PRP8 72 267 2   0,28   2 0,28 
    SF3B2 80 323   1   3,86 1 3,86 
Inter SF3A1 CWC27 115 192   2   4,67 2 4,67 
    GPKOW 210 349   1   2,09 1 2,09 
    ISY1 2 7 1 1 6,62 5,50 2 6,62 
    
  
84   1   4,80 1 4,80 
    
  
121   1   5,27 1 5,27 
    
 
30 84 1   3,78   1 3,78 
    
  
127 2   6,59   2 6,59 
    
  
260 1 1 2,57 1,77 2 2,57 
    
 
37 84 1 1 3,99 4,08 2 4,08 
    
  
101 1   4,45   1 4,45 
    
  
105 6 3 7,82 5,61 9 7,82 
    
  
127 1 1 5,55 5,21 2 5,55 
    
 
115 55 4 4 8,45 6,34 8 8,45 
    
  
84 5 5 7,39 7,41 10 7,41 
    
  
105 2 2 5,94 4,29 4 5,94 
    
  
121   1   7,04 1 7,04 
    
 
131 121 1   3,26   1 3,26 
    PPIE 2 218 8 5 10,00 9,59 13 10,00 
    
 
131 104   3   4,62 3 4,62 
    
 
210 88 7 2 9,14 12,51 9 12,51 
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104 9 5 8,65 8,89 14 8,89 
    
 
223 104 1 2 3,84 7,60 3 7,60 
    
  
108 2 3 5,30 3,69 5 5,30 
    
  
114 1 4 2,88 4,01 5 4,01 
    
 
230 108 2   7,92   2 7,92 
    
  
114 1   6,53   1 6,53 
    
  
123 4 1 10,80 4,93 5 10,80 
    
 
231 108 4 3 10,01 7,41 7 10,01 
    
  
114   2   5,50 2 5,50 
    
  
123 3 3 11,17 8,80 6 11,17 
    
  
134 1 4 11,97 6,50 5 11,97 
    
 
251 108 1   5,99   1 5,99 
    PRP19 2 179 2 1 8,21 9,01 3 9,01 
    RU2A 188 221 3   7,24   3 7,24 
    
 
223 205 3 3 5,52 4,84 6 5,52 
    
 
264 67   1   1,49 1 1,49 
    
 
316 193   2   8,13 2 8,13 
    SF3A2 102 118   2   4,23 2 4,23 
    SF3A3 131 219 5 3 8,40 6,04 8 8,40 
    
  
220 8   23,37   8 23,37 
    
 
188 89 15 9 7,82 8,08 24 8,08 
    
  
92 26 19 11,18 8,92 45 11,18 
    
 
231 212 1 2 2,73 7,00 3 7,00 
    
 
251 29 13 6 10,18 8,09 19 10,18 
    
 
258 29 19 26 14,88 12,53 45 14,88 
    
 
259 29 3   7,84   3 7,84 
    SF3B1 467 522 1   1,52   1 1,52 
    SF3B2 115 466 1   3,09   1 3,09 
    
 
210 275 5 2 10,50 8,25 7 10,50 
    
 
217 275 2   5,37   2 5,37 
    SYF1 2 257   1   7,77 1 7,77 
    
  
708 13 14 13,35 10,58 27 13,35 
    
  
794 2 1 6,04 5,25 3 6,04 
    
 
55 549 12 6 12,34 15,68 18 15,68 
    
  
590   1   8,43 1 8,43 
    
  
794 4   6,87   4 6,87 
    
 
115 590 4   10,10   4 10,10 
    
  
794   2   4,31 2 4,31 
    
 
131 794 1   4,59   1 4,59 
    
 
223 76 2   4,04   2 4,04 
    
 
399 708   2   9,76 2 9,76 
    
 
533 708   1   5,14 1 5,14 
Inter SF3A2 AQR 42 662   2   2,80 2 2,80 
    CRNL1 118 175 1 1 4,00 1,27 2 4,00 
    
 
194 680 1   0,89   1 0,89 
    CWC27 103 184 1 1 4,88 3,44 2 4,88 
    KIN17 48 157   1   2,23 1 2,23 
    PLRG1 118 320   1   2,42 1 2,42 
    PPIE 42 284   1   3,99 1 3,99 
    PPIL2 91 418 10 20 11,08 9,21 30 11,08 
    
 
101 392   1   4,79 1 4,79 
    
  
393   3   9,76 3 9,76 
    
 
107 423 7 16 7,66 8,46 23 8,46 
    PRCC 121 414   1   1,89 1 1,89 
    PRP19 103 425 1   3,41   1 3,41 
    SF3A1 118 102   2   4,23 2 4,23 
    SF3A3 77 390 1   3,78   1 3,78 
    
 
91 390 28 21 14,70 13,47 49 14,70 
    SF3B4 88 46 1 2 2,63 2,80 3 2,80 
    
 
91 2   1   5,41 1 5,41 
    SNIP1 121 342 1   4,92   1 4,92 
Inter SF3A3 ISY1 69 266 2 1 23,89 5,77 3 23,89 
    PPIE 219 134 5 1 6,68 2,68 6 6,68 
    PPIL1 97 52   1   2,39 1 2,39 
    RSMB 175 54 3   4,98   3 4,98 
    RU2A 64 172 1 1 5,84 3,43 2 5,84 
    
  
179   1   9,27 1 9,27 
    
  
221   3   10,20 3 10,20 
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69 56   1   5,33 1 5,33 
    
  
172 4 4 5,87 4,42 8 5,87 
    
  
179 11 21 15,81 11,99 32 15,81 
    
  
221   5   11,00 5 11,00 
    RU2B 463 103 3 3 11,65 9,14 6 11,65 
    
  
111 2 1 4,12 4,46 3 4,46 
    
 
496 224 8 5 10,73 11,11 13 11,11 
    
  
225 1 1 11,23 10,13 2 11,23 
    SF3A1 29 251 13 6 10,18 8,09 19 10,18 
    
  
258 19 26 14,88 12,53 45 14,88 
    
  
259 3   7,84   3 7,84 
    
 
89 188 15 9 7,82 8,08 24 8,08 
    
 
92 188 26 19 11,18 8,92 45 11,18 
    
 
212 231 1 2 2,73 7,00 3 7,00 
    
 
219 131 5 3 8,40 6,04 8 8,40 
    
 
220 131 8   23,37   8 23,37 
    SF3A2 390 77 1   3,78   1 3,78 
    
  
91 28 21 14,70 13,47 49 14,70 
    SF3B2 69 280 19 17 7,06 5,96 36 7,06 
    
 
420 514 1 3 6,50 5,19 4 6,50 
    
 
466 604   1   4,30 1 4,30 
    SF3B3 89 1074 1   3,50   1 3,50 
    
 
463 1074 27 36 9,17 11,96 63 11,96 
    
 
466 980   1   6,24 1 6,24 
    
  
984   4   5,27 4 5,27 
    
  
1074 17 16 10,78 8,64 33 10,78 
    
 
496 974 6 8 11,29 12,14 14 12,14 
    SF3B4 29 183 3 1 7,38 5,48 4 7,38 
    SMD2 157 118 1   8,17   1 8,17 
    SRRM2 308 1428 1   0,88   1 0,88 
Inter SF3B1 BUD13 816 499 3   6,12   3 6,12 
    CTBL1 6 31 2 2 6,24 5,44 4 6,24 
    
  
56 2 2 10,60 11,18 4 11,18 
    
  
57   1   14,05 1 14,05 
    
  
83 16 21 19,29 17,06 37 19,29 
    
  
84 10 7 10,38 11,45 17 11,45 
    
  
91 9 6 9,13 6,39 15 9,13 
    
  
95 10 8 8,97 6,16 18 8,97 
    
 
21 91 5 5 8,40 5,87 10 8,40 
    
  
95 2   6,69   2 6,69 
    DHX16 6 69 21 14 10,16 6,71 35 10,16 
    
 
21 69 5 2 8,24 6,29 7 8,24 
    
 
22 69 2 7 4,67 6,28 9 6,28 
    
  
73   1   8,12 1 8,12 
    
 
733 860 2 3 11,31 11,23 5 11,31 
    PPIL2 6 82   1   3,27 1 3,27 
    
  
90 1   4,32   1 4,32 
    
 
496 198   1   2,70 1 2,70 
    PRP19 816 266 1   3,87   1 3,87 
    PRP8 943 1505 14 7 5,51 3,95 21 5,51 
    RBMX2 120 8   1   4,28 1 4,28 
    
  
101 1 5 4,07 8,28 6 8,28 
    
 
121 101   1   6,48 1 6,48 
    
 
700 77   1   3,48 1 3,48 
    
 
741 77 19 12 12,12 9,04 31 12,12 
    
  
119 1   8,55   1 8,55 
    
  
204 1   2,06   1 2,06 
    
 
786 8 1 3 5,29 7,54 4 7,54 
    RU2A 175 191 4 4 4,88 5,22 8 5,22 
    
  
192   1   4,31 1 4,31 
    
 
177 191 2   4,32   2 4,32 
    
  
192 1   3,34   1 3,34 
    SF3A1 522 467 1   1,52   1 1,52 
    SF3B2 1292 486 16 14 9,55 9,77 30 9,77 
    SF3B3 1292 965 11 7 7,24 8,07 18 8,07 
    SF3B6 163 125 3 9 9,96 10,75 12 10,75 
    
 
175 116 1 1 3,56 4,55 2 4,55 
    
 
182 116 1   5,64   1 5,64 
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195 116 9 6 12,64 9,99 15 12,64 
    
 
656 125   3   9,77 3 9,77 
    
 
700 125 4 4 11,70 8,15 8 11,70 
    SNIP1 182 301   3   4,75 3 4,75 
    
 
700 223 3   15,42   3 15,42 
    
 
816 216 4   6,48   4 6,48 
    SNW1 6 311 1 1 4,52 4,61 2 4,61 
    
 
22 379   1   3,30 1 3,30 
    
 
816 456 17 12 9,20 7,41 29 9,20 
    
  
468   3   3,28 3 3,28 
    
 
943 441 15 7 7,71 7,07 22 7,71 
    U520 21 343   1   5,52 1 5,52 
Inter SF3B2 BUD13 326 339   1   1,38 1 1,38 
    CDC5L 543 187 1 2 4,15 7,04 3 7,04 
    
 
570 187   1   1,76 1 1,76 
    
 
577 174   1   2,47 1 2,47 
    CRNL1 570 175 2 2 3,94 3,93 4 3,94 
    
  
178   1   1,57 1 1,57 
    
  
182 5 4 8,03 11,74 9 11,74 
    CWC15 556 91 2   7,23   2 7,23 
    ISY1 556 41   1   1,94 1 1,94 
    PPIE 275 88   2   6,70 2 6,70 
    
  
104 1   7,39   1 7,39 
    PRP17 570 440 4 4 9,59 5,60 8 9,59 
    PRP8 323 1636 1   2,74   1 2,74 
    
 
770 609   1   1,97 1 1,97 
    RSMB 320 57   1   7,58 1 7,58 
    RU2A 280 179 1 4 3,71 4,03 5 4,03 
    RU2B 352 85   1   2,95 1 2,95 
    
  
93   1   3,52 1 3,52 
    
  
101   1   6,45 1 6,45 
    
  
103   1   4,32 1 4,32 
    
  
111 8 3 9,25 6,22 11 9,25 
    RUXE 323 80   1   3,86 1 3,86 
    SF3A1 275 210 5 2 10,50 8,25 7 10,50 
    
  
217 2   5,37   2 5,37 
    
 
466 115 1   3,09   1 3,09 
    SF3A3 280 69 19 17 7,06 5,96 36 7,06 
    
 
514 420 1 3 6,50 5,19 4 6,50 
    
 
604 466   1   4,30 1 4,30 
    SF3B1 486 1292 16 14 9,55 9,77 30 9,77 
    SF3B3 602 1074   1   4,37 1 4,37 
    
 
604 1074 14 14 13,82 9,05 28 13,82 
    
 
605 1074 22 20 20,59 19,63 42 20,59 
    
 
877 1206 1   4,22   1 4,22 
    SMD3 352 31 2 1 7,40 6,95 3 7,40 
    SNR40 891 270 1   3,30   1 3,30 
    SNW1 877 193   1   11,22 1 11,22 
    SYF1 275 36 2 1 4,38 4,67 3 4,67 
    U520 877 469   1   5,67 1 5,67 
    
  
1874 4 2 12,50 10,24 6 12,50 
Inter SF3B3 DHX16 126 1019 12 8 12,64 11,21 20 12,64 
    
  
1027 34 48 11,86 11,97 82 11,97 
    
 
296 1019 3 1 5,58 9,21 4 9,21 
    KIN17 26 231 11 5 12,74 9,88 16 12,74 
    
 
296 231   3   9,47 3 9,47 
    PHF5A 137 13   1   4,82 1 4,82 
    
  
95   1   4,86 1 4,86 
    PRP8 2 1732 1   1,43   1 1,43 
    
 
942 68 3 1 4,89 3,32 4 4,89 
    R113A 1206 276 30 15 15,80 9,30 45 15,80 
    
 
1207 276   3   9,26 3 9,26 
    RU2B 1074 111 7 7 13,76 13,15 14 13,76 
    SF3A3 974 496 6 8 11,29 12,14 14 12,14 
    
 
980 466   1   6,24 1 6,24 
    
 
984 466   4   5,27 4 5,27 
    
 
1074 89 1   3,50   1 3,50 
    
  
463 27 36 9,17 11,96 63 11,96 
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Type Protein 1 Protein 2 Residue 1 Residue 2 
Spectral count Scoremax Total spec. 
count 
Best 
Scoremax Lumos QExHF Lumos QExHF 
    
  
466 17 16 10,78 8,64 33 10,78 
    SF3B1 965 1292 11 7 7,24 8,07 18 8,07 
    SF3B2 1074 602   1   4,37 1 4,37 
    
  
604 14 14 13,82 9,05 28 13,82 
    
  
605 22 20 20,59 19,63 42 20,59 
    
 
1206 877 1   4,22   1 4,22 
Inter SF3B4 R113A 2 311   1   1,74 1 1,74 
    SF3A2 2 91   1   5,41 1 5,41 
    
 
46 88 1 2 2,63 2,80 3 2,80 
    SF3A3 183 29 3 1 7,38 5,48 4 7,38 
Inter SF3B6 CDC5L 29 106 1 2 3,04 5,82 3 5,82 
    SF3B1 116 175 1 1 3,56 4,55 2 4,55 
    
  
182 1   5,64   1 5,64 
    
  
195 9 6 12,64 9,99 15 12,64 
    
 
125 163 3 9 9,96 10,75 12 10,75 
    
  
656   3   9,77 3 9,77 
    
  
700 4 4 11,70 8,15 8 11,70 
    SMD2 106 98 1   0,89   1 0,89 
    SNIP1 125 216 1   6,66   1 6,66 
Inter SMD1 CDC5L 86 291 2   8,38   2 8,38 
    KIN17 9 33 1   0,01   1 0,01 
    RSMB 41 5 6 9 8,10 7,27 15 8,10 
    
  
8 3 8 12,27 11,47 11 12,27 
    
 
86 5   2   5,65 2 5,65 
    SMD2 1 37   1   2,15 1 2,15 
    
 
86 18 2 2 3,91 6,35 4 6,35 
    SNR40 44 8   1   2,89 1 2,89 
    ZN830 44 102 1   4,67   1 4,67 
Inter SMD2 CDC5L 98 264 1   1,02   1 1,02 
    
 
118 782   1   9,25 1 9,25 
    CWC22 8 149 1   0,50   1 0,50 
    
 
50 250   1   0,20 1 0,20 
    DHX16 98 228 1   1,71   1 1,71 
    ISY1 98 259 2   3,99   2 3,99 
    
  
260 3 3 5,24 4,86 6 5,24 
    PPIL2 98 230 1   3,66   1 3,66 
    PRP19 51 192 3 1 3,33 3,10 4 3,33 
    RBM22 88 185   2   2,41 2 2,41 
    SF3A3 118 157 1   8,17   1 8,17 
    SF3B6 98 106 1   0,89   1 0,89 
    SMD1 18 86 2 2 3,91 6,35 4 6,35 
    
 
37 1   1   2,15 1 2,15 
    SRRM2 98 2667 1   4,89   1 4,89 
Inter SMD3 CDC5L 104 201   1   2,93 1 2,93 
    IF4A3 99 15 2 1 5,81 3,26 3 5,81 
    RSMB 78 88 1 2 3,23 5,23 3 5,23 
    
 
84 88   3   5,63 3 5,63 
    
 
87 5 3   4,40   3 4,40 
    
  
88   1   3,28 1 3,28 
    RU2B 31 101   1   4,43 1 4,43 
    SF3B2 31 352 2 1 7,40 6,95 3 7,40 
    U5S1 87 421 1 4 4,15 6,06 5 6,06 
Inter SNIP1 DHX16 216 860 3 2 9,62 9,69 5 9,69 
    RBMX2 216 71 2   5,03   2 5,03 
    
  
72 3 1 6,18 4,84 4 6,18 
    RU2B 79 111   1   3,11 1 3,11 
    SF3A2 342 121 1   4,92   1 4,92 
    SF3B1 216 816 4   6,48   4 6,48 
    
 
223 700 3   15,42   3 15,42 
    
 
301 182   3   4,75 3 4,75 
    SF3B6 216 125 1   6,66   1 6,66 
    SNW1 342 339 49 45 15,91 15,15 94 15,91 
    
  
344 28 25 14,37 16,79 53 16,79 
    
  
376   1   3,63 1 3,63 
    
  
379 13 18 4,50 5,08 31 5,08 
    
 
353 339 12 15 9,17 10,08 27 10,08 
    
 
355 319 1   3,29   1 3,29 
    
  
323 14 12 12,54 10,15 26 12,54 
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Type Protein 1 Protein 2 Residue 1 Residue 2 
Spectral count Scoremax Total spec. 
count 
Best 
Scoremax Lumos QExHF Lumos QExHF 
    
  
330 1   5,76   1 5,76 
    
  
339 7 15 7,39 9,38 22 9,38 
    
  
344   2   5,68 2 5,68 
    
  
379 2 1 6,72 3,36 3 6,72 
    
 
359 339 4   9,68   4 9,68 
    U520 2 2080 1   3,60   1 3,60 
    U5S1 257 788 1   2,73   1 2,73 
Inter SNR40 CDC5L 18 771 7 6 6,41 7,68 13 7,68 
    
 
270 782 2 2 2,95 6,68 4 6,68 
    
  
795 17 11 9,39 5,90 28 9,39 
    
 
275 771   2   6,92 2 6,92 
    
  
782   8   10,60 8 10,60 
    PPIL1 1 80 5 6 5,97 7,97 11 7,97 
    
 
8 80   1   6,01 1 6,01 
    
 
18 80 3 1 4,39 3,94 4 4,39 
    
  
161 1   3,56   1 3,56 
    PRP19 1 122 2 8 8,37 12,84 10 12,84 
    
  
179   2   5,34 2 5,34 
    
 
8 122   2   5,93 2 5,93 
    
 
18 32 1 1 3,35 3,58 2 3,58 
    
  
122 2 1 8,17 6,13 3 8,17 
    
 
270 122 1 7 2,13 7,02 8 7,02 
    
  
179   2   2,35 2 2,35 
    
  
192 1   3,37   1 3,37 
    
 
275 122 32 30 13,41 10,74 62 13,41 
    
  
192 8 5 12,96 12,89 13 12,96 
    
  
244 1 6 3,79 8,32 7 8,32 
    
 
322 122 1   3,68   1 3,68 
    PRP8 286 29 3 14 6,07 8,40 17 8,40 
    
  
36 1 2 8,50 6,65 3 8,50 
    
  
43 3 2 6,84 4,94 5 6,84 
    
 
349 48   2   3,99 2 3,99 
    
  
50 3 2 10,85 6,83 5 10,85 
    R113A 349 164 1   2,60   1 2,60 
    RSMB 1 57 1 1 4,10 4,65 2 4,65 
    SF3B2 270 891 1   3,30   1 3,30 
    SMD1 8 44   1   2,89 1 2,89 
    SNW1 1 153   1   5,48 1 5,48 
    
  
193 2 2 10,60 9,60 4 10,60 
    
 
18 48 1   4,59   1 4,59 
    
  
97 2 2 5,04 5,42 4 5,42 
    
  
193 2 1 8,73 4,68 3 8,73 
    
 
349 170 2 1 5,73 4,68 3 5,73 
    SPF27 18 158 1 4 6,09 11,91 5 11,91 
    
  
168 2 6 7,38 8,82 8 8,82 
    
  
177   2   4,80 2 4,80 
    
 
270 168   1   1,69 1 1,69 
    
 
275 168 27 28 16,45 17,59 55 17,59 
    
  
177 1 3 7,65 4,58 4 7,65 
    
  
191 4 4 8,97 8,43 8 8,97 
    
 
322 168 1   4,43   1 4,43 
    SYF1 8 62   1   1,44 1 1,44 
Inter SNW1 BUD13 441 604 2 2 5,54 5,35 4 5,54 
    
  
605 7 5 14,66 17,06 12 17,06 
    
 
503 474 1 1 2,71 3,47 2 3,47 
    CDC5L 258 28 1   5,25   1 5,25 
    
 
266 28 3 9 8,05 9,99 12 9,99 
    
 
311 124 1   5,37   1 5,37 
    CRNL1 48 357   1   5,04 1 5,04 
    
 
108 397 5 5 9,26 8,29 10 9,26 
    
 
110 397 8 5 8,54 9,53 13 9,53 
    
 
115 397 3 3 10,11 5,18 6 10,11 
    
 
217 229   2   3,02 2 3,02 
    CWC15 153 18 21 24 11,11 11,74 45 11,74 
    
 
311 152   3   11,67 3 11,67 
    CWC22 376 648 1   9,05   1 9,05 
    ISY1 317 121   1   1,68 1 1,68 
    PLRG1 110 173   1   4,48 1 4,48 
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Type Protein 1 Protein 2 Residue 1 Residue 2 
Spectral count Scoremax Total spec. 
count 
Best 
Scoremax Lumos QExHF Lumos QExHF 
    
  
180 3 5 8,32 9,25 8 9,25 
    
  
181 1   3,51   1 3,51 
    
 
153 363   1   6,44 1 6,44 
    
 
158 320 18 15 14,27 12,23 33 14,27 
    
  
363 4 4 8,96 4,65 8 8,96 
    
 
217 363   2   3,31 2 3,31 
    PPIL1 81 58 1   12,15   1 12,15 
    
 
97 158 28 20 14,71 12,35 48 14,71 
    
 
193 52 1   2,66   1 2,66 
    
  
80 3 11 6,74 7,82 14 7,82 
    PPIL2 240 277 7 3 8,35 11,94 10 11,94 
    PRCC 48 137 4   3,86   4 3,86 
    
  
139 2   3,32   2 3,32 
    
 
97 193   2   9,21 2 9,21 
    
 
110 193   2   7,98 2 7,98 
    
  
207   1   5,50 1 5,50 
    
 
193 414 3 10 9,29 8,51 13 9,29 
    PRP8 158 666 5 7 7,07 6,94 12 7,07 
    
  
2113   1   2,30 1 2,30 
    
 
236 702 3 2 6,90 7,33 5 7,33 
    
 
266 727 1 1 2,73 4,97 2 4,97 
    
  
796 1 3 3,95 3,63 4 3,95 
    
 
416 847 4 6 7,92 6,30 10 7,92 
    
 
441 1505 7 2 9,55 11,45 9 11,45 
    
  
1984   1   3,00 1 3,00 
    
 
452 1993   2   5,75 2 5,75 
    
 
468 1993 8 10 6,00 6,42 18 6,42 
    
  
1994   2   3,96 2 3,96 
    
  
2031   2   5,19 2 5,19 
    
  
2049 1   3,33   1 3,33 
    
 
476 1801 3 3 6,63 6,48 6 6,63 
    
  
2049 1   4,12   1 4,12 
    
 
503 1801 2 2 6,07 6,16 4 6,16 
    
  
1838 6 5 6,75 5,33 11 6,75 
    RBM22 81 286 8 8 12,64 21,62 16 21,62 
    
 
153 40 2 1 4,22 3,40 3 4,22 
    
 
193 76 2 1 4,41 4,37 3 4,41 
    
  
114 1 1 5,63 7,06 2 7,06 
    
  
139   4   5,63 4 5,63 
    SF3B1 311 6 1 1 4,52 4,61 2 4,61 
    
 
379 22   1   3,30 1 3,30 
    
 
441 943 15 7 7,71 7,07 22 7,71 
    
 
456 816 17 12 9,20 7,41 29 9,20 
    
 
468 816   3   3,28 3 3,28 
    SF3B2 193 877   1   11,22 1 11,22 
    SNIP1 319 355 1   3,29   1 3,29 
    
 
323 355 14 12 12,54 10,15 26 12,54 
    
 
330 355 1   5,76   1 5,76 
    
 
339 342 49 45 15,91 15,15 94 15,91 
    
  
353 12 15 9,17 10,08 27 10,08 
    
  
355 7 15 7,39 9,38 22 9,38 
    
  
359 4   9,68   4 9,68 
    
 
344 342 28 25 14,37 16,79 53 16,79 
    
  
355   2   5,68 2 5,68 
    
 
376 342   1   3,63 1 3,63 
    
 
379 342 13 18 4,50 5,08 31 5,08 
    
  
355 2 1 6,72 3,36 3 6,72 
    SNR40 48 18 1   4,59   1 4,59 
    
 
97 18 2 2 5,04 5,42 4 5,42 
    
 
153 1   1   5,48 1 5,48 
    
 
170 349 2 1 5,73 4,68 3 5,73 
    
 
193 1 2 2 10,60 9,60 4 10,60 
    
  
18 2 1 8,73 4,68 3 8,73 
    SYF1 48 420 2   7,80   2 7,80 
    U520 236 151 1   5,86   1 5,86 
    
 
452 1176 1   5,23   1 5,23 
    ZN830 311 13 3 1 6,34 5,53 4 6,34 
    
 
315 13 4 3 8,84 8,25 7 8,84 
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Type Protein 1 Protein 2 Residue 1 Residue 2 
Spectral count Scoremax Total spec. 
count 
Best 
Scoremax Lumos QExHF Lumos QExHF 
Inter SPF27 BUD31 177 42 1   0,43   1 0,43 
    CDC5L 97 685 11 6 5,63 4,70 17 5,63 
    
 
168 312 3   5,87   3 5,87 
    
 
177 771 69 69 15,74 16,94 138 16,94 
    
 
191 782 12 10 10,53 10,17 22 10,53 
    
 
218 795 2 2 4,79 4,37 4 4,79 
    
  
799   2   3,49 2 3,49 
    CWC22 155 598   2   3,80 2 3,80 
    PPIL1 168 80 10 12 9,74 8,90 22 9,74 
    PRP19 47 179 1 1 3,43 5,71 2 5,71 
    
  
244 2 3 4,13 6,97 5 6,97 
    
 
168 122   2   9,89 2 9,89 
    
  
179 3 5 11,24 11,35 8 11,35 
    
  
244 5 6 9,50 9,97 11 9,97 
    
  
266   2   5,50 2 5,50 
    
 
177 244   1   3,56 1 3,56 
    
 
218 244   4   5,22 4 5,22 
    PRP8 155 1516   1   2,03 1 2,03 
    SNR40 158 18 1 4 6,09 11,91 5 11,91 
    
 
168 18 2 6 7,38 8,82 8 8,82 
    
  
270   1   1,69 1 1,69 
    
  
275 27 28 16,45 17,59 55 17,59 
    
  
322 1   4,43   1 4,43 
    
 
177 18   2   4,80 2 4,80 
    
  
275 1 3 7,65 4,58 4 7,65 
    
 
191 275 4 4 8,97 8,43 8 8,97 
    ZN830 168 149 4   8,13   4 8,13 
Inter SRRM2 DHX16 130 69   3   5,97 3 5,97 
    
 
131 69   1   3,77 1 3,77 
    ISY1 169 259   1   1,87 1 1,87 
    PRP8 1467 1831   1   2,96 1 2,96 
    RBMX2 228 101   1   3,23 1 3,23 
    SF3A3 1428 308 1   0,88   1 0,88 
    SMD2 2667 98 1   4,89   1 4,89 
    U520 101 599 1   4,79   1 4,79 
    
 
169 1134   1   3,61 1 3,61 
    
 
2680 1176 2 1 5,43 4,57 3 5,43 
    ZN830 161 216   1   2,96 1 2,96 
Inter SYF1 AQR 2 950 3 3 11,71 11,71 6 11,71 
    
  
954 12 16 6,32 8,25 28 8,25 
    
  
1002 5 1 6,34 5,28 6 6,34 
    CDC5L 532 522 12 11 6,94 7,18 23 7,18 
    
 
654 290 7 9 5,96 11,85 16 11,85 
    
  
294 31 23 22,28 18,10 54 22,28 
    
 
677 312 1 1 8,19 11,57 2 11,57 
    CRNL1 482 427 15 9 9,90 6,95 24 9,90 
    
  
460   1   7,93 1 7,93 
    
  
461 4 9 5,37 7,04 13 7,04 
    
 
794 787 4 2 6,49 7,70 6 7,70 
    CWC22 654 330 1   5,83   1 5,83 
    CWC27 539 180 1 1 4,39 3,50 2 4,39 
    ISY1 2 190 5 3 5,76 6,21 8 6,21 
    
  
260 10 11 10,22 12,04 21 12,04 
    
  
266 2 1 4,43 5,57 3 5,57 
    
 
83 188 5 3 5,37 4,77 8 5,37 
    
 
257 84   1   3,12 1 3,12 
    
  
138 11 8 11,39 12,61 19 12,61 
    
 
794 7 1   4,32   1 4,32 
    
  
41   4   8,69 4 8,69 
    
  
44   2   3,17 2 3,17 
    PLRG1 2 237   1   1,77 1 1,77 
    
 
420 135 1 1 5,77 5,48 2 5,77 
    PPIE 2 218 3 11 6,32 10,13 14 10,13 
    
 
36 108 3 4 5,59 7,83 7 7,83 
    
  
114 1 1 5,93 3,81 2 5,93 
    
 
76 104 1 1 3,93 5,43 2 5,43 
    
  
108 5 9 4,14 5,19 14 5,19 
    
  
123 1 1 3,11 2,68 2 3,11 
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Type Protein 1 Protein 2 Residue 1 Residue 2 
Spectral count Scoremax Total spec. 
count 
Best 
Scoremax Lumos QExHF Lumos QExHF 
    
  
134 3   6,00   3 6,00 
    
 
212 108 1   3,66   1 3,66 
    
  
114   1   4,71 1 4,71 
    PPIL2 50 418 1   3,79   1 3,79 
    PRCC 420 207 3 5 7,47 7,31 8 7,47 
    
  
216 2 2 9,41 7,17 4 9,41 
    
  
223 1 3 5,40 8,12 4 8,12 
    
 
423 193   2   7,77 2 7,77 
    
 
458 193 13 10 10,82 11,29 23 11,29 
    
  
207 5 2 8,55 7,76 7 8,55 
    
  
216 1 1 4,41 3,41 2 4,41 
    PRP19 708 192 2 2 5,70 8,37 4 8,37 
    
  
244 1 1 3,48 4,26 2 4,26 
    
  
266   6   12,79 6 12,79 
    RU2A 2 205 39 20 11,40 8,14 59 11,40 
    SF3A1 76 223 2   4,04   2 4,04 
    
 
257 2   1   7,77 1 7,77 
    
 
549 55 12 6 12,34 15,68 18 15,68 
    
 
590 55   1   8,43 1 8,43 
    
  
115 4   10,10   4 10,10 
    
 
708 2 13 14 13,35 10,58 27 13,35 
    
  
399   2   9,76 2 9,76 
    
  
533   1   5,14 1 5,14 
    
 
794 2 2 1 6,04 5,25 3 6,04 
    
  
55 4   6,87   4 6,87 
    
  
115   2   4,31 2 4,31 
    
  
131 1   4,59   1 4,59 
    SF3B2 36 275 2 1 4,38 4,67 3 4,67 
    SNR40 62 8   1   1,44 1 1,44 
    SNW1 420 48 2   7,80   2 7,80 
    U520 677 699   1   4,92 1 4,92 
    ZN830 482 279 2 5 5,46 8,41 7 8,41 
    
 
708 117 1   8,06   1 8,06 
    
  
137 5 4 7,48 9,08 9 9,08 
    
  
140 2 1 7,00 5,29 3 7,00 
    
 
794 140 1   4,10   1 4,10 
    
  
149   1   3,84 1 3,84 
Inter U520 BUD13 975 68 1   8,76   1 8,76 
    CWC22 1146 584   1   1,41 1 1,41 
    GPKOW 14 50   1   3,05 1 3,05 
    
  
192   1   3,71 1 3,71 
    
 
46 192 3 1 6,91 4,54 4 6,91 
    
 
60 50 1 3 4,91 6,76 4 6,76 
    
 
73 192 4 5 5,89 5,80 9 5,89 
    
 
83 192 3 6 4,73 6,77 9 6,77 
    
 
155 346 1 1 3,67 3,87 2 3,87 
    
 
695 61   2   6,13 2 6,13 
    
 
1049 372   1   9,98 1 9,98 
    ISY1 2091 260   1   3,02 1 3,02 
    KIN17 1146 293   2   3,19 2 3,19 
    
 
1169 272   1   3,73 1 3,73 
    PLRG1 453 487   1   2,88 1 2,88 
    PRP8 14 1210 2   7,73   2 7,73 
    
  
1306 2 3 6,62 6,62 5 6,62 
    
  
1344 15 14 14,63 16,45 29 16,45 
    
  
1649 4   17,94   4 17,94 
    
  
2249 1 3 5,80 7,57 4 7,57 
    
 
60 2031 1   3,77   1 3,77 
    
  
2034 6 7 14,84 13,43 13 14,84 
    
  
2049 11 8 17,24 17,13 19 17,24 
    
 
73 1994 29 24 19,19 11,51 53 19,19 
    
 
105 1993 3 2 7,46 3,35 5 7,46 
    
 
107 2031 1 1 6,25 7,19 2 7,19 
    
  
2049 1 1 5,90 4,04 2 5,90 
    
 
144 1993 5   7,11   5 7,11 
    
 
147 1993   1   2,33 1 2,33 
    
 
177 2031 3 1 5,59 8,71 4 8,71 
    
  
2034 8 6 11,94 8,73 14 11,94 
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Scoremax Lumos QExHF Lumos QExHF 
    
  
2049 2 2 7,92 5,21 4 7,92 
    
 
178 2031 1 1 4,54 7,63 2 7,63 
    
  
2034 2   10,24   2 10,24 
    
  
2049 1 1 2,78 1,98 2 2,78 
    
 
256 2244 1   5,36   1 5,36 
    
 
733 2031 6 6 8,07 8,06 12 8,07 
    
  
2034 9 6 7,20 6,80 15 7,20 
    
 
770 2034 2 3 6,56 8,85 5 8,85 
    
  
2049 10 13 13,07 11,70 23 13,07 
    
 
1034 2049   1   8,06 1 8,06 
    
  
2070 1   4,40   1 4,40 
    
 
1039 2031 3 1 9,00 4,87 4 9,00 
    
  
2034 15 14 8,48 8,07 29 8,48 
    
  
2049 17 19 14,60 12,83 36 14,60 
    
  
2070 12 14 13,61 14,76 26 14,76 
    
 
1049 2031   2   3,88 2 3,88 
    
  
2034 4 6 5,89 10,30 10 10,30 
    
  
2049 9 7 18,15 20,74 16 20,74 
    
  
2070 3 5 9,54 13,06 8 13,06 
    
 
1134 2049 2 2 5,37 7,43 4 7,43 
    
 
1142 2049 4 9 5,86 6,97 13 6,97 
    
 
1145 2070   1   4,63 1 4,63 
    
 
1146 1636 4 2 6,86 10,16 6 10,16 
    
  
2049 6 7 9,53 10,28 13 10,28 
    
 
1557 1300   1   3,59 1 3,59 
    R113A 557 319 3 5 5,79 4,99 8 5,79 
    
 
770 319 12 6 6,29 3,97 18 6,29 
    
 
2026 25 6 5 7,69 6,44 11 7,69 
    
 
2087 25 4 4 4,70 4,95 8 4,95 
    SF3B1 343 21   1   5,52 1 5,52 
    SF3B2 469 877   1   5,67 1 5,67 
    
 
1874 877 4 2 12,50 10,24 6 12,50 
    SNIP1 2080 2 1   3,60   1 3,60 
    SNW1 151 236 1   5,86   1 5,86 
    
 
1176 452 1   5,23   1 5,23 
    SRRM2 599 101 1   4,79   1 4,79 
    
 
1134 169   1   3,61 1 3,61 
    
 
1176 2680 2 1 5,43 4,57 3 5,43 
    SYF1 699 677   1   4,92 1 4,92 
    U5S1 284 682   1   8,05 1 8,05 
    ZN830 1134 44   1   2,63 1 2,63 
Inter U5S1 CDC5L 446 466 4 6 4,12 4,94 10 4,94 
    CWC22 359 330 1   6,22   1 6,22 
    CWC27 352 393 6 2 14,28 5,73 8 14,28 
    
 
359 393   1   5,13 1 5,13 
    IF4A3 244 152 4 7 11,23 12,38 11 12,38 
    
 
694 152 1 1 4,58 3,56 2 4,58 
    KIN17 341 10 1 3 3,79 3,53 4 3,79 
    PRP8 359 366 37 33 14,67 13,05 70 14,67 
    
 
405 218 50 45 18,31 15,17 95 18,31 
    
 
409 218 33 18 13,05 10,81 51 13,05 
    
 
712 1210   1   1,29 1 1,29 
    RBMX2 352 263 1   4,35   1 4,35 
    
 
609 197   1   2,67 1 2,67 
    SMD3 421 87 1 4 4,15 6,06 5 6,06 
    SNIP1 788 257 1   2,73   1 2,73 
    U520 682 284   1   8,05 1 8,05 
Inter ZN830 AQR 339 201 2   5,02   2 5,02 
    
 
343 201 5 1 9,34 6,06 6 9,34 
    CDC5L 137 255 1   4,97   1 4,97 
    
 
149 255 1 2 3,25 3,74 3 3,74 
    CRNL1 83 771   2   6,42 2 6,42 
    
 
216 445 2 2 5,16 5,44 4 5,44 
    
 
228 445 5 8 9,15 7,06 13 9,15 
    
  
475 2 1 3,24 3,04 3 3,24 
    
 
234 445 18 20 10,46 13,76 38 13,76 
    
  
460 11 16 12,03 10,60 27 12,03 
    
  
475 8 6 11,26 11,79 14 11,79 
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Type Protein 1 Protein 2 Residue 1 Residue 2 
Spectral count Scoremax Total spec. 
count 
Best 
Scoremax Lumos QExHF Lumos QExHF 
    
  
485 1   2,84   1 2,84 
    CTBL1 78 56 5 7 8,63 8,82 12 8,82 
    
 
104 56   7   18,19 7 18,19 
    
 
117 31   1   4,87 1 4,87 
    
 
149 31   1   4,97 1 4,97 
    CWC15 26 147 3 3 5,54 5,95 6 5,95 
    
 
28 183 1   2,89   1 2,89 
    
 
272 40 1   0,60   1 0,60 
    PPIL2 182 313 4   7,49   4 7,49 
    
  
462 1   8,86   1 8,86 
    
 
190 313 5 14 11,12 11,80 19 11,80 
    
  
450   2   4,28 2 4,28 
    
  
462 2 1 5,23 3,06 3 5,23 
    
 
216 313   2   7,50 2 7,50 
    
 
228 313 12 14 10,15 8,92 26 10,15 
    
  
450 8 15 7,97 7,69 23 7,97 
    
  
454 2 4 4,88 9,32 6 9,32 
    
  
462 7 7 10,95 10,98 14 10,98 
    
 
234 312 1   4,53   1 4,53 
    
  
313 29 33 13,86 14,99 62 14,99 
    
  
450 4 7 5,51 7,02 11 7,02 
    
  
454 10 8 8,24 8,84 18 8,84 
    
  
460 4   7,98   4 7,98 
    
  
462 13 9 12,81 12,31 22 12,81 
    
 
262 277   1   7,82 1 7,82 
    PRP19 104 122 1   3,81   1 3,81 
    
 
149 122 2 2 8,36 7,80 4 8,36 
    
  
425 1 2 3,63 3,56 3 3,63 
    PRP8 102 477 1   3,62   1 3,62 
    SMD1 102 44 1   4,67   1 4,67 
    SNW1 13 311 3 1 6,34 5,53 4 6,34 
    
  
315 4 3 8,84 8,25 7 8,84 
    SPF27 149 168 4   8,13   4 8,13 
    SRRM2 216 161   1   2,96 1 2,96 
    SYF1 117 708 1   8,06   1 8,06 
    
 
137 708 5 4 7,48 9,08 9 9,08 
    
 
140 708 2 1 7,00 5,29 3 7,00 
    
  
794 1   4,10   1 4,10 
    
 
149 794   1   3,84 1 3,84 
    
 
279 482 2 5 5,46 8,41 7 8,41 
    U520 44 1134   1   2,63 1 2,63 
 
